documents incorporated reference document part proxy statement annual meeting part iii shareholders held may filed securities exchange commission within days close fiscal year covered reporttable contents part item business item risk factors cautionary factors may affect future results item b unresolved staff comments item properties item legal proceedings executive officers registrant item reserved part ii item market registrants common equity related stockholder matters issuer purchases equity securities item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data financial statements notes consolidated financial statements report independent registered public accounting firm b supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures managements report item b information part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accountant fees services part iv item exhibits financial statement schedules signatures consent independent registered public accounting firm part item business company global health care company delivers innovative health solutions prescription medicines vaccines biologic therapies animal health consumer care products markets directly joint ventures companys operations principally managed products basis comprised four operating segments pharmaceutical animal health consumer care alliances segments one reportable segment pharmaceutical segment pharmaceutical segment includes human health pharmaceutical vaccine products marketed either directly company joint ventures human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities company also animal health operations discover develop manufacture market animal health products including vaccines company sells veterinarians distributors animal producers additionally company consumer care operations develop manufacture market overthecounter foot care sun care products sold wholesale retail drug food chain mass merchandiser outlets united states canada november merck co inc old merck scheringplough corporation scheringplough merged merger merger scheringplough acquired shares old merck became whollyowned subsidiary scheringplough renamed merck sharp dohme corp scheringplough continued surviving public company renamed merck co inc new merck company however accounting purposes merger treated acquisition old merck considered accounting acquirer accordingly accompanying financial statements reflect old mercks standalone operations existed prior completion merger results scheringploughs business included new mercks financial statements periods subsequent completion merger therefore new mercks financial results reflect full year legacy scheringplough operations references report accompanying financial statements merck periods prior merger refer old merck periods completion merger new merck financial information information pharmaceutical segment see item managements discussion analysis financial condition results operations item financial statements supplementary data product service marks appearing type form different surrounding text trademarks service marks owned licensed promoted distributed merck subsidiaries affiliates except noted cozaar hyzaar registered trademarks ei du pont de nemours company wilmington de trademarks services marks respective owners overview company made progress driving revenue growth key products expanding global reach including within emerging markets improving cost structure making strategic investments business advancing latestage pipeline continuing task integrating legacy companies postmerger sales increased billion driven largely incremental revenue resulting inclusion full year results legacy scheringplough products remicade infliximab treatment inflammatory diseases nasonex mometasone furoate monohydrate inhaled nasal corticosteroid treatment nasal allergy symptoms temodar temozolomide treatment certain types brain tumors pegintron peginterferon alphab treating chronic hepatitis c clarinex desloratadine nonsedating antihistamine well inclusion full year results zetia ezetimibe vytorin ezetimibesimvastatin cholesterol modifying medicines prior merger substantially sales zetia vytorin recognized merckscheringplough partnership msp partnership results old mercks interest msp partnership recorded equity income affiliates result merger msp partnership whollyowned company therefore revenues products reflected sales additionally company recognized full year sales legacy scheringplough animal health consumer care products sales include revenue legacy scheringplough msp partnership products postmerger period december also contributing sales increase growth januvia sitagliptin phosphate janumet sitagliptin phosphate metformin hydrochloride treatment type diabetes isentress raltegravir antiretroviral therapy use combination therapy treatment hiv infection adult patients singulair montelukast sodium medicine indicated chronic treatment asthma relief symptoms allergic rhinitis increases partially offset lower sales cozaar losartan potassium hyzaar losartan potassium hydrochlorothiazide treatment hypertension lost patent protection united states april number major european markets march revenue also negatively affected lower sales fosamax alendronate sodium fosamax plus alendronate sodiumcholecalciferol treatment case fosamax prevention osteoporosis lost market exclusivity united states several major european markets lower revenue companys relationship astrazeneca lp azlp well lower sales gardasil human papillomavirus quadrivalent types vaccine recombinant vaccine help prevent cervical vulvar vaginal anal cancers precancerous dysplastic lesions genital warts caused human papillomavirus hpv types contained vaccine lower sales zocor simvastatin companys statin modifying cholesterol addition implementation certain provisions us health care reform legislation resulted increased medicaid rebates impacts reduced revenues approximately million additionally many countries european union eu undertaken austerity measures aimed reducing costs health care implemented pricing actions negatively impacted sales sales remicade followon product simponi billion aggregate company involved arbitration centocor ortho biotech inc centocor subsidiary johnson johnson centocor seeking terminate companys rights continue market remicade simponi arbitration hearing concluded company awaiting arbitration panels decision see item financial statements supplementary data note contingencies environmental liabilities unfavorable outcome arbitration would material adverse effect companys financial position liquidity results operations since merger company continued advancement drug candidates pipeline us food drug administration fda approved dulera inhalation aerosol mometasone furoateformoterol fumarate dihydrate new fixeddose combination asthma treatment patients years age older addition intravenous formulation brinavess vernakalant merck exclusive marketing rights outside united states canada mexico granted marketing approval eu rapid conversion recent onset atrial fibrillation sinus rhythm adults nonsurgery patients atrial fibrillation seven days less postcardiac surgery patients atrial fibrillation three days less also fda approved new indication gardasil prevention anal cancer caused hpv types prevention anal intraepithelial neoplasia grades anal dysplasias precancerous lesions caused hpv types males females years age additionally september two supplemental new drug applications snda saphris asenapine treatment schizophrenia adults acute treatment bipolar disorder adults approved united states expand products indications also company entered copromotion agreement commercialization daxas treatment symptomatic chronic obstructive pulmonary disease company launched certain european markets company currently three candidates review fda boceprevir investigational oral hepatitis c protease inhibitor mka xr companys investigational extendedrelease formulation janumet mkd investigational combination januvia zocor treatment diabetes dyslipidemia addition sch nomace oral contraceptive combines selective progestin beta estradiol currently review eu additionally mk cubicin daptomycin injection currently review japan company marketing rights also company currently candidates phase iii development anticipates making new drug application nda respect certain candidates including mk ridaforolimus novel mtor inhibitor evaluated treatment metastatic soft tissue bone sarcomas mk saflutan tafluprost reduction elevated intraocular pressure appropriate patients primary openangle glaucoma ocular hypertension mkc ezetimibe combined atorvastatin investigational medication treatment dyslipidemia mk telcagepant companys investigational medication acute treatment migraine another phase iii candidate vorapaxar respect company recently informed chairman one studies discontinue study drug investigators begin close study timely orderly fashion company recorded material impairment charge related intangible asset see research development company continues make progress achieving cost savings across areas including consolidation sales marketing research development application companys lean manufacturing sourcing strategies expanded operations full integration msp partnership savings result various actions including merger restructuring program discussed previously announced ongoing cost reduction activities legacy companies well nonrestructuringrelated activities companys procurement savings initiative company realized billion net cost savings activities february company commenced actions global restructuring program merger restructuring program conjunction integration legacy merck legacy scheringplough businesses merger restructuring program intended optimize cost structure combined company additional actions program continued part restructuring actions taken thus far merger restructuring program company expects reduce total workforce measured time merger approximately across company worldwide addition company eliminated positions vacant time merger workforce reductions primarily come elimination duplicative positions sales administrative headquarters organizations well sale closure certain manufacturing research development sites consolidation office facilities company continue pursue productivity efficiencies evaluate manufacturing supply chain capabilities ongoing basis may result future restructuring actions period company also continue hire new employees strategic growth areas business necessary connection merger restructuring program separation costs companys existing severance programs worldwide recorded fourth quarter extent costs probable reasonably estimable company commenced accruing costs related enhanced termination benefits offered employees merger restructuring program first quarter necessary criteria met company recorded total pretax restructuring costs billion billion related program restructuring actions taken thus far merger restructuring program expected substantially completed end exception certain manufacturing facilities actions total cumulative pretax costs estimated approximately billion billion company estimates approximately twothirds cumulative pretax costs relate cash outlays primarily related employee separation expense approximately onethird cumulative pretax costs noncash relating primarily accelerated depreciation facilities closed divested company expects restructuring actions taken thus far merger restructuring program result annual savings approximately billion billion march united states enacted health care reform legislation important market reforms began continue full implementation merck incurred costs result legislation including increased medicaid rebates impacts reduced revenues company also recorded charge associated legislation changed tax law require taxation prescription drug subsidy companys retiree health benefit plans companies receive reimbursement medicare part additional provisions legislation come effect including assessment annual health care reform fee branded prescription drug manufacturers importers requirement drug manufacturers pay discount medicare part utilization incurred beneficiaries medicare part coverage gap ie socalled donut hole new provisions decrease revenues increase costs earnings per common share eps assuming dilution reflect net unfavorable impact resulting amortization purchase accounting adjustments process research development iprd impairment charges including charge related vorapaxar clinical development program restructuring mergerrelated costs well legal reserve relating vioxx vioxx liability reserve discussed partially offset gain recognized astrazenecas exercise option acquire certain assets company nongaap eps excluding items see item managements discussion analysis financial condition results operations nongaap income non gaap eps december merck announced board directors elected kenneth c frazier mercks president chief executive officer president well member board effective january mr frazier succeeds richard clark continue serve chairman board product sales sales companys products follows years ended december pharmaceutical bone respiratory immunology dermatology singulair remicade nasonex fosamax clarinex arcoxia proventil asmanex cardiovascular zetia vytorin integrilin diabetes obesity januvia janumet diversified brands cozaarhyzaar zocor propecia claritin rx vasotecvaseretic remeron proscar infectious disease isentress pegintron cancidas primaxin invanz avelox rebetol crixivanstocrin neurosciences ophthalmology maxalt cosopttrusopt subutexsuboxone oncology temodar emend caelyx intron vaccines proquadmmr iivarivax gardasil rotateq pneumovax zostavax womens health endocrine nuvaring follistim aq implanon cerazette pharmaceutical total pharmaceutical segment sales segment sales total segment sales sales legacy scheringplough products reflect results postmerger period addition prior merger substantially sales zetia vytorin recognized msp partnership results old mercks interest msp partnership recorded equity income affiliates result merger msp partnership whollyowned company accordingly sales msp partnership products merger reflected table sales zetia vytorin reflect old mercks sales products latin america part msp partnership amounts reflect sales vaccines sold major european markets companys joint venture sanofi pasteur msd results reflected equity income affiliates amounts however reflect supply sales sanofi pasteur msd pharmaceutical primarily reflects sales human pharmaceutical products including products within franchises listed separately reflects nonreportable segments including animal health consumer care revenue companys relationship azlp primarily relating sales nexium well prilosec revenue azlp billion billion billion respectively revenues primarily comprised miscellaneous corporate revenues thirdparty manufacturing sales sales related divested products businesses supply sales included segment results pharmaceutical companys pharmaceutical products include therapeutic preventive agents generally sold prescription treatment human disorders among bone respiratory immunology dermatology singulair remicade nasonex fosamax clarinex arcoxia etoricoxib treatment arthritis pain asmanex twisthaler mometasone furoate inhalation powder oral drypowder corticosteroid inhaler firstline maintenance treatment asthma patients older proventil hfa albuterol sulfate inhalation aerosol relief bronchospasm patients years older cardiovascular zetia marketed ezetrol outside united states vytorin marketed inegy outside united states integrilin eptifibatide injection platelet receptor gp iibiiia inhibitor treatment patients acute coronary syndrome undergoing percutaneous coronary intervention united states well prevention early myocardial infarction patients acute coronary syndrome countries diabetes obesity januvia janumet treatment type diabetes diversified brands cozaar hyzaar zocor propecia finasteride product treatment male pattern hair loss claritin rx vasotec enalapril maleate vaseretic enalapril maleatehydrochlorothiazide hypertension andor heart failure products proscar finasteride urology product treatment symptomatic benign prostate enlargement remeron mirtazapine antidepressant infectious disease isentress pegintron primaxin imipenem cilastatin sodium cancidas caspofungin acetate antifungal product invanz ertapenem sodium treatment certain infections avelox moxifloxacin company markets united states broadspectrum fluoroquinolone antibiotic certain respiratory skin infections rebetol ribavirin usp capsules oral solution use combination pegintron intron interferon alphab recombinant treating chronic hepatitis c crixivan indinavir sulfate stocrin efavirenz antiretroviral therapies treatment hiv infection neurosciences ophthalmology maxalt rizatriptan benzoate product acute treatment migraine cosopt dorzolamide hydrochloride timolol maleate ophthalmic solution trusopt dorzolamide hydrochloride ophthalmic solution oncology temodar emend aprepitant prevention chemotherapyinduced postoperative nausea vomiting intron injection marketed chronic hepatitis b c numerous anticancer indications worldwide including adjuvant therapy malignant melanoma vaccines proquad measles mumps rubella varicella virus vaccine live pediatric combination vaccine help prevent measles mumps rubella varicella mmr ii measles mumps rubella virus vaccine live vaccine help prevent measles mumps rubella varivax varicella virus vaccine live vaccine help prevent chickenpox varicella gardasil rotateq rotavirus vaccine live oral pentavalent vaccine help protect rotavirus gastroenteritis infants children pneumovax pneumococcal vaccine polyvalent vaccine help prevent pneumococcal disease zostavax zoster vaccine live vaccine help prevent shingles herpes zoster patients aged older womens health endocrine nuvaring etonogestrelethinyl estradiol vaginal ring vaginal contraceptive ring follistim aq follitropin beta injection fertility treatment implanon etonogestrel implant singlerod subdermal contraceptive implant cerazette progestin oral contraceptive animal health animal health segment discovers develops manufactures markets animal health products including vaccines principal marketed products segment include livestock products nuflor antibiotic range use cattle swine bovilisvista vaccine lines infectious diseases cattle banamine bovine swine antiinflammatory estrumate treatment fertility disorders cattle regumatematrix fertility management swine horses resflor combination broadspectrum antibiotic nonsteroidal antiinflammatory drug bovine respiratory disease zilmax revalor improve production efficiencies beef cattle mpac swine pneumonia vaccine porcilis vaccine line infectious diseases swine poultry products nobilisinnovax vaccine lines poultry paracox coccivac coccidiosis vaccines companion animal products nobivaccontinuum vaccine lines flexible dog cat vaccination otomaxmometamaxposatex ear ointments acute chronic otitis caninsulinvetsulin diabetes mellitus treatment dogs cats panacursafeguard broadspectrum anthelmintic dewormer use many animals scaliborexspot protecting bites fleas ticks mosquitoes sandflies aquaculture products slice parasiticide sea lice salmon aquavacnorvax vaccines bacterial viral disease fish compact pd vaccine salmon aquaflor antibiotic farmraised fish consumer care consumer care segment develops manufactures markets overthecounter foot care sun care products principal products segment include overthecounter products claritin nondrowsy antihistamines miralax treatment occasional constipation coricidin hbp decongestantfree coldflu medicine people high blood pressure afrin nasal decongestant spray zegerid otc treatment frequent heartburn foot care dr scholls foot care products lotrimin topical antifungal products tinactin topical antifungal products foot sneaker odorwetness products sun care coppertone sun care lotions sprays dry oils solarcaine sunburn relief products discussion sales companys products see item managements discussion analysis financial condition results operations product approvals june fda approved dulera inhalation aerosol new fixeddose combination asthma treatment patients years age older dulera combines inhaled corticosteroid longacting betaagonist september intravenous formulation brinavess granted marketing approval eu iceland norway rapid conversion recent onset atrial fibrillation sinus rhythm adults nonsurgery patients atrial fibrillation seven days less postcardiac surgery patients atrial fibrillation three days less brinavess acts preferentially atria first product new class pharmacologic agents cardioversion atrial fibrillation launch eu april cardiome pharma corp merck announced collaboration license agreement development commercialization vernakalant agreement provides merck exclusive rights outside united states canada mexico vernakalant intravenous formulation august fda approved saphris asenapine acute treatment schizophrenia adults acute treatment manic mixed episodes associated bipolar disorder without psychotic features adults september two sndas saphris approved united states expand products indications treatment schizophrenia adults monotherapy acute treatment manic mixed episodes associated bipolar disorder adults adjunctive therapy either lithium valproate acute treatment manic mixed episodes associated bipolar disorder adults september asenapine sold brand name sycrest received marketing approval eu treatment moderate severe manic episodes associated bipolar disorder adults marketing approval include indication schizophrenia marketing approval applies eu member states october merck h lundbeck lundbeck announced worldwide commercialization agreement sycrest sublingual tablets mg mg terms agreement lundbeck paid fee make product supply payments exchange exclusive commercial rights sycrest markets outside united states china japan merck retain exclusive commercial rights asenapine united states china japan concurrently merck continuing pursue regulatory approval asenapine parts world joint ventures astrazeneca lp old merck entered agreement astra ab astra develop market astra products united states old merck astra formed equally owned joint venture developed marketed astras new prescription medicines united states including prilosec omeprazole first class medications known proton pump inhibitors slows production acid cells stomach lining old merck astra restructured joint venture whereby old merck acquired astras interest joint venture renamed kbi inc kbi contributed kbis operating assets new us limited partnership named astra pharmaceuticals lp partnership exchange limited partner interest astra contributed net assets wholly owned subsidiary astra usa inc partnership exchange general partner interest partnership renamed astrazeneca lp azlp upon astras merger zeneca group plc astrazeneca merger became exclusive distributor products kbi retained rights company earns certain partnership returns well ongoing revenue based sales current future kbi products partnership returns include priority return provided partnership agreement variable returns based part upon sales certain former astra usa inc products preferential return representing companys share undistributed partnership azlp generally accepted accounting principles gaap earnings astrazeneca merger triggered partial redemption march old mercks interest certain azlp product rights upon redemption old merck received billion azlp amount based primarily multiple old mercks average annual variable returns derived sales former astra usa inc products three years prior redemption limited partner share agreed value old merck recorded billion pretax gain partial redemption partial redemption old mercks interest product rights result change old mercks limited partnership interest described item managements discussion analysis financial condition results operations certain adjustments old merck recorded aggregate pretax gain billion conjunction restructuring discussed astra purchased option asset option payment million recorded deferred income buy old mercks interest kbi products excluding gastrointestinal medicines nexium prilosec nonppi products april astrazeneca exercised asset option merck received million astrazeneca representing net present value march projected future pretax revenue received old merck nonppi products appraised value recorded reduction companys investment azlp company recognized million deferred income component income expense net addition old merck granted astra option shares option buy old mercks common stock interest kbi therefore old mercks interest nexium prilosec exercisable exercise price shares option based net present value estimated future net sales nexium prilosec determined time exercise subject certain trueup mechanisms company believes likely astrazeneca exercise shares option sanofi pasteur msd old merck pasteur mrieux connaught sanofi pasteur sa formed joint venture market human vaccines europe collaborate development combination vaccines distribution existing eu european free trade association old merck sanofi pasteur contributed among things european vaccine businesses equal shares joint venture known pasteur mrieux msd snc sanofi pasteur msd snc joint venture maintains presence directly affiliates branches belgium italy germany spain france austria ireland sweden portugal netherlands switzerland united kingdom distributors rest territory johnson johnsonomerck consumer pharmaceuticals company old merck formed joint venture johnson johnson develop market broad range nonprescription medicines us consumers owned joint venture also includes canada significant joint venture products pepcid ac famotidine overthecounter form old mercks ulcer medication pepcid famotidine well pepcid complete overthecounter product combines companys ulcer medication antacids calcium carbonate magnesium hydroxide licenses subsidiary scheringplough entered licensing agreement centocor johnson johnson company market remicade prescribed treatment inflammatory diseases scheringploughs subsidiary exercised option contract centocor license rights develop commercialize simponi fully human monoclonal antibody company exclusive marketing rights products outside united states japan certain asian markets december scheringplough centocor revised distribution agreement regarding development commercialization distribution remicade simponi extending companys rights exclusively market remicade match duration companys exclusive marketing rights simponi addition scheringplough centocor agreed share certain development costs relating simponis autoinjector delivery system october european commission ec approved simponi treatment rheumatoid arthritis immune system disorders two presentations novel autoinjector prefilled syringe result companys marketing rights products extend years first commercial sale simponi within eu following receipt pricing reimbursement approval within eu operating expenses subject certain adjustments company entitled receive approximate share profits companys distribution companys marketing territory december beginning companys share profits change time share profits products share profits remain fixed thereafter remainder term company may independently develop market simponi crohns disease indication territories option centocor participate centocor instituted arbitration proceeding terminate agreement companys rights distribute products see item risk factors item financial statements supplementary data note contingencies environmental liabilities competition markets company conducts business pharmaceutical industry highly competitive highly regulated companys competitors include worldwide researchbased pharmaceutical companies smaller research companies limited therapeutic focus generic drug consumer health care manufacturers companys operations may affected technological advances competitors industry consolidation patents granted competitors competitive combination products new products competitors generic availability competitors branded products new information clinical trials marketed products postmarketing surveillance generic competition companys products mature addition patent positions increasingly challenged competitors outcome highly uncertain adverse result patent dispute preclude commercialization products negatively affect sales existing products could result recognition impairment charge respect certain products competitive pressures intensified pressures industry grown effect operations competitive factors patent disputes predicted pharmaceutical competition involves rigorous search technological innovations ability market innovations effectively longstanding emphasis research development company well positioned compete search technological innovations additional resources meet market challenges include quality control flexibility meet customer specifications efficient distribution system strong technical information service company active acquiring marketing products external alliances joint ventures licenses refining sales marketing efforts address changing industry conditions however introduction new products processes competitors may result price reductions product displacements even products protected patents example number compounds available treat particular disease typically increases time result slowed sales growth companys products therapeutic category global efforts toward health care cost containment continue exert pressure product pricing market access pressure particularly intense several european countries implemented austerity measures aimed reducing costs areas health care united states federal state governments many years also pursued methods reduce cost drugs vaccines pay example federal laws require company pay specified rebates medicines reimbursed medicaid provide discounts outpatient medicines purchased certain public health service entities disproportionate share hospitals hospitals meeting certain criteria federal vaccines children entitlement program us centers disease control prevention cdc funds purchases recommended pediatric vaccines public sector price immunization medicaideligible uninsured native american certain underinsured children merck awarded cdc contract supply pediatric vaccines vaccines children program backdrop united states enacted major health care reform legislation various insurance market reforms began last year continue full implementation new law expected expand access health care million americans end decade previously regular access health care respect effect law pharmaceutical industry law increased mandated medicaid rebate expanded rebate medicaid managed care utilization increased types entities eligible federal b drug discount program law also requires pharmaceutical manufacturers pay discount medicare part utilization beneficiaries medicare part coverage gap ie socalled donut hole also beginning pharmaceutical manufacturers required pay annual health care reform fee total annual industry fee billion assessed company proportion share sales certain government programs medicare medicaid although included health care reform law congress also considered may consider proposals increase governments role pharmaceutical pricing medicare program proposals may include removing current legal prohibition secretary health human services intervening price negotiations medicare drug benefit program plans pharmaceutical companies may also include mandating payment rebates pharmaceutical utilization medicare drug benefit plans addition congress may consider proposals allow certain conditions importation medicines countries full impact us health care reform well continuing budget pressures governments around world predicted time addressing cost containment pressures company makes continuing effort demonstrate medicines provide value patients pay health care company works markets historically low rates government spending health care encourage governments increase investments thereby improve citizens access appropriate health care including medicines animal health business intense competition affected several factors including regulatory legislative issues scientific technological advances product innovation quality price companys products effective promotional efforts frequent introduction generic products competitors companys consumer care operations face competition consumer health care businesses well retailers carry private label brands companys competitive position affected several factors including regulatory legislative issues scientific technological advances quality price companys products promotional efforts growth lower cost private label brands operating conditions become challenging global pressures competition industry regulation cost containment efforts although one predict effect factors companys business company continually takes measures evaluate adapt improve organization business practices better meet customer needs believes well positioned respond evolving health care environment market forces government regulation pharmaceutical industry subject regulation regional country state local agencies around world governmental regulation legislation tends focus standards processes determining drug safety effectiveness well conditions sale reimbursement especially related pricing products particular importance fda united states administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals many cases fda requirements practices increased amount time resources necessary develop new products bring market united states us health care reform legislation passed full implementation date significantly expands access health care also contains number provisions imposing new obligations pharmaceutical industry including example increase mandated rebate medicaid program new discount requirement medicare part program eu adopted directives legislation concerning classification labeling advertising wholesale distribution approval marketing medicinal products human use provide mandatory standards throughout eu may supplemented implemented additional regulations eu member states companys policies procedures already consistent substance directives consequently believed material effect companys business january ec launched sector inquiry pharmaceutical industry rules eu competition law sector inquiry allows ec gather information general operation market competition investigation suspected anticompetitive behavior specific firms part inquiry old mercks offices germany inspected authorities beginning january preliminary report ec issued november following public consultation period final report issued july final report confirmed decline number novel medicines reaching market instances delayed market entry generic medicines discussed industry practices may contributed phenomena among things final report expressed concern settlements patent disputes originator generic companies suggested ec monitor anticompetitive effects ec issued inquiries respect subject investigation including company ec alleged company subsidiaries engaged unlawful practices company believes continue able conduct operations including launching new drugs market regulatory environment access medicines global health care company mercks primary role discover develop innovative medicines vaccines company also recognizes important role play helping improve access products around world companys efforts regard wideranging example company recognized pricing many products differential pricing framework taking consideration factors countrys level economic development public health need building companys efforts merck undertaken collaborations many stakeholders improve access medicines enhance quality life people around world example partnership merck government bhutan australian cervical cancer foundation bhutan became first lowincome country world successfully implement national hpv vaccination program program merck providing gardasil free charge first year program provide gardasil companys access price five years also merck worked partner wellcome trust develop hillemann laboratories established september initiative focus developing affordable vaccines prevent diseases commonly affect lowincome countries merck also past provided funds merck company foundation independent organization partnered variety organizations dedicated improving global health one partnerships african comprehensive hivaids partnership botswana collaboration government botswana bill melinda gates foundation renewed supports botswanas response hivaids comprehensive sustainable approach hiv prevention care treatment support privacy data protection company subject number privacy data protection laws regulations globally legislative regulatory landscape privacy data protection continues evolve increasing attention privacy data protection issues potential affect directly companys business including recently enacted laws regulations united states internationally requiring notification individuals government authorities security breaches involving certain categories personal information distribution company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions human health vaccines sold primarily physicians wholesalers physician distributors government entities companys professional representatives communicate effectiveness safety value companys pharmaceutical vaccine products health care professionals private practice group practices hospitals managed care organizations company sells animal health products veterinarians distributors animal producers companys overthecounter foot care sun care products sold wholesale retail drug food chain mass merchandiser outlets united states canada raw materials raw materials supplies generally available multiple sources purchased worldwide normally available quantities adequate meet needs companys business patents trademarks licenses patent protection considered aggregate material importance companys marketing human health products united states major foreign markets patents may cover products per se pharmaceutical formulations processes intermediates useful manufacture products uses products protection individual products extends varying periods accordance legal life patents various countries protection afforded may also vary country country depends upon type patent scope coverage food drug administration modernization act fda modernization act includes pediatric exclusivity provision may provide additional six months market exclusivity united states indications new currently marketed drugs certain agreed upon pediatric studies completed applicant exclusivity provisions authorized prescription drug user fee act passed september current us patent law provides additional patent term patent term restoration periods patented product regulatory review fda patent portfolios developed products introduced company normally provide market exclusivity company following key us patent protection including patent term restoration pediatric exclusivity major marketed products product year expiration us crixivan compound formulation maxalt singulair cancidas compound composition propecia formulationuse asmanex use formulation avelox dulera use combination integrilin compound useformulation nasonex useformulationformulation temodar emend follistim aq pegintron conjugates mature ifnalpha zolinza pending patent term restoration invanz compound composition zostavax use zetiavytorin nuvaring delivery system noxafil rotateq clarinex formulation comvax method makingvectors intron recombivax method makingvectors saphrissycrest useformulation subject pending patent term restoration application januviajanumet compound salt isentress gardasil method makinguseproduct process compound patent unless otherwise noted company determined enforce additional patent set expire agreement dr reddys laboratories inc may launch generic us january settlement teva pharmaceuticals inc may launch generic us early february six months pediatric market exclusivity may extend date august agreement barr laboratories inc may launch generic us august agreement glenmark pharmaceuticals inc may launch generic us december virtue litigation settlement generic manufacturers given right enter us market expiration product patent normally results loss market exclusivity covered pharmaceutical product commercial benefits may continue derived latergranted patents processes intermediates related economical method manufacture active ingredient product ii patents relating use product iii patents relating novel compositions formulations iv united states certain countries market exclusivity may available relevant law effect product patent expiration pharmaceutical products also depends upon many factors nature market position product growth market complexities economics process manufacture active ingredient product requirements new drug provisions federal food drug cosmetic act similar laws regulations countries patents provided us market exclusivity cozaar hyzaar expired april addition cozaar hyzaar lost patent protection number major european markets march accordingly company experiencing significant decline cozaarhyzaar worldwide sales company expects decline continue addition patent provides us market exclusivity singulair companys largest selling product expires august company expects within two years following patent expiration lose substantially us sales singulair declines coming first full year following patent expiration also patent singulair expire number major european markets august company expects sales singulair markets decline significantly thereafter although six month pediatric market exclusivity may extend date markets february compound patent provides market exclusivity maxalt united states expires june although six month pediatric market exclusivity may extend date december addition patent maxalt expire number major european markets company anticipates sales united states european markets decline significantly patent expiries additions market exclusivity sought united states countries relevant laws including laws increasing patent life benefits increases patent life partially offset general increase number incentives use generic products additionally improvements intellectual property laws sought united states countries reform patent relevant laws implementation international treaties information respect companys patents see item risk factors item financial statements supplementary data note contingencies environmental liabilities worldwide companys important products sold trademarks considered aggregate material importance trademark protection continues countries long used countries long registered registration fixed terms renewed indefinitely royalty income patent knowhow licenses rights amounted million merck also incurred royalty expenses amounting billion patent knowhow licenses holds research development companys business characterized introduction new products new uses existing products strong research development program approximately people employed companys research activities research development expenses billion billion billion included restructuring costs years well billion iprd impairment charges company maintains ongoing commitment research broad range therapeutic areas clinical development support new products company maintains number longterm exploratory fundamental research programs biology chemistry well research programs directed toward product development companys research development model designed increase productivity improve probability success prioritizing companys research development resources disease areas unmet medical needs scientific opportunity commercial opportunity merck managing research development portfolio across diverse approaches discovery development balancing investments appropriately novel innovative targets potential major impact human health developing bestinclass approaches delivering maximum value new medicines vaccines new indications new formulations another important component companys sciencebased diversification based expanding companys portfolio modalities include small molecules vaccines also biologics peptides small proteins antibodies rnai merck moved diversify portfolio merck bioventures division potential harness market opportunity presented biological medicine patent expiries delivering high quality followon biologic products enhance access patients worldwide company continue pursue appropriate external licensing opportunities integration efforts research development continue focus integrating research operations legacy companies including providing effective transition employees realizing projected merger synergies form cost savings revenue growth opportunities maintaining momentum companys latestage pipeline overall companys global operating model align franchise function well align resources disease area priorities balance capacity across discovery phases allow company act upon programs highest probability success additionally across disease area priorities companys strategy designed expand access worldwide external science incorporate external research key component companys early discovery pipeline order translate basic research productivity latestage clinical success companys clinical pipeline includes candidates multiple disease areas including atherosclerosis cancer cardiovascular diseases diabetes infectious diseases inflammatoryautoimmune diseases insomnia migraine neurodegenerative diseases ophthalmics osteoporosis psychiatric diseases respiratory diseases womens health company supplements internal research aggressive licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well new technologies development human health products industry practice government regulations united states foreign countries provide determination effectiveness safety new chemical compounds preclinical tests controlled clinical evaluation new drug vaccine may marketed united states recorded data preclinical clinical experience included nda drug biologics license application bla vaccine biologic submitted fda required approval companys scientists discover new small molecule compound biologics molecule believe promise treat medical condition company commences preclinical testing compound preclinical testing includes laboratory testing animal safety studies gather data chemistry pharmacology immunogenicity toxicology pending acceptable preclinical data company initiate clinical testing accordance established regulatory requirements clinical testing begins phase studies designed assess safety tolerability pharmacokinetics preliminary pharmacodynamic activity compound humans favorable additional larger phase ii studies initiated determine efficacy compound affected population define appropriate dosing compound well identify adverse effects could limit compounds usefulness data phase ii trials satisfactory company commences largescale phase iii trials confirm compounds efficacy safety upon completion trials satisfactory company submits regulatory filings appropriate regulatory agencies around world product candidate approved marketing assurance compound result particular program obtain regulatory approvals necessary marketed vaccine development follows general pathway drugs preclinical testing focuses vaccines safety ability elicit protective immune response immunogenicity premarketing vaccine clinical trials typically done three phases initial phase clinical studies conducted normal subjects evaluate safety tolerability immunogenicity vaccine candidate phase ii studies doseranging studies finally phase iii trials provide necessary data effectiveness safety successful company submits regulatory filings appropriate regulatory agencies also stage proposed manufacturing facility undergoes preapproval inspection production vaccine progress examined detail united states fda review process begins complete nda submitted received fda pursuant prescription drug user fee act fda review period targets ndas supplemental ndas either six months priority review ten months standard review within days receipt nda fda determines application sufficiently complete permit substantive review fda also assesses time whether application granted priority review standard review review timelines defined fda generally act upon application within timelines unless major amendment submitted either companys initiative fdas request pending application occurs fda may extend review period allow review new information days extensions review period communicated company fda act application issuing approval letter complete response letter research development update company currently number candidates regulatory review united states internationally boceprevir investigational oral hepatitis c virus protease inhibitor currently development full data results two pivotal latestage studies boceprevir presented november annual meeting american association study liver disease showed boceprevir demonstrated significantly higher sustained virologic response rates adult patients previously failed treatment adult patients new treatment chronic hepatitis c virus genotype compared control primary objective studies based data regulatory applications boceprevir submitted accepted expedited review united states eu mka xr companys investigational extendedrelease formulation janumet accepted standard review fda company also moving forward planned regulatory filings countries outside united states extendedrelease formulation janumet investigational treatment type diabetes combines sitagliptin active component januvia metformin extended release commonlyprescribed medication type diabetes single tablet formulation designed provide new treatment option health care providers patients need two oral agents help control blood sugar convenience daily dosing sch nomace oral contraceptive combines selective progestin beta estradiol estrogen identical one naturally present womens body drug currently review eu also phase iii development us market mk cubicin daptomycin injection currently review japan previously disclosed cubist pharmaceuticals inc cubist entered license agreement old merck development commercialization cubicin treatment staph infection japan company commercial rights drug candidate merck develop commercialize cubicin whollyowned subsidiary japan cubist commercializes cubicin united states mkd combination januvia zocor treatment diabetes dyslipidemia accepted standard review fda addition candidates regulatory review company drug candidates phase iii development vorapaxar thrombin receptor antagonist antiplatelet protease activated receptor inhibitor studied prevention treatment thrombosis merck studying vorapaxar two major clinical endpoint trials evaluate investigational medicine prevention cardiac events tracer study patients acute coronary syndrome ended trap also known timi study patients prior heart attack stroke peripheral artery disease continuing large part studies designed eventdriven trials patients planned followed minimum one year completed enrollment january merck announced combined data safety monitoring board dsmb two studies reviewed available safety efficacy data made recommendations study changes chairpersons steering committees two studies study chairpersons agreed implement changes result tracer study patients discontinue study drug investigators begin close study timely orderly fashion trap study study drug continued patients experienced previous heart attack peripheral arterial disease approximately patients enrolled study immediately discontinued patients experienced stroke prior entry study course study merck subsequently announced chairman trap study reported investigators dsmb communicated based data safety efficacy available trials recommended subjects history stroke receive vorapaxar dsmb observed increase intracranial hemorrhage patients history stroke outweighed considerations potential benefit merck plans update projections regulatory filings vorapaxar company received efficacy safety data tracer determine updated completion date trap tracer accumulated predefined number primary major secondary endpoints although patients continue receive study drug pre specified oneyear follow merck continues expect efficacy safety data tracer become available later submitted presentation appropriate medical meetings result developments company concluded impairment triggering event related vorapaxar intangible asset although great deal information related developments remains unknown company utilizing market participant assumptions considering several different scenarios company concluded best estimate current fair value intangible asset related vorapaxar million resulted recognition impairment charge billion company continue monitor remaining asset value impairment mk ridaforolimus novel mtor mammalian target rapamycin inhibitor evaluated treatment cancer merck currently developing ridaforolimus multiple cancer indications exclusive license collaboration agreement ariad pharmaceuticals inc ariad january ariad announced topline data showing ridaforolimus met primary endpoint improved progressionfree survival compared placebo phase iii succeed trial conducted patients metastatic soft tissue bone sarcomas previously favorable response chemotherapy complete findings succeed trial submitted presentation upcoming medical meeting trial remains active study participants continue followed gather additional data secondary endpoints including overall survival safety profile ridaforolimus merck currently plans file nda fda oral ridaforolimus subject final collection analysis available data trial mk saflutan tafluprost preservative free synthetic analogue prostaglandin f reduction elevated intraocular pressure appropriate patients primary openangle glaucoma ocular hypertension april old merck santen pharmaceutical co ltd announced worldwide licensing agreement tafluprost company continues anticipate filing nda fda saflutan previously disclosed old merck submitted filing nda fda mkc ezetimibe combined atorvastatin investigational medication treatment dyslipidemia fda refused file application fda identified additional manufacturing stability data needed company anticipates filing nda previously disclosed old merck announced delaying filing us application mk telcagepant companys investigational calcitonin generelated peptide cgrpreceptor antagonist acute treatment migraine decision based findings phase iia exploratory study small number patients taking telcagepant twice daily three months prevention migraine found marked elevations liver transaminases daily dosing regimen prevention study different dosing regimen used phase iii studies telcagepant intermittently administered one two doses treat individual migraine attacks occurred following meetings regulatory agencies end merck conducting additional safety study part overall phase iii program telcagepant company continues anticipate filing nda fda sch bridion sugammadex medication designed rapidly reverse effects certain muscle relaxants used part general anesthesia ensure patients remain immobile surgical procedures bridion received regulatory approval eu australia new zealand japan number markets prior merger scheringplough received complete response letter fda bridion following communication fda company assessing agencys feedback order determine new timetable response sch investigational allergy immunotherapy sublingual tablet ait grass pollen allergy company north american rights march data phase iii study children adolescents ages years grass pollen allergic rhinoconjunctivitis presented american academy allergy asthma immunology annual meeting allergic rhinoconjunctivitis runny nose itchy watery eyes due allergies common condition children adolescents ait dissolvable oral tablet designed prevent allergy symptoms inducing protective immune response allergies thereby treating underlying cause disease merck investigating ait treatment grass pollen allergic rhinoconjunctivitis children adults anticipated us filing date sch assessment sch ait ragweed allergy also phase iii development north american market anticipated filing date sch assessment sch zenhale fixed dose combination two previously approved drugs treatment asthma mometasone furoate formoterol fumarate dehydrate november company advised european medicines agency ema withdrawing application marketing authorization zenhale approved use asthma patients years age older united states dulera inhalation aerosol company decided withdraw application zenhale address questions outstanding company committee medicinal products human use ema company expects resubmit application future mkc candidate currently phase iii clinical development combines januvia pioglitazone another type diabetes therapy company expects file nda mkc fda mk odanacatib oral onceweekly investigational treatment osteoporosis postmenopausal women osteoporosis disease reduces bone density strength results increased risk bone fractures odanacatib cathepsin k inhibitor selectively inhibits cathepsin k enzyme cathepsin k known play central role function osteoclasts cells break existing bone tissue particularly protein components bone inhibition cathepsin k novel approach treatment osteoporosis fouryear data odanacatib presented october american society bone mineral research annual meeting clinical preclinical studies continue provide data potential odanacatib increase bone density cortical thickness bone strength treating osteoporosis company continues anticipate filing nda fda v ninevalent hpv vaccine development expand protection cancercausing hpv types phase iii clinical program underway merck anticipates filing bla fda mka drug candidate combines extendedrelease niacin novel flushing inhibitor laropiprant mka demonstrated ability lower ldlcholesterol ldlc bad cholesterol raise hdlcholesterol hdlc good cholesterol lower triglycerides significantly less flushing traditional extended release niacin alone high ldl c low hdlc elevated triglycerides risk factors associated heart attacks strokes april old merck received nonapprovable action letter fda response nda mka meeting discuss letter fda stated additional efficacy safety data required suggested old merck wait results treatment hdl reduce incidence vascular events hpsthrive cardiovascular outcomes study expected completed company anticipates filing nda fda mk mka approved countries outside united states treatment dyslipidemia particularly patients combined mixed dyslipidemia characterized elevated levels ldlc triglycerides low hdlc patients primary hypercholesterolemia heterozygous familial nonfamilial marketed tredaptive cordaptive certain countries tredaptive used patients combination statins cholesterol lowering effects statin monotherapy inadequate tredaptive used monotherapy patients statins considered inappropriate tolerated mkb drug candidate combines novel approach raising hdlc lowering triglycerides extendedrelease niacin combined laropiprant proven benefits simvastatin one combination product merck seek approval mkb united states files complete response relating mka mk investigational dual orexin receptor antagonist potential new approach treatment chronic insomnia currently phase iii development june clinical results phase iib study presented annual meeting associated professional sleep societies showed mk significantly effective placebo improving overall sleep efficiency night one end week four patients primary insomnia mk generally welltolerated study orexins neuropeptides chemical messengers released specialized neurons hypothalamus region brain believed important regulator brains sleepwake process phase iii trials studying efficacy safety mk elderly nonelderly insomnia patients ongoing merck anticipates filing regulatory applications mk sch elonva corifollitropin alpha injection approved eu controlled ovarian stimulation combination gnrh antagonist development multiple follicles women participating assisted reproductive technology program currently phase iii development united states company continues anticipate filing nda fda sch preladenant selective adenosine receptor antagonist phase iii development treatment parkinsons disease company continues anticipate filing nda fda beyond v inactivated varicellazoster virus vaccine phase iii development prevention herpes zoster company anticipates filing nda fda beyond mk anacetrapib investigational inhibitor cholesteryl ester transfer protein cetp investigated lipid management raise hdlc reduce ldlc november researchers presented results phase iii define determining efficacy tolerability cetp inhibition anacetrapib study anacetrapib american heart association scientific sessions trial patients coronary heart disease chd chd risk equivalents anacetrapib showed significant differences placebo primary safety measures studied significant differences mean changes blood pressure anacetrapib placebo treatment groups significant differences serum electrolytes aldosterone levels week treatment phase prespecified adjudicated cardiovascular endpoint defined cardiovascular death myocardial infarction unstable angina stroke occurred anacetrapibtreated patients compared placebotreated patients weeks anacetrapib decreased ldlc increased hdlc patients already treated statin guidelinerecommended ldlc goal based results company intends move forward study anacetrapib large cardiovascular clinical outcomes trial company anticipates filing nda fda beyond chart reflects companys current research pipeline february candidates shown phase iii include specific products candidates shown phase ii include advanced compound specific mechanism listed compounds mechanism currently intended commercialization given therapeutic area small molecules biologics given mknumber schnumber designations vaccine candidates given vnumber designations candidates phase additional indications therapeutic area additional claims line extensions formulations inline products shown phase ii allergy sch immunotherapy cancer mk dalotuzumab sch dinaciclib clostridium difficile infection mka contraception medicated ius sch copd sch navarixin diabetes mellitus mk hepatitis c mk vaniprevir insomnia mk mk osteoporosis mk pediatric vaccine v pneumoconjugate vaccine v progeria sch lonafarnib psoriasis sch staph infection v thrombosis mk betrixaban phase iii allergy sch grass pollen sch ragweed asthma sch zenhale eu atherosclerosis mka extendedrelease niacin laropiprant us mkb extendedrelease niacin laropiprantsimvastatin mk anacetrapib cervical cancer v hpv vaccine valent contraception sch nomace us diabetes mkc sitagliptinpioglitazone fertility sch corifollitropin alfa injection us glaucoma mk saflutan us insomnia mk suvorexant migraine mk telcagepant neuromuscular blockade reversal sch bridion us osteoporosis mk odanacatib parkinsons disease sch preladenant sarcoma mk ridaforolimus thrombosis sch vorapaxar herpes zoster v inactivated vzv vaccine combination products development atherosclerosis mkc ezetimibeatorvastatin review contraception sch nomace eu staph infection mk daptomycin injection diabetes mka xr sitagliptin extendedrelease metformin us mkd sitagliptinsimvastatin hepatitis c sch boceprevir footnotes north american rights japanese rights employees december company approximately employees worldwide approximately employed united states including puerto rico approximately worldwide employees company represented various collective bargaining groups february company commenced actions global restructuring program merger restructuring program conjunction integration legacy merck legacy scheringplough businesses merger restructuring program intended optimize cost structure combined company additional actions program continued part restructuring actions taken thus far merger restructuring program company anticipates substantially completed end exception certain manufacturing facilities actions company expects reduce total workforce measured time merger approximately across company worldwide addition company eliminated positions vacant time merger workforce reductions primarily come elimination duplicative positions sales administrative headquarters organizations well sale closure certain manufacturing research development sites consolidation office facilities since inception program december company eliminated positions program position eliminations comprised actual headcount reductions elimination contractors vacant positions october old merck announced global restructuring program restructuring program reduce cost structure increase efficiency enhance competitiveness part restructuring program company expects eliminate approximately positions active employees vacancies across company worldwide end reductions occur united states since inception program december company eliminated positions including vacancies program prior merger scheringplough commenced productivity transformation program designed reduce avoid costs increase productivity position eliminations associated program largely complete environmental matters company believes compliance issues associated applicable environmental laws regulations would material adverse effect company company also remediating environmental contamination resulting past industrial activity certain sites expenditures remediation environmental liabilities million million million estimated million years amounts consider potential recoveries parties company taken active role identifying providing costs managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million december although possible predict certainty outcome environmental matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures material adverse effect companys financial position results operations liquidity capital resources year merck believes climate change could present risks business potential impacts climate change business include increased operating costs due additional regulatory requirements physical risks companys facilities water limitations disruptions supply chain potential risks integrated companys business planning including investment reducing energy water use greenhouse gas emissions company believe risks material business time geographic area information companys operations outside united states conducted primarily subsidiaries sales worldwide subsidiaries outside united states sales sales sales increase proportion sales outside united states primarily due inclusion results scheringplough following close merger companys worldwide business subject risks currency fluctuations governmental actions governmental proceedings abroad company regard risks deterrent expansion operations abroad however company closely reviews methods operations adopts strategies responsive changing economic political conditions result merger merck expanded operations countries located latin america middle east africa eastern europe asia pacific business developing areas sometimes less stable offers important opportunities growth time financial information geographic areas companys business discussed item financial statements supplementary data available information companys internet website address wwwmerckcom company make available free charge investors portion website annual report quarterly reports form q current reports form k amendments reports filed furnished pursuant section securities exchange act amended soon reasonably practicable reports electronically filed furnished securities exchange commission sec companys corporate governance guidelines charters board directors six standing committees available companys website wwwmerckcomaboutleadership information available print stockholder requests company item risk factors investors carefully consider information set forth including following risk factors deciding invest companys securities risks ones company faces additional risks currently known company company presently deems immaterial may also impair business operations companys business financial condition results operations prospects could materially adversely affected risks also contains forwardlooking statements involve risks uncertainties companys results could materially differ anticipated forwardlooking statements result certain factors including risks faces described elsewhere see cautionary factors may affect future results certain companys major products going lose patent protection near future occurs company expects significant decline sales products company depends upon patents provide exclusive marketing rights products period time product patents several companys products recently expired united states countries company faces strong competition lower priced generic drugs loss patent protection one companys products typically leads rapid loss sales product lower priced generic versions drug become available case products contribute significantly companys sales loss patent protection material adverse effect companys business cash flow results operations financial position prospects patent provides us market exclusivity singulair companys largest selling product us sales approximately billion expires august company expects within two years following patent expiration lose substantially us sales singulair declines coming first full year following patent expiration also patent singulair expire number major european markets august company expects sales singulair markets decline significantly thereafter although six month pediatric market exclusivity may extend date markets february addition patent provides us market exclusivity maxalt expire june although six month pediatric market exclusivity may extend date december company expects significant decline us sales thereafter addition previously disclosed astrazeneca right exercise options acquire companys interest nexium prilosec company believes likely astrazeneca exercise right chart listing us patent protection companys major marketed products set forth item business patents trademarks licenses company dependent patent rights patent rights invalidated circumvented business would adversely affected patent protection considered aggregate material importance companys marketing human health products united states major foreign markets patents covering products introduced normally provide market exclusivity important successful marketing sale products company seeks patents covering products markets intends sell products meaningful patent protection available even company succeeds obtaining patents covering products third parties government authorities may challenge seek invalidate circumvent patents patent applications important companys business defend successfully patent rights provide market exclusivity products company often involved patent disputes relating challenges patents infringement similar claims company company aggressively defends important patents within outside united states including filing claims infringement parties see item financial statements supplementary data note contingencies environmental liabilities particular manufacturers generic pharmaceutical products time time file abbreviated new drug applications anda fda seeking market generic forms companys products prior expiration relevant patents owned company company normally responds vigorously defending patent including filing lawsuits alleging patent infringement patent litigation challenges companys patents costly unpredictable may deprive company market exclusivity patented product cases third party patents may prevent company marketing selling product particular geographic area additionally certain foreign governments indicated compulsory licenses patents may granted case national emergencies could diminish eliminate sales profits regions negatively affect companys results operations recent court decisions relating companies us patents potential us legislation relating patent reform well regulatory initiatives may result erosion intellectual property protection one important products lose patent protection profitable markets sales products likely decline significantly result generic versions products becoming available case certain legacy scheringplough msp partnership products loss could result material noncash impairment charge companys results operations may adversely affected lost sales unless company successfully launched commercially successful replacement products patent provides us market exclusivity companys largest selling product singulair expires august company expects within two years following patent expiration lose substantially us sales singulair declines coming first full year following patent expiration also patent singulair expire number major european markets august company expects sales singulair markets decline significantly thereafter although six month pediatric market exclusivity may extend date markets february key company products generate significant amount companys profits cash flows events adversely affect markets leading products could material negative impact results operations cash flows companys ability generate profits operating cash flow depends largely upon continued profitability companys key products singulair remicade vytorin zetia januvia nasonex isentress temodar result companys dependence key products event adversely affects products markets products could significant impact results operations cash flows events could include loss patent protection increased costs associated manufacturing generic overthecounter availability companys product competitive product discovery previously unknown side effects increased competition introduction new effective treatments discontinuation removal market product reason events material adverse effect sales certain legacy scheringplough msp partnership products event could result material noncash impairment charge companys research development efforts may succeed developing commercially successful products company may able acquire commercially successful products ways consequence company may able replace sales successful products lost patent protection like major pharmaceutical companies order remain competitive company must continue launch new products year declines sales products cozaar hyzaar fosamax loss market exclusivity mean companys future success dependent pipeline new products including new products may develop joint ventures products able obtain license acquisition accomplish company commits substantial effort funds resources research development dedicated resources various collaborations third parties high rate failure inherent research develop new drugs treat diseases result high risk funds invested company research programs generate financial returns risk profile compounded fact research long investment cycle bring pharmaceutical compound discovery phase market may take decade failure occur point process including later process significant funds invested description research development process see research development phase testing highly regulated phase substantial risk company encounter serious obstacles achieve goals accordingly company may abandon product invested substantial amounts time resources risks encountered research development process include following preclinical testing new compound may yield disappointing results clinical trials new drug may successful new drug may effective may harmful side effects new drug may approved fda intended use may possible obtain patent new drug sales new product may disappointing company state certainty whether products development approved launched whether able develop license otherwise acquire compounds product candidates products whether products launched commercially successful company must maintain continuous flow successful new products successful new indications brand extensions existing products sufficient cover substantial research development costs replace sales lost profitable products cozaar hyzaar singular lose patent protection displaced competing products therapies failure short term long term would material adverse effect companys business results operations cash flow financial position prospects companys success dependent successful development marketing new products subject substantial risks products appear promising development may fail reach market numerous reasons including following findings ineffectiveness superior safety efficacy competing products harmful side effects clinical preclinical testing failure receive necessary regulatory approvals including delays approval new products new indications increasing uncertainties time required obtain regulatory approvals benefitrisk standards applied regulatory agencies determining whether grant approvals lack economic feasibility due manufacturing costs factors preclusion commercialization proprietary rights others connection merger company assessed prioritized pipeline identify promising highpotential compounds development future certain legacy scheringplough pipeline programs cancelled company believes commercial prospects reduced company may recognize material noncash impairment charges programs measured fair value capitalized connection merger noncash impairment charges company anticipates would excluded companys nongaap earnings could material companys future gaap earnings example discussed company recognized noncash impairment charge billion respect vorapaxar legacy scheringplough pipeline program companys products including products development marketed unless company obtains maintains regulatory approval companys activities including research preclinical testing clinical trials manufacturing marketing products subject extensive regulation numerous federal state local governmental authorities united states including fda foreign regulatory authorities including eu united states fda particular importance company administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals many cases fda requirements increased amount time money necessary develop new products bring market united states regulation outside united states also primarily focused drug safety effectiveness many cases cost reduction fda foreign regulatory authorities substantial discretion require additional testing delay withhold registration marketing approval mandate product withdrawals even company successful developing new products able market products unless obtained required regulatory approvals jurisdiction proposes market new products obtained company must maintain approval long plans market new products jurisdiction approval required companys failure obtain approval significant delays approval process failure maintain approval jurisdiction prevent selling new products jurisdiction approval obtained ever company would able realize revenues new products jurisdiction approval company faces intense competition lowercost generic products general company faces increasing competition lowercost generic products patent rights protect products varying strengths durations addition countries patent protection significantly weaker united states eu united states political pressure reduce spending prescription drugs led legislation encourages use generic products although companys policy actively protect patent rights generic challenges companys products arise time may able prevent emergence generic competition products loss patent protection product typically followed promptly generic substitutes reducing companys sales product availability generic substitutes companys drugs may adversely affect results operations cash flow addition proposals emerge time time united states countries legislation encourage early rapid approval generic drugs proposal enacted law could worsen substantial negative effect companys sales potentially business cash flow results operations financial position prospects company faces intense competition competitors products addition factors could certain circumstances lead noncash impairment charges companys products face intense competition competitors products competition may increase new products enter market event competitors products may safer effective effectively marketed sold companys products alternatively case generic competition including generic availability competitors branded products may equally safe effective products sold substantially lower price companys products result company fails maintain competitive position could material adverse effect business cash flow results operations financial position prospects addition legacy scheringplough products measured fair value capitalized connection merger saphris former msp partnership products vytorin zetia experience difficulties market negatively impact product cash flows company may recognize material noncash impairment charges respect value products noncash impairment charges company anticipates would excluded companys nongaap earnings could material companys future gaap earnings current uncertainty global economic conditions together austerity measures taken governments europe could negatively affect companys operating results current uncertainty global economic conditions may result slowdown global economy could affect companys business reducing prices drug wholesalers retailers hospitals government agencies managed health care providers may able willing pay companys products reducing demand companys products could turn negatively impact companys sales result material adverse effect companys business cash flow results operations financial position prospects many companys brands experienced positive growth trends eu environment eu across europe challenging many countries announced austerity measures aimed reducing costs areas health care implementation pricing actions varies country many announced measures reduce prices generic patented drugs company taking steps mitigate immediate impact eu possible austerity measures could negatively affect companys revenue performance beyond company anticipates company faces pricing pressure respect products company faces increasing pricing pressure globally managed care organizations institutions government agencies programs could negatively affect companys sales profit margins united states include practices managed care groups institutional governmental purchasers ii us federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act patient protection affordable care act changes health care system enacted part health care reform united states well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries could result pricing pressures increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries could result pricing pressures outside united states numerous major markets pervasive government involvement funding health care regard fix pricing reimbursement pharmaceutical vaccine products consequently markets company subject government decision making budgetary actions respect products company expects pricing pressures increase future health care industry continue subject increasing regulation political action company believes health care industry continue subject increasing regulation well political legal action future proposals reform health care system considered congress state legislatures major health care reform adopted law united states important market reforms began last year continue full implementation new law expected expand access health care million americans end decade merck incurred additional costs result new law including increased medicaid rebates impacts reduced revenues minimum rebate states participating medicaid program increased companys branded prescription drugs medicaid rebate extended medicaid managed care organizations eligibility federal b drug discount program extended rural referral centers sole community hospitals critical access hospitals certain free standing cancer hospitals certain additional childrens hospitals beginning law requires drug manufacturers pay discount medicare part utilization incurred beneficiaries medicare part coverage gap ie socalled donut hole also beginning company incur annual health care reform fee assessed branded prescription drug manufacturers importers fee calculated based industrys total sales branded prescription drugs specified government programs percentage manufacturers sales included determined tiered scale based manufacturers individual revenues manufacturers portion total annual fee fee billion based manufacturers proportion total includable sales prior year company predict likelihood future changes health care industry general pharmaceutical industry particular impact may companys results operations financial condition business company experiencing difficulties delays manufacturing certain products previously disclosed old merck past experienced difficulties manufacturing certain vaccines products issues continuing particular respect manufacture companys varicella zoster viruscontaining vaccines varivax proquad zostavax similarly company past experienced difficulties manufacturing certain animal health products currently experiencing difficulty manufacturing certain womens health products company working issues assurance issues finally resolved addition difficulties company experiencing currently company may experience difficulties delays inherent manufacturing products failure company vendors suppliers comply current good manufacturing practices applicable regulations quality assurance guidelines could lead manufacturing shutdowns product shortages delays product manufacturing ii construction delays related construction new facilities expansion existing facilities including intended support future demand companys products iii manufacturing distribution problems including changes manufacturing production sites limits manufacturing capacity due regulatory requirements changes types products produced physical limitations could impact continuous supply manufacturing difficulties result product shortages leading lost sales company faces significant litigation related vioxx september old merck voluntarily withdrew vioxx arthritis acute pain medication market worldwide although old merck settled major portion us product liability litigation company still faces material litigation arising voluntary withdrawal vioxx addition vioxx product liability lawsuits various purported class actions individual lawsuits brought old merck several current former officers directors old merck alleging old merck made false misleading statements regarding vioxx violation federal state securities laws suits referred vioxx securities lawsuits vioxx securities lawsuits transferred judicial panel multidistrict litigation jpml us district court district new jersey district judge stanley r chesler inclusion nationwide mdl shareholder mdl consolidated purposes june old merck moved dismiss fifth amended class action complaint consolidated securities class action plaintiffs filed opposition august old merck filed reply september motion currently pending district court addition several individual securities lawsuits filed foreign institutional investors also consolidated vioxx securities lawsuits stipulation defendants required respond complaints resolution motions dismiss consolidated securities class action addition various putative class actions brought old merck several current former employees officers directors company alleging violations erisa suits referred vioxx erisa lawsuits together vioxx securities lawsuits vioxx shareholder lawsuits vioxx shareholder lawsuits discussed fully item financial statements supplementary data note contingencies environmental liabilities old merck also named defendant actions various countries outside united states suits referred vioxx foreign lawsuits old merck also sued states one county private citizen qui tam lawsuit respect marketing vioxx us department justice doj issued subpoenas requesting information relating old mercks research marketing selling activities respect vioxx federal health care investigation criminal statutes investigation includes subpoenas witnesses appear grand jury previously disclosed march old merck received letter us attorneys office district massachusetts identifying target grand jury investigation regarding vioxx company established million reserve vioxx liability reserve connection anticipated resolution dojs investigation companys discussions government ongoing concluded certainty definitive resolution also ongoing investigations local authorities europe company cooperating authorities investigations investigations including doj investigation referred vioxx investigations company predict outcome investigations however could result potential civil andor criminal remedies vioxx product liability litigation discussed fully item financial statements supplementary data note contingencies environmental liabilities company currently anticipates three us vioxx product liability lawsuits tried company predict timing trials related vioxx litigation company believes meritorious defenses vioxx product liability lawsuits vioxx shareholder lawsuits vioxx foreign lawsuits collectively vioxx lawsuits vigorously defend companys insurance coverage respect vioxx lawsuits adequate cover defense costs losses merck spent approximately million aggregate legal defense costs worldwide related vioxx lawsuits ii vioxx investigations collectively vioxx litigation merck recorded charges million add reserve solely future legal defense costs related vioxx litigation million december million december vioxx legal defense costs reserve amount vioxx legal defense costs reserve based certain assumptions described item financial statements supplementary data note contingencies environmental liabilities best estimate minimum amount defense costs company believes incurred connection remaining aspects vioxx litigation however events additional trials vioxx litigation events could arise course vioxx litigation could affect ultimate amount defense costs incurred company addition mentioned company established vioxx liability reserve connection anticipated resolution dojs investigation company currently able estimate additional amounts may required pay connection vioxx lawsuits vioxx investigations proceedings still expected continue years company predict course proceedings take view inherent difficulty predicting outcome litigation particularly many claimants claimants seek unspecified damages company unable predict outcome matters time reasonably estimate possible loss range loss respect vioxx lawsuits included settlement program vioxx liability reserve company established reserves potential liability relating vioxx lawsuits included settlement program vioxx investigations series unfavorable outcomes vioxx lawsuits vioxx investigations resulting payment substantial damages fines resulting criminal penalties could material adverse effect companys business cash flow results operations financial position prospects issues concerning vytorin enhance clinical trial adverse effect sales vytorin zetia united states results ongoing trials could adverse effect sales company sells vytorin zetia previously disclosed january legacy companies announced results enhance clinical trial imaging trial patients heterozygous familial hypercholesterolemia rare genetic condition causes high levels ldl bad cholesterol greatly increases risk premature coronary artery disease previously reported despite fact ezetimibesimvastatin mg vytorin significantly lowered ldl bad cholesterol simvastatin mg alone significant difference treatment ezetimibesimvastatin simvastatin alone prespecified primary endpoint change thickness carotid artery walls two years measured ultrasound improveit trial underway designed provide cardiovascular outcomes data ezetimibesimvastatin patients acute coronary syndrome incremental benefit ezetimibesimvastatin cardiovascular morbidity mortality demonstrated simvastatin established january fda announced completed review final clinical study report enhance fda stated results enhance change position elevated ldl cholesterol risk factor cardiovascular disease lowering ldl cholesterol reduces risk cardiovascular disease discussion concerning shareholder litigation arising enhance study see item financial statements supplementary data note contingencies environmental liabilities improveit trial scheduled completion improveit trial blinded interim efficacy analysis conducted dsmb trial approximately endpoints accrued dsmb recommended continuing trial changes study protocol another blinded interim efficacy analysis planned dsmb approximately primary events accrued based results interim analysis trial halted concerns related vytorin could material adverse effect sales vytorin zetia following announcements enhance clinical trial results sales vytorin zetia declined united states issues concerning enhance clinical trial adverse effect sales vytorin zetia could continue adverse effect sales sales products materially adversely affected companys business cash flow results operations financial position prospects could also materially adversely affected addition unfavorable outcomes resulting litigation concerning sale promotion products could material adverse effect companys business cash flow results operations financial position prospects arbitration proceeding commenced centocor scheringplough may result companys loss rights market remicade simponi subsidiary company party distribution agreement centocor wholly owned subsidiary johnson johnson scheringplough subsidiary rights distribute commercialize rheumatoid arthritis treatment remicade simponi nextgeneration treatment certain territories section c distribution agreement either party acquired third party otherwise comes control defined section distribution agreement third party promptly notify party subject change control party subject change control right however later thirty days notification notify writing party subject change control termination agreement taking effect immediately used herein change control shall mean merger reorganization consolidation combination party agreement surviving corporation ii person within meaning section section securities exchange act excluding partys affiliates becomes beneficial owner directly indirectly securities party representing fifty percent either thenoutstanding shares common stock party b combined voting power partys thenoutstanding voting securities iii individuals effective date april constitute board directors party incumbent board cease reason constitute least majority board directors party provided however individual becoming director subsequent effective date whose election nomination election partys shareholders approved vote least majority directors comprising incumbent board shall considered though individual member incumbent board excluding purpose individual whose initial assumption office occurs result actual threatened election contest respect election removal directors actual threatened solicitation proxies consents behalf person board iv approval shareholders party complete liquidation complete dissolution party section distribution agreement defines control mean ability entity controlling entity directly indirectly ownership securities agreement method direct manner fifty percent outstanding voting rights entity controlled entity whether represented securities shall cast right receive fifty percent profits earnings otherwise control management decisions entity also controlled entity may centocor delivered scheringplough notice initiating arbitration proceeding resolve whether result proposed merger centocor permitted terminate distribution agreement related agreements part arbitration process centocor taken position right terminate distribution agreement grounds merger scheringplough scheringplough subsidiary party distribution agreement acquired third party otherwise comeing control defined section third party andor ii undergoing change control defined section c company vigorously contesting centocors attempt terminate distribution agreement result merger hearing arbitration completed late december arbitration panel conclude centocor permitted terminate distribution agreement result merger centocor fact terminates distribution agreement companys subsidiary would able distribute remicade simponi addition arbitration centocor claiming damages amount determined result mercks alleged nontermination distribution agreement centocor prevail arbitration merck could liable net damages including offsets mitigation arbitration panel finds centocor incurred result nontermination sales remicade simponi billion million respectively unfavorable outcome arbitration would material adverse effect companys financial position liquidity results operations addition company would required record material noncash impairment charge respect termination marketing rights finally due uncertainty surrounding outcome arbitration parties may choose settle dispute mutually agreeable terms agreement reached centocor resolve dispute distribution agreement may result terms distribution agreement modified manner may reduce benefits distribution agreement company pharmaceutical products develop unexpected safety efficacy concerns unexpected safety efficacy concerns arise respect marketed products whether scientifically justified leading product recalls withdrawals declining sales well product liability consumer fraud andor claims changes laws regulations could adversely affect companys business aspects companys business including research development manufacturing marketing pricing sales litigation intellectual property rights subject extensive legislation regulation changes applicable federal state laws agency regulations could material adverse effect companys business reliance third party relationships outsourcing arrangements could adversely affect companys business company depends third parties including suppliers alliances pharmaceutical biotechnology companies third party service providers key aspects business including development manufacture commercialization products support information technology systems failure third parties meet contractual regulatory obligations company development factors materially disrupt relationships company third parties could material adverse effect companys business company increasingly dependent sophisticated information technology infrastructure company increasingly dependent sophisticated information technology infrastructure significant breakdown intrusion interruption corruption systems data breaches could material adverse effect business addition company currently proceeding multiyear implementation enterprise wide resource planning system implemented united states includes modification design operation documentation internal controls financial reporting company intends implement resource planning system major european markets canada material problems implementation could material adverse effect companys business developments following regulatory approval may adversely affect sales companys products even product reaches market certain developments following regulatory approval including results postmarketing phase iv trials may decrease demand companys products including following rereview products already marketed new scientific information evolution scientific theories recall loss marketing approval products already marketed changing government standards public expectations regarding safety efficacy labeling changes greater scrutiny advertising promotion past several years clinical trials postmarketing surveillance certain marketed drugs company competitors within industry raised safety concerns led recalls withdrawals adverse labeling marketed products clinical trials postmarketing surveillance certain marketed drugs also raised concerns among prescribers patients relating safety efficacy pharmaceutical products general negatively affected sales products addition increased scrutiny outcomes clinical trials led increased volatility market reaction matters often attract litigation even basis litigation groundless considerable resources may needed respond addition following wake product withdrawals significant safety issues health authorities fda ema pharmaceutical medical device agency increased focus safety assessing benefitrisk balance drugs health authorities appear become cautious making decisions approvability new products indications rereviewing select products already marketed adding uncertainties regulatory processes also greater regulatory scrutiny especially united states advertising promotion particular directtoconsumer advertising previously unknown side effects discovered increase negative publicity regarding known side effects companys products could significantly reduce demand product require company take actions could negatively affect sales including removing product market restricting distribution applying labeling changes current environment pharmaceutical companies operate company risk product liability claims products negative events animal health industry could negative impact future results operations future sales key animal health products could adversely impacted number risk factors including certain risks specific animal health business example outbreak disease carried animals bovine spongiform encephalopathy bse mad cow disease could lead widespread death precautionary destruction well reduced consumption demand animals could adversely impact companys results operations also outbreak highly contagious diseases near companys main production sites could require company immediately halt production vaccines sites force company incur substantial expenses procuring raw materials vaccines elsewhere risks specific animal health include epidemics pandemics government procurement pricing practices weather global agribusiness economic events animal health segment companys business becomes significant impact events future results operations would also become significant company working sanofiaventis create animal health joint venture previously disclosed company agreed create animal health joint venture sanofiaventis agreement companies contribute respective animal health businesses new equallyowned joint venture transaction expected close third quarter animal health joint venture established period integration animal health business could suffer possible integration process could result loss key employees result disruption companys ongoing animal health business identify inconsistencies standards controls procedures policies adversely affect joint ventures ability maintain relationships customers suppliers distributors parties disruption integration process could material adverse effect joint ventures business expected important contributor companys business results operations formation animal health joint venture expected dilutive companys earnings first months transaction closes biologics carry unique risks uncertainties could negative impact future results operations successful development testing manufacturing commercialization biologics particularly human animal health vaccines long expensive uncertain process unique risks uncertainties biologics including may limited access supply normal diseased tissue samples cell lines pathogens bacteria viral strains biological materials addition government regulations multiple jurisdictions united states european states within eu could result restricted access transport use materials company loses access sufficient sources materials tighter restrictions imposed use materials company may able conduct research activities planned may incur additional development costs development manufacturing marketing biologics subject regulation fda ema regulatory bodies regulations often complex extensive regulations applicable pharmaceutical products example united states bla including preclinical clinical trial data extensive data regarding manufacturing procedures required human vaccine candidates fda approval required release manufactured lot manufacturing biologics especially large quantities often complex may require use innovative technologies handle living microorganisms lot approved biologic must undergo thorough testing identity strength quality purity potency manufacturing biologics requires facilities specifically designed validated purpose sophisticated quality assurance quality control procedures necessary slight deviations anywhere manufacturing process including filling labeling packaging storage shipping quality control testing may result lot failures product recalls spoilage changes made manufacturing process company may required provide preclinical clinical data showing comparable identity strength quality purity potency products changes biologics frequently costly manufacture production ingredients derived living animal plant material biologics made synthetically particular keeping demand vaccines may difficult due complexity producing vaccines use biologically derived ingredients lead allegations harm including infections allergic reactions closure product facilities due possible contamination events could result substantial costs company exposed market risk fluctuations currency exchange rates interest rates company operates multiple jurisdictions virtually sales denominated currencies local jurisdiction additionally company entered enter acquisition licensing borrowings financial transactions may give rise currency interest rate exposure since company certainty foresee mitigate adverse fluctuations fluctuations currency exchange rates interest rates could negatively affect companys results operations financial position cash flows order mitigate adverse impact market fluctuations company time time enter hedging agreements hedging agreements currency options interest rate swaps may limit exposure exchange rate interest rate fluctuations attempts mitigate risks may costly always successful company subject evolving complex tax laws may result additional liabilities may affect results operations company subject evolving complex tax laws jurisdictions operates significant judgment required determining companys tax liabilities companys tax returns periodically examined various tax authorities company believes accrual tax contingencies adequate open years based past experience interpretations tax law judgments potential actions tax authorities however due complexity tax contingencies ultimate resolution tax matters may result payments greater less amounts accrued february president obamas administration proposed significant changes us international tax laws including changes would limit us tax deductions expenses related unrepatriated foreignsource income modify us foreign tax credit rules determine whether proposals enacted law changes may made proposals prior enacted law changes us international tax laws enacted could significant impact financial results company addition company may impacted changes tax laws including tax rate changes changes laws related remittance foreign earnings deferral limitations impacting us tax treatment foreign earnings new tax laws revised tax law interpretations domestic foreign jurisdictions company may fail realize anticipated cost savings revenue enhancements benefits expected merger could adversely affect value companys common stock success merger depend part companys ability successfully combine businesses old merck scheringplough realize anticipated benefits cost savings combination two companies combined company able achieve objectives within anticipated time frame value companys common stock may adversely affected possible integration process could result loss key employees result disruption legacy companys ongoing businesses identify inconsistencies standards controls procedures policies adversely affect ability maintain relationships customers suppliers distributors creditors lessors clinical trial investigators managers achieve anticipated benefits merger specifically issues must addressed integrating operations two legacy companies order realize anticipated benefits merger include among things integrating research development manufacturing distribution marketing promotion activities information technology systems old merck schering plough conforming standards controls procedures accounting policies business cultures compensation structures companies identifying eliminating redundant underperforming operations assets managing tax costs inefficiencies associated integrating operations combined company integration efforts two companies also divert management attention resources inability realize full extent anticipated benefits merger well delays encountered integration process could adverse effect companys business results operations may affect value shares company common stock addition actual integration may result additional unforeseen expenses anticipated benefits integration plan may realized actual cost sales synergies may lower company expects may take longer achieve anticipated company able adequately address challenges may unable successfully integrate operations two legacy companies realize anticipated benefits integration two legacy companies delays encountered integration process could material adverse effect revenues expenses operating results financial condition company although company expects significant benefits increased cost savings result merger assurance company realize anticipated benefits product liability insurance products may limited cost prohibitive unavailable result number factors product liability insurance become less available cost increased significantly respect product liability company self insures substantially risk availability commercial insurance become restrictive company evaluated risks determined cost obtaining product liability insurance outweighs likely benefits coverage available insurance certain product liabilities effective august including liability legacy merck products first sold date company continually assess efficient means address risk however guarantee insurance coverage obtained obtained sufficient fully cover product liabilities may arise company may able realize expected benefits investments emerging markets company taking steps increase presence emerging markets however guarantee companys efforts expand sales emerging markets succeed countries within emerging markets may especially vulnerable periods global financial instability may limited resources spend health care order company successfully implement emerging markets strategy must attract retain qualified personnel company may also required increase reliance thirdparty agents within less developed markets addition many countries currencies fluctuate substantially currencies devalue offset devaluations companys financial performance within countries could adversely affected reasons sales within emerging markets carry significant risks however failure continue expand companys business emerging markets could material adverse effect business financial condition results companys operations company significant global operations expose additional risks adverse event could material negative impact companys results operations extent companys operations outside united states significant risks inherent conducting global business include changes medical reimbursement policies programs pricing restrictions key markets multiple regulatory requirements could restrict companys ability manufacture sell products key markets trade protection measures import export licensing requirements foreign exchange fluctuations diminished protection intellectual property countries possible nationalization expropriation discussed company required remeasure local currency operations venezuela us dollars venezuelan economy determined hyperinflationary also january december venezuelan government devalued currency actions continue adverse effect companys results operations financial position cash flows furthermore company believes credit economic conditions within greece spain italy portugal among members eu deteriorated conditions well inherent variability timing cash receipts resulted may continue result increase average length time takes collect accounts receivable outstanding countries december companys accounts receivable greece italy spain portugal totaled approximately billion hospital public sector receivables greece approximately greek government announced would exchange zero coupon bonds outstanding accounts receivable related certain government sponsored institutions addition may changes companys business political position instability disruption destruction significant geographic region regardless cause including war terrorism riot civil insurrection social unrest natural manmade disasters including famine flood fire earthquake storm disease cautionary factors may affect future results cautionary statements private securities litigation reform act report including annual report written reports oral statements made time time company may contain socalled forwardlooking statements based managements current expectations subject risks uncertainties may cause results differ materially set forth statements one identify forwardlooking statements use words anticipates expects plans estimates forecasts projects words similar meaning one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product development product approvals product potential development programs one must carefully consider statement understand many factors could cause actual results differ materially companys forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially company assume obligation update forwardlooking statement company cautions place undue reliance forwardlooking statements although possible predict identify factors may include following competition generic products companys products lose patent protection increased brand competition therapeutic areas important companys longterm business performance difficulties uncertainties inherent new product development outcome lengthy complex process new product development inherently uncertain drug candidate fail stage process one latestage product candidates could fail receive regulatory approval new product candidates may appear promising development fail reach market efficacy safety concerns inability obtain necessary regulatory approvals difficulty excessive cost manufacture andor infringement patents intellectual property rights others furthermore sales new products may prove disappointing fail reach anticipated levels pricing pressures united states abroad including rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement pricing general changes government laws regulations enforcement thereof affecting companys business efficacy safety concerns respect marketed products whether scientifically justified leading product recalls withdrawals declining sales significant litigation related vioxx vytorin zetia arbitration proceeding involving companys right distribute remicade simponi legal factors including product liability claims antitrust litigation governmental investigations including tax disputes environmental concerns patent disputes branded generic competitors could preclude commercialization products negatively affect profitability existing products lost market opportunity resulting delays uncertainties approval process fda foreign regulatory authorities increased focus privacy issues countries around world including united states eu legislative regulatory landscape privacy data protection continues evolve increasing amount focus privacy data protection issues potential affect directly companys business including recently enacted laws majority states united states requiring security breach notification changes tax laws including changes related taxation foreign earnings changes accounting pronouncements promulgated standardsetting regulatory bodies including financial accounting standards board sec adverse company economic factors company control including changes inflation interest rates foreign currency exchange rates list considered exhaustive statement potential risks uncertainties see risk factors item b unresolved staff comments none item properties companys corporate headquarters located whitehouse station new jersey companys us commercial operations headquartered upper gwynedd pennsylvania companys us pharmaceutical business conducted divisional headquarters located upper gwynedd whitehouse station new jersey companys vaccines business conducted divisional headquarters located west point pennsylvania mercks animal health global headquarters located boxmeer netherlands principal us research facilities located rahway kenilworth summit union new jersey west point palo alto california nebraska animal health principal research facilities outside us located netherlands scotland company also production facilities human health products locations united states puerto rico outside united states subsidiaries company owns interest manufacturing plants properties australia canada japan singapore south africa countries western europe central south america asia capital expenditures billion compared billion united states amounted million million abroad expenditures amounted million million company subsidiaries principal facilities manufacturing plants titles consider satisfactory company considers properties good operating condition machinery equipment well maintained plants manufacture products suitable intended purposes capacities projected capacities adequate current projected needs existing company products capacity plants converted needed modification requirements newly introduced future products item legal proceedings information called item incorporated herein reference note contingencies environmental liabilities included part ii item financial statements supplementary data executive officers registrant ages february kenneth c frazier age january president chief executive officer merck co inc may president merck co inc responsible companys three largest worldwide divisions global human health merck manufacturing division merck research laboratories november executive vice president president global human health merck co inc formerly scheringplough corporation responsible companys marketing sales organizations worldwide including global pharmaceutical vaccine franchises august executive vice president president global human health old merck responsible companys marketing sales organizations worldwide including global pharmaceutical vaccine franchises november executive vice president general counsel old merck responsible legal public affairs functions merck company foundation notforprofit charitable organization affiliated company december senior vice president general counsel old merck responsible legal public affairs functions merck company foundation notforprofit charitable organization affiliated company adele ambrose age november senior vice president chief communications officer merck co inc formerly scheringplough corporation responsible global communications organization december vice president chief communications officer old merck responsible global communications organization april sabbatical prior april ms ambrose executive vice president public relations investor communications att wireless wireless services provider september april richard bowles iii age november executive vice president chief compliance officer merck co inc formerly scheringplough corporation responsible companys compliance function including global safety environment systems assurance ethics privacy prior november dr bowles senior vice president global quality operations scheringplough corporation since march john canan age november senior vice president financeglobal controller merck co inc formerly scheringplough corporation responsible companys global controllers organization including accounting controls external reporting financial standards policies january senior vice president controller old merck responsible corporate controllers group september vice president controller old merck responsible corporate controllers group willie deese age november executive vice president president merck manufacturing division mmd merck co inc formerly scheringplough corporation responsible companys global manufacturing procurement distribution logistics functions january executive vice president president mmd old merck responsible companys global manufacturing procurement distribution logistics functions may president mmd old merck responsible companys global manufacturing procurement operational excellence functions january senior vice president global procurement old merck mirian graddickweir age november executive vice president human resources merck co inc formerly scheringplough corporation responsible global human resources organization january executive vice president human resources old merck responsible global human resources organization september senior vice president human resources old merck prior september dr graddickweir executive vice president human resources employee communications att communications services provider held several senior human resources leadership positions att years bridgette p heller age march executive vice president president merck consumer care merck co inc responsible merck consumer care organization prior march ms heller president johnson johnsons baby global business unit global president baby kids wound care prior joining johnson johnson ms heller founder managing partner heller associates peter n kellogg age november executive vice president chief financial officer merck co inc formerly scheringplough corporation responsible companys worldwide financial organization investor relations corporate development licensing companys joint venture relationships august executive vice president chief financial officer old merck responsible companys worldwide financial organization investor relations corporate development licensing companys joint venture relationships prior august mr kellogg executive vice president finance chief financial officer biogen idec biotechnology company since november merger biogen inc idec pharmaceuticals corporation peter kim age november executive vice president president merck research laboratories merck co inc formerly scheringplough corporation responsible companys research development efforts worldwide january executive vice president president merck research laboratories old merck responsible companys research development efforts worldwide january president merck research laboratories old merck responsible companys research development efforts worldwide raul e kohan age november executive vice president president animal health merck co inc formerly scheringplough corporation responsible companys animal health organization october senior vice president president intervetscheringplough animal health scheringplough corporation october deputy head animal health senior vice president corporate excellence administrative services scheringplough corporation february senior vice president president animal health scheringplough corporation prior february mr kohan group head global specialty operations president animal health scheringplough corporation since bruce n kuhlik age november executive vice president general counsel merck co inc formerly scheringplough corporation responsible legal communications public policy functions merck company foundation notforprofit charitable organization affiliated company january executive vice president general counsel old merck responsible legal communications public policy functions merck company foundation notforprofit charitable organization affiliated company august senior vice president general counsel old merck responsible legal communications public policy functions merck company foundation notforprofit charitable organization affiliated company may vice president associate general counsel old merck primary responsibility companys vioxx litigation defense prior may mr kuhlik senior vice president general counsel pharmaceutical research manufacturers america since october michael rosenblatt md age december executive vice president chief medical officer merck co inc companys primary voice global medical community critical issues patient safety oversee companys global center scientific affairs prior december dr rosenblatt dean tufts university school medicine since j chris scalet age november executive vice president global services chief information officer cio merck co inc formerly scheringplough corporation responsible global shared services across human resources finance site services information services function enterprise business process redesign initiative january executive vice president global services cio old merck responsible global shared services across human resources finance site services information services function enterprise business process redesign initiative january senior vice president global services cio old merck responsible global shared services across human resources finance site services information services function enterprise business process redesign initiative march senior vice president information services cio old merck responsible areas information technology services including application development technical support voice data communications computer operations worldwide adam h schechter age may executive vice president president global human health merck co inc responsible companys pharmaceutical vaccine marketing sales organizations worldwide november president global human health us marketintegration leader merck co inc formerly scheringplough corporation commercial responsibility united states companys portfolio prescription medicines leader integration efforts merckscheringplough merger across divisions functions august president global pharmaceuticals global human health global responsibilities companys atherosclerosiscardiovascular diabetesobesity oncology specialtyneuroscience respiratory bone arthritis analgesia franchises well commercial responsibility united states companys portfolio prescription medicines july president us human health commercial responsibility united states companys portfolio prescription medicines october general manager us human health responsible neuropsychiatry osteoporosis migraine respiratory new products franchises mervyn turner age december chief strategy officer senior vice president merck research laboratories merck co inc responsible leading formulation execution companys long term strategic plan additional responsibilities within merck research laboratories november chief strategy officer senior vice president emerging markets research development merck research laboratories merck co inc formerly schering plough corporation responsible leading formulation execution companys long term strategic plan additional responsibilities emerging markets research development within merck research laboratories november chief strategy officer senior vice president worldwide licensing external research merck research laboratories old merck october senior vice president worldwide licensing external research old merck officers listed serve pleasure board directors none officers elected pursuant arrangement understanding officer board part ii item market registrants common equity related stockholder matters issuer purchases equity securities principal market trading companys common stock new york stock exchange nyse symbol sgp prior merger mrk merger common stock market price information set forth table based historical nyse market prices following table also sets forth calendar periods indicated dividend per share information cash dividends paid per common share year th q rd q nd q st q common stock market prices th q rd q nd q st q high low high low old merck paid quarterly cash dividends per common share annual amount january approximately shareholders record equity compensation plan information following table summarizes information options warrants rights equity compensation companys old merck scheringploughs equity plans close business december table include information tax qualified plans msd employee savings security plan scheringplough employees savings plan number securities number remaining available securities future issuance issued upon weightedaverage equity exercise exercise price compensation plans outstanding outstanding excluding options warrants options warrants securities rights rights reflected column plan category b c equity compensation plans approved security holders equity compensation plans approved security holders total includes options purchase shares company common stock rights following shareholderapproved plans merck sharp dohme incentive stock plans merck co inc nonemployee directors stock option plans merck co inc scheringplough stock incentive plans excludes approximately shares restricted stock units performance share units assuming maximum payouts merck sharp dohme incentive stock plans shares restricted stock units performance share units excluding accrued dividends merck co inc scheringplough stock incentive plan also excludes shares phantom stock deferred msd deferral program table include information equity compensation plans options warrants rights assumed company connection mergers acquisitions pursuant remain outstanding options warrants rights collectively assumed plans include rosetta inpharmatics inc employee stock option plans total shares merck common stock may purchased assumed plans weighted average exercise price grants may made assumed plans performance graph following graph assumes investment december reinvestment dividends companys common shares sp index composite peer group major usbased pharmaceutical companies abbott laboratories bristolmyers squibb company johnson johnson eli lilly company pfizer inc comparison fiveyear cumulative total return merck co inc composite peer group sp index end period value cagr merck peer grp sp merck peer grp sp performance graph reflects scheringplough stock per forman ce decemb er th ro ugh close f er ger new rcks ck perfor mance n vember december assumes cash component merger consideration reinvested new merck stock closing price november compound annual growth rate october wyeth pfizer inc completed previously announced merger pfizerwyeth merger wyeth became whollyowned subsidiary pfizer inc discussed november old merck scheringplough completed merger together pfizerwyeth merger transactions old merck subsequently renamed merck sharp dohme corp became whollyowned subsidiary scheringplough subsequently renamed merck co inc result transactions wyeth old merck longer exist publicly traded entities ceased trading common stock close business respective merger dates wyeth old merck permanently removed peer group index item selected financial data following selected financial data read conjunction item managements discussion analysis financial condition results operations consolidated financial statements notes thereto contained item financial statements supplementary data report merck co inc subsidiaries millions except per share amounts results year sales materials production costs marketing administrative expenses research development expenses restructuring costs equity income affiliates income expense net income taxes taxes income net income net income attributable noncontrolling interests net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders cash dividends declared cash dividends paid per common share capital expenditures depreciation average common shares outstanding millions average common shares outstanding assuming dilution millions yearend position working capital property plant equipment net total assets longterm debt total equity yearend statistics number stockholders record number employees amounts include amortization purchase accounting adjustments inprocess research development impairment charges billion reflected research development expenses impact restructuring actions reserve related vioxx gain recognized astrazenecas exercise option acquire certain assets company favorable impact certain tax items addition results reflect unfavorable effects implementation certain provisions us health care reform legislation enacted amounts include impact merger scheringplough corporation november including recognition gain representing fair value stepup mercks previously held interest merckscheringplough partnership result obtaining controlling interest amortization purchase accounting adjustments recorded postmerger period also included gain sale mercks interest merial limited favorable impact certain tax items impact restructuring actions additional legal defense costs amounts include gain distribution astrazeneca lp gain related sale remaining worldwide rights aggrastat favorable impact certain tax items impact restructuring actions additional legal defense costs expense contribution merck company foundation amounts include impact us vioxx settlement agreement charge restructuring actions civil governmental investigations charge insurance arbitration settlement gain inprocess research development expense resulting acquisition additional vioxx legal defense costs gains sales assets product divestitures well net gain settlements certain patent disputes amounts include impact restructuring actions inprocess research development expenses resulting acquisitions additional vioxx legal defense costs amount reflects dividends paid common shareholders old merck addition approximately million dividends paid subsequent merger scheringplough million paid prior merger relating common stock preferred stock dividends declared scheringplough item managements discussion analysis financial condition results operations description mercks business company global health care company delivers innovative health solutions prescription medicines vaccines biologic therapies animal health consumer care products markets directly joint ventures companys operations principally managed products basis comprised four operating segments pharmaceutical animal health consumer care alliances segments one reportable segment pharmaceutical segment pharmaceutical segment includes human health pharmaceutical vaccine products marketed either directly company joint ventures human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities company also animal health operations discover develop manufacture market animal health products including vaccines company sells veterinarians distributors animal producers additionally company consumer care operations develop manufacture market overthecounter foot care sun care products sold wholesale retail drug food chain mass merchandiser outlets united states canada november merck co inc old merck scheringplough corporation scheringplough merged merger merger scheringplough acquired shares old merck became whollyowned subsidiary scheringplough renamed merck sharp dohme corp scheringplough continued surviving public company renamed merck co inc new merck company however accounting purposes merger treated acquisition old merck considered accounting acquirer accordingly accompanying financial statements reflect old mercks standalone operations existed prior completion merger results scheringploughs business included new mercks financial statements periods subsequent completion merger therefore new mercks financial results reflect full year legacy scheringplough operations references report accompanying financial statements merck periods prior merger refer old merck periods completion merger new merck overview company made progress driving revenue growth key products expanding global reach including within emerging markets improving cost structure making strategic investments business advancing latestage pipeline continuing task integrating legacy companies postmerger sales increased billion driven largely incremental revenue resulting inclusion full year results legacy scheringplough products remicade treatment inflammatory diseases nasonex inhaled nasal corticosteroid treatment nasal allergy symptoms temodar treatment certain types brain tumors pegintron treating chronic hepatitis c clarinex nonsedating antihistamine well inclusion full year results zetia vytorin cholesterol modifying medicines prior merger substantially sales zetia vytorin recognized merckscheringplough partnership msp partnership results old mercks interest msp partnership recorded equity income affiliates result merger msp partnership whollyowned company therefore revenues products reflected sales additionally company recognized full year sales legacy scheringplough animal health consumer care products sales include revenue legacy schering plough msp partnership products postmerger period december also contributing sales increase growth januvia janumet treatment type diabetes isentress antiretroviral therapy use combination therapy treatment hiv infection adult patients singulair medicine indicated chronic treatment asthma relief symptoms allergic rhinitis increases partially offset lower sales cozaar hyzaar treatment hypertension lost patent protection united states april number major european markets march revenue also negatively affected lower sales fosamax fosamax plus treatment case fosamax prevention osteoporosis lost market exclusivity united states several major european markets lower revenue companys relationship astrazeneca lp azlp well lower sales gardasil vaccine help prevent cervical vulvar vaginal anal cancers precancerous dysplastic lesions genital warts caused human papillomavirus hpv types contained vaccine lower sales zocor companys statin modifying cholesterol addition implementation certain provisions us health care reform legislation resulted increased medicaid rebates impacts reduced revenues approximately million additionally many countries european union eu undertaken austerity measures aimed reducing costs health care implemented pricing actions negatively impacted sales sales remicade followon product simponi billion aggregate company involved arbitration centocor ortho biotech inc centocor subsidiary johnson johnson centocor seeking terminate companys rights continue market remicade simponi arbitration hearing concluded company awaiting arbitration panels decision see note consolidated financial statements unfavorable outcome arbitration would material adverse effect companys financial position liquidity results operations since merger company continued advancement drug candidates pipeline us food drug administration fda approved dulera inhalation aerosol new fixeddose combination asthma treatment patients years age older addition intravenous formulation brinavess merck exclusive marketing rights outside united states canada mexico granted marketing approval eu rapid conversion recent onset atrial fibrillation sinus rhythm adults nonsurgery patients atrial fibrillation seven days less postcardiac surgery patients atrial fibrillation three days less also fda approved new indication gardasil prevention anal cancer caused hpv types prevention anal intraepithelial neoplasia grades anal dysplasias precancerous lesions caused hpv types males females years age additionally september two supplemental new drug applications snda saphris treatment schizophrenia adults acute treatment bipolar disorder adults approved united states expand products indications also company entered copromotion agreement commercialization daxas treatment symptomatic chronic obstructive pulmonary disease company launched certain european markets company currently three candidates review fda boceprevir investigational oral hepatitis c protease inhibitor mka xr companys investigational extendedrelease formulation janumet mkd investigational combination januvia zocor treatment diabetes dyslipidemia addition sch nomace oral contraceptive combines selective progestin beta estradiol currently review eu additionally mk cubicin daptomycin injection currently review japan company marketing rights also company currently candidates phase iii development anticipates making new drug application nda respect certain candidates including mk ridaforolimus novel mtor inhibitor evaluated treatment metastatic soft tissue bone sarcomas mk saflutan tafluprost reduction elevated intraocular pressure appropriate patients primary openangle glaucoma ocular hypertension mkc ezetimibe combined atorvastatin investigational medication treatment dyslipidemia mk telcagepant companys investigational medication acute treatment migraine another phase iii candidate vorapaxar respect company recently informed chairman one studies discontinue study drug investigators begin close study timely orderly fashion company recorded material impairment charge related intangible asset see research development company continues make progress achieving cost savings across areas including consolidation sales marketing research development application companys lean manufacturing sourcing strategies expanded operations full integration msp partnership savings result various actions including merger restructuring program discussed previously announced ongoing cost reduction activities legacy companies well nonrestructuringrelated activities companys procurement savings initiative company realized billion net cost savings activities february company commenced actions global restructuring program merger restructuring program conjunction integration legacy merck legacy scheringplough businesses merger restructuring program intended optimize cost structure combined company additional actions program continued part restructuring actions taken thus far merger restructuring program company expects reduce total workforce measured time merger approximately across company worldwide addition company eliminated positions vacant time merger workforce reductions primarily come elimination duplicative positions sales administrative headquarters organizations well sale closure certain manufacturing research development sites consolidation office facilities company continue pursue productivity efficiencies evaluate manufacturing supply chain capabilities ongoing basis may result future restructuring actions period company also continue hire new employees strategic growth areas business necessary connection merger restructuring program separation costs companys existing severance programs worldwide recorded fourth quarter extent costs probable reasonably estimable company commenced accruing costs related enhanced termination benefits offered employees merger restructuring program first quarter necessary criteria met company recorded total pretax restructuring costs billion billion related program restructuring actions taken thus far merger restructuring program expected substantially completed end exception certain manufacturing facilities actions total cumulative pretax costs estimated approximately billion billion company estimates approximately twothirds cumulative pretax costs relate cash outlays primarily related employee separation expense approximately onethird cumulative pretax costs noncash relating primarily accelerated depreciation facilities closed divested company expects restructuring actions taken thus far merger restructuring program result annual savings approximately billion billion march united states enacted health care reform legislation important market reforms began continue full implementation merck incurred costs result legislation including increased medicaid rebates impacts reduced revenues company also recorded charge associated legislation changed tax law require taxation prescription drug subsidy companys retiree health benefit plans companies receive reimbursement medicare part additional provisions legislation come effect including assessment annual health care reform fee branded prescription drug manufacturers importers requirement drug manufacturers pay discount medicare part utilization incurred beneficiaries medicare part coverage gap ie socalled donut hole new provisions decrease revenues increase costs earnings per common share eps assuming dilution reflect net unfavorable impact resulting amortization purchase accounting adjustments process research development iprd impairment charges including charge related vorapaxar clinical development program restructuring mergerrelated costs well legal reserve relating vioxx vioxx liability reserve discussed partially offset gain recognized astrazenecas exercise option acquire certain assets company nongaap eps excluding items see nongaap income nongaap eps december merck announced board directors elected kenneth c frazier mercks president chief executive officer president well member board effective january mr frazier succeeds richard clark continue serve chairman board competition health care environment competition markets company conducts business pharmaceutical industry highly competitive highly regulated companys competitors include worldwide researchbased pharmaceutical companies smaller research companies limited therapeutic focus generic drug consumer health care manufacturers companys operations may affected technological advances competitors industry consolidation patents granted competitors competitive combination products new products competitors generic availability competitors branded products new information clinical trials marketed products postmarketing surveillance generic competition companys products mature addition patent positions increasingly challenged competitors outcome highly uncertain adverse result patent dispute preclude commercialization products negatively affect sales existing products could result recognition impairment charge respect certain products competitive pressures intensified pressures industry grown effect operations competitive factors patent disputes predicted pharmaceutical competition involves rigorous search technological innovations ability market innovations effectively longstanding emphasis research development company well positioned compete search technological innovations additional resources meet market challenges include quality control flexibility meet customer specifications efficient distribution system strong technical information service company active acquiring marketing products external alliances joint ventures licenses refining sales marketing efforts address changing industry conditions however introduction new products processes competitors may result price reductions product displacements even products protected patents example number compounds available treat particular disease typically increases time result slowed sales growth companys products therapeutic category global efforts toward health care cost containment continue exert pressure product pricing market access pressure particularly intense several european countries implemented austerity measures aimed reducing costs areas health care united states federal state governments many years also pursued methods reduce cost drugs vaccines pay example federal laws require company pay specified rebates medicines reimbursed medicaid provide discounts outpatient medicines purchased certain public health service entities disproportionate share hospitals hospitals meeting certain criteria federal vaccines children entitlement program us centers disease control prevention cdc funds purchases recommended pediatric vaccines public sector price immunization medicaideligible uninsured native american certain underinsured children merck awarded cdc contract supply pediatric vaccines vaccines children program backdrop united states enacted major health care reform legislation various insurance market reforms began last year continue full implementation new law expected expand access health care million americans end decade previously regular access health care respect effect law pharmaceutical industry law increased mandated medicaid rebate expanded rebate medicaid managed care utilization increased types entities eligible federal b drug discount program law also requires pharmaceutical manufacturers pay discount medicare part utilization beneficiaries medicare part coverage gap ie socalled donut hole also beginning pharmaceutical manufacturers required pay annual health care reform fee total annual industry fee billion assessed company proportion share sales certain government programs medicare medicaid although included health care reform law congress also considered may consider proposals increase governments role pharmaceutical pricing medicare program proposals may include removing current legal prohibition secretary health human services intervening price negotiations medicare drug benefit program plans pharmaceutical companies may also include mandating payment rebates pharmaceutical utilization medicare drug benefit plans addition congress may consider proposals allow certain conditions importation medicines countries full impact us health care reform well continuing budget pressures governments around world predicted time addressing cost containment pressures company makes continuing effort demonstrate medicines provide value patients pay health care company works markets historically low rates government spending health care encourage governments increase investments thereby improve citizens access appropriate health care including medicines animal health business intense competition affected several factors including regulatory legislative issues scientific technological advances product innovation quality price companys products effective promotional efforts frequent introduction generic products competitors companys consumer care operations face competition consumer health care businesses well retailers carry private label brands companys competitive position affected several factors including regulatory legislative issues scientific technological advances quality price companys products promotional efforts growth lower cost private label brands operating conditions become challenging global pressures competition industry regulation cost containment efforts although one predict effect factors companys business company continually takes measures evaluate adapt improve organization business practices better meet customer needs believes well positioned respond evolving health care environment market forces government regulation pharmaceutical industry subject regulation regional country state local agencies around world governmental regulation legislation tends focus standards processes determining drug safety effectiveness well conditions sale reimbursement especially related pricing products particular importance fda united states administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals many cases fda requirements practices increased amount time resources necessary develop new products bring market united states us health care reform legislation passed full implementation date significantly expands access health care also contains number provisions imposing new obligations pharmaceutical industry including example increase mandated rebate medicaid program new discount requirement medicare part program eu adopted directives legislation concerning classification labeling advertising wholesale distribution approval marketing medicinal products human use provide mandatory standards throughout eu may supplemented implemented additional regulations eu member states companys policies procedures already consistent substance directives consequently believed material effect companys business january european commission ec launched sector inquiry pharmaceutical industry rules eu competition law sector inquiry allows ec gather information general operation market competition investigation suspected anticompetitive behavior specific firms part inquiry old mercks offices germany inspected authorities beginning january preliminary report ec issued november following public consultation period final report issued july final report confirmed decline number novel medicines reaching market instances delayed market entry generic medicines discussed industry practices may contributed phenomena among things final report expressed concern settlements patent disputes originator generic companies suggested ec monitor anticompetitive effects ec issued inquiries respect subject investigation including company ec alleged company subsidiaries engaged unlawful practices company believes continue able conduct operations including launching new drugs market regulatory environment access medicines global health care company mercks primary role discover develop innovative medicines vaccines company also recognizes important role play helping improve access products around world companys efforts regard wideranging example company recognized pricing many products differential pricing framework taking consideration factors countrys level economic development public health need building companys efforts merck undertaken collaborations many stakeholders improve access medicines enhance quality life people around world example partnership merck government bhutan australian cervical cancer foundation bhutan became first lowincome country world successfully implement national hpv vaccination program program merck providing gardasil free charge first year program provide gardasil companys access price five years also merck worked partner wellcome trust develop hillemann laboratories established september initiative focus developing affordable vaccines prevent diseases commonly affect lowincome countries merck also past provided funds merck company foundation independent organization partnered variety organizations dedicated improving global health one partnerships african comprehensive hivaids partnership botswana collaboration government botswana bill melinda gates foundation renewed supports botswanas response hivaids comprehensive sustainable approach hiv prevention care treatment support privacy data protection company subject number privacy data protection laws regulations globally legislative regulatory landscape privacy data protection continues evolve increasing attention privacy data protection issues potential affect directly companys business including recently enacted laws regulations united states internationally requiring notification individuals government authorities security breaches involving certain categories personal information operating results sales worldwide sales totaled billion compared billion foreign exchange favorably affected global sales performance revenue increase driven largely incremental sales resulting inclusion full year results legacy scheringplough products remicade nasonex temodar pegintron clarinex well inclusion full year results zetia vytorin prior merger substantially sales zetia vytorin recognized msp partnership results old mercks interest msp partnership recorded equity income affiliates result merger msp partnership whollyowned company therefore revenues products reflected sales additionally company recognized full year sales legacy scheringplough animal health consumer care products sales include revenue legacy scheringplough msp partnership products postmerger period december also contributing sales increase growth januvia janumet isentress singulair increases partially offset lower sales cozaar hyzaar lost patent protection united states april number major european markets march revenue also negatively affected lower sales fosamax fosamax plus lost market exclusivity united states several major european markets lower revenue companys relationship azlp well lower sales gardasil zocor addition implementation certain provisions us health care reform legislation resulted increased medicaid rebates impacts reduced revenues approximately million domestic sales billion compared billion foreign sales billion compared billion increases driven primarily incremental sales resulting inclusion full year legacy scheringplough msp partnership products domestic sales increase also driven higher sales januvia janumet singulair isentress increases partially offset lower sales cozaar hyzaar fosamax fosamax plus gardasil rotateq well lower revenue companys relationship azlp foreign sales growth reflects strong performance januvia janumet isentress singulair partially offset lower sales cozaar hyzaar fosamax fosamax plus foreign sales represented total sales many companys brands experienced positive growth trends eu environment eu across europe challenging many countries announced austerity measures aimed reducing costs areas health care implementation pricing actions varies country many announced measures reduce prices generic patented drugs company taking steps mitigate immediate impact eu austerity measures negatively affected companys revenue performance company anticipates continue negatively affect revenue performance worldwide sales totaled billion increase compared foreign exchange unfavorably affected global sales performance revenue increase largely reflects incremental sales resulting inclusion legacy scheringplough msp partnership products postmerger period also contributing sales increase growth januvia janumet isentress singulair varivax pneumovax increases partially offset lower sales fosamax fosamax plus gardasil cosopt trusopt lost us market exclusivity october lower revenue companys relationship azlp products experienced declines include rotateq zocor primaxin sales companys products follows years ended december pharmaceutical bone respiratory immunology dermatology singulair remicade nasonex fosamax clarinex arcoxia proventil asmanex cardiovascular zetia vytorin integrilin diabetes obesity januvia janumet diversified brands cozaarhyzaar zocor propecia claritin rx vasotecvaseretic remeron proscar infectious disease isentress pegintron cancidas primaxin invanz avelox rebetol crixivanstocrin neurosciences ophthalmology maxalt cosopttrusopt subutexsuboxone oncology temodar emend caelyx intron vaccines proquadmmr iivarivax gardasil rotateq pneumovax zostavax womens health endocrine nuvaring follistim aq implanon cerazette pharmaceutical total pharmaceutical segment sales segment sales total segment sales sales legacy scheringplough products reflect results postmerger period addition prior merger substantially sales zetia vytorin recognized msp partnership results old mercks interest msp partnership recorded equity income affiliates result merger msp partnership whollyowned company accordingly sales msp partnership products merger reflected table sales zetia vytorin reflect old mercks sales products latin america part msp partnership amounts reflect sales vaccines sold major european markets companys joint venture sanofi pasteur msd results reflected equity income affiliates amounts however reflect supply sales sanofi pasteur msd pharmaceutical primarily reflects sales human pharmaceutical products including products within franchises listed separately reflects nonreportable segments including animal health consumer care revenue companys relationship azlp primarily relating sales nexium well prilosec revenue azlp billion billion billion respectively revenues primarily comprised miscellaneous corporate revenues thirdparty manufacturing sales sales related divested products businesses supply sales included segment results pharmaceutical segment sales bone respiratory immunology dermatology worldwide sales singulair onceaday oral medicine indicated chronic treatment asthma relief symptoms allergic rhinitis grew reaching billion reflecting price increases positive performance japan global sales singulair rose billion primarily driven favorable pricing strong performance japan asia pacific singulair continues number one prescribed product us respiratory market us sales singulair billion patent provides us market exclusivity singulair expires august company expects within two years following patent expiration lose substantially us sales singulair declines coming first full year following patent expiration addition patent singulair expire number major european markets august company expects sales singulair markets decline significantly thereafter although six month pediatric market exclusivity may extend date markets february sales remicade treatment inflammatory diseases billion million postmerger period remicade marketed company outside united states except japan certain asian markets products compete remicade launched past several years october ec approved simponi oncemonthly subcutaneous treatment certain inflammatory diseases january simponi approved eu use combination methotrexate adults severe active progressive rheumatoid arthritis previously treated methotrexate reduction rate progression joint damage measured xray rheumatoid arthritis patients company launched simponi countries launches international markets planned sales simponi million see note consolidated financial statements discussion arbitration proceedings involving companys rights market remicade simponi global sales nasonex inhaled nasal corticosteroid treatment nasal allergy symptoms billion million postmerger period worldwide sales fosamax fosamax plus marketed fosavance throughout eu fosamac japan treatment case fosamax prevention osteoporosis decreased million declined billion medicines lost market exclusivity united states also lost market exclusivity several major european markets accordingly company experiencing significant sales declines within fosamax product franchise company expects declines continue global sales clarinex marketed aerius many countries outside united states nonsedating antihistamine million million post merger period products included bone respiratory immunology dermatology franchise include among others arcoxia treatment arthritis pain proventil inhalation aerosol relief bronchospasm asmanex inhaled corticosteroid asthma june fda approved dulera inhalation aerosol new fixeddose combination asthma treatment patients years age older dulera combines inhaled corticosteroid longacting betaagonist cardiovascular sales zetia cholesterol absorption inhibitor also marketed ezetrol outside united states vytorin combination product containing active ingredients zetia zocor marketed outside united states inegy billion billion respectively million million respectively postmerger period prior merger substantially sales products recognized msp partnership results old mercks interest msp partnership recorded equity income affiliates result merger msp partnership whollyowned company therefore revenues products reflected sales total sales zetia vytorin including sales recognized msp partnership billion billion respectively november oxford university clinical trial service unit presented results sharp study heart renal protection study american society nephrology meeting vytorin mg reduced incidence first major vascular events defined nonfatal heart attacks cardiac death stroke revascularization procedure highly statistically significant compared placebo prespecified primary endpoint study sharp study involved patients average advanced endstage chronic kidney disease merck plans seek regulatory approvals use vytorin patients chronic kidney disease based results sharp study improveit large cardiovascular outcomes study evaluating zetiavytorin patients acute coronary syndrome fully enrolled approximately patients blinded interim efficacy analysis conducted data safety monitoring board dsmb trial approximately primary events accrued dsmb recommended continuing trial changes study protocol another blinded interim efficacy analysis planned dsmb approximately primary events accrued improveit trial scheduled completion global sales integrilin injection treatment patients acute coronary syndrome sold company united states canada million million postmerger period september intravenous formulation brinavess vernakalant granted marketing approval eu iceland norway rapid conversion recent onset atrial fibrillation sinus rhythm adults nonsurgery patients atrial fibrillation seven days less postcardiac surgery patients atrial fibrillation three days less brinavess acts preferentially atria first product new class pharmacologic agents cardioversion atrial fibrillation launch eu april cardiome pharma corp merck announced collaboration license agreement development commercialization vernakalant agreement provides merck exclusive rights outside united states canada mexico vernakalant intravenous formulation diabetes obesity global sales januvia mercks dipeptidyl peptidase dpp inhibitor treatment type diabetes billion billion billion reflecting continued growth united states internationally due part launch new indications addition growth reflects apparent safety concerns limited sales competing product dpp inhibitors represent class prescription medications improve blood sugar control patients type diabetes enhancing natural body system called incretin system helps regulate glucose affecting beta cells alpha cells pancreas worldwide sales janumet mercks oral antihyperglycemic agent combines sitagliptin januvia metformin single tablet target three key defects type diabetes million million million reflecting growth united states internationally due ongoing launches certain markets mka xr companys investigational extendedrelease formulation janumet accepted standard review fda company also moving forward planned regulatory filings countries outside united states extendedrelease formulation janumet investigational treatment type diabetes combines sitagliptin metformin extended release commonlyprescribed medication type diabetes single tablet formulation designed provide new treatment option health care providers patients need two oral agents help control blood sugar convenience daily dosing diversified brands mercks diversified brands human health pharmaceutical products approaching expiration marketing exclusivity longer protected patents developed markets continue core part companys offering markets around world global sales cozaar companion agent hyzaar combination cozaar hydrochlorothiazide treatment hypertension fell billion patents provided us market exclusivity cozaar hyzaar expired april addition cozaar hyzaar lost patent protection number major european markets march accordingly company experiencing significant decline cozaarhyzaar worldwide sales company expects decline continue global sales cozaar hyzaar billion comparable sales reflecting unfavorable effect foreign exchange offset strong performance products united states hyzaar japan marketed preminent products contained diversified brands franchise include among others zocor statin modifying cholesterol propecia product treatment male pattern hair loss prescription claritin treatment seasonal outdoor allergies yearround indoor allergies vasotecvaseretic hypertension andor heart failure remeron antidepressant proscar urology product treatment symptomatic benign prostate enlargement remeron lost market exclusivity united states january certain markets eu september infectious disease worldwide sales isentress hiv integrase inhibitor use combination antiretroviral agents treatment hiv infection treatmentnave treatment experienced adults billion million million sales growth periods reflects positive performance united states well internationally resulting continued uptake since launch isentress works inhibiting insertion hiv dna human dna integrase enzyme inhibiting integrase performing essential function helps limit ability virus replicate infect new cells november company reported initial results phase iii study investigating efficacy safety treatment regimen including isentress tablets daily treatmentnave adult patients infected hiv study although treatment regimen included isentress daily enabled patients achieve viral suppression isentress daily demonstrate noninferiority treatment regimen included isentress twice daily based initial results following recommendation independent data monitoring committee merck terminated study worldwide sales pegintron treating chronic hepatitis c million million postmerger period september company initiated voluntary recall pegintron single dose redipen injection united states consultation fda well recalls globally resulting reduction revenue approximately million representing estimated sales returns addition company recognized charge approximately million materials production primarily inventory discard costs recall conducted precautionary measure due thirdparty manufacturing issue could affected small number redipens recall specific pegintron redipen affect pegintron vial products sales primaxin antibacterial product decreased million declined million results reflect competitive pressures also reflect supply constraints patents primaxin expired worldwide multiple generics approved europe accordingly company experiencing decline sales product company expects decline continue products contained infectious diseases franchise include among others cancidas antifungal product invanz treatment certain infections avelox fluoroquinolone antibiotic treatment certain respiratory skin infections rebetol use combination pegintron treating chronic hepatitis c crixivan stocrin antiretroviral therapies treatment hiv infection compound patent provides us market exclusivity crixivan expires neurosciences ophthalmology global sales maxalt mercks tablet acute treatment migraine declined million reflecting generic availability competing product sales maxalt grew million compound patent provides market exclusivity maxalt united states expires june although six month pediatric market exclusivity may extend date december addition patent maxalt expire number major european markets company anticipates sales united states european markets decline significantly patent expiries worldwide sales ophthalmic products cosopt trusopt declined million fell million patent provided us market exclusivity cosopt trusopt expired october trusopt also lost market exclusivity number major european markets patent cosopt expire number major european markets march company expects sales markets decline significantly thereafter august fda approved saphris asenapine acute treatment schizophrenia adults acute treatment manic mixed episodes associated bipolar disorder without psychotic features adults september two sndas saphris approved united states expand products indications treatment schizophrenia adults monotherapy acute treatment manic mixed episodes associated bipolar disorder adults adjunctive therapy either lithium valproate acute treatment manic mixed episodes associated bipolar disorder adults september asenapine sold brand name sycrest received marketing approval eu treatment moderate severe manic episodes associated bipolar disorder adults marketing approval include indication schizophrenia marketing approval applies eu member states october merck h lundbeck lundbeck announced worldwide commercialization agreement sycrest sublingual tablets mg mg terms agreement lundbeck paid fee make product supply payments exchange exclusive commercial rights sycrest markets outside united states china japan merck retain exclusive commercial rights asenapine united states china japan concurrently merck continuing pursue regulatory approval asenapine parts world merck continues focus building brand awareness saphris united states merck launched black cherry flavor sublingual tablet provide additional taste option merck continues monitor assess saphrissycrest related intangible asset increasing brand awareness additional flavor option lundbecks launch product eu successful company may take noncash impairment charge respect saphrissycrest charge could material bridion reversal certain muscle relaxants surgery currently approved countries launched countries outside united states bridion phase iii development united states sales bridion million neurosciences ophthalmology franchise also includes products subutexsuboxone treatment opiate addiction march merck sold rights subutexsuboxone nearly markets back reckitt benckiser group plc reckitt rights products major markets reverted reckitt july remainder revert reckitt sales subutexsuboxone million oncology sales temodar marketed temodal outside united states treatment certain types brain tumors billion million postmerger period november merck announced federal appellate court ruled favor temodar patent infringement suit barr laboratories barr affiliate teva pharmaceuticals teva appellate court rejected barrs arguments reversed lower court ruling us patent unenforceable teva seeking fda approval sell generic version temodar connection tevas prior agreement launch appeal merck agreed object tevas launch generic version temodar august us patent exclusivity periods otherwise expire february temodar lost patent exclusivity eu generic products marketed global sales emend treatment chemotherapyinduced nausea vomiting grew million driven increases united states due launch japan emend sales increased million products oncology franchise include among others caelyx treatment ovarian cancer metastatic breast cancer kaposis sarcoma intron treating melanoma marketing rights caelyx reverted johnson johnson december sales caelyx million vaccines following discussion vaccines include sales vaccines sold major european markets sanofi pasteur msd spmsd companys joint venture sanofi pasteur results reflected equity income affiliates see selected joint venture affiliate information supply sales spmsd however included worldwide sales gardasil recorded merck declined million decreased billion gardasil worlds topselling hpv vaccine indicated girls women years age prevention cervical vulvar vaginal cancers caused hpv types precancerous dysplastic lesions caused hpv types genital warts caused hpv types gardasil also approved united states use boys men ages years age prevention genital warts caused hpv types december fda approved new indication gardasil prevention anal cancer caused hpv types prevention anal intraepithelial neoplasia grades anal dysplasias precancerous lesions caused hpv types males females years age sales performance driven largely declines united states well australia continue affected saturation yearold female cohort sales include million revenue result government purchases cdcs strategic national stockpile company party certain third party license agreements respect gardasil including crosslicense settlement agreement glaxosmithkline result agreements company pays royalties worldwide gardasil sales vary country included materials production costs january fda issued second complete response letter regarding sbla use gardasil women ages fda completed review response old merck provided july fdas first complete response letter issued june recommended old merck submit additional data month study completed merck provided response fda fourth quarter discussions continue fda determine adult women study data may included prescribing information gardasil complete response letter affect current indications gardasil females ages global sales rotateq vaccine help protect rotavirus gastroenteritis infants children recorded merck declined million sales benefited modestly temporary competitor supply issue sales declined million reflecting competitive pressures recent years company experienced difficulties producing varicella zoster virus vzvcontaining vaccines difficulties resulted supply constraints proquad varivax zostavax company manufacturing bulk varicella producing doses varivax zostavax limited quantity proquad pediatric combination vaccine help protect measles mumps rubella varicella one vzvcontaining vaccines became available united states ordering second quarter actual market demand dictate long supply last sales recorded merck proquad million million proquad available ordering due supply constraints mercks sales varivax vaccine help prevent chickenpox varicella million billion million sales reflect million million respectively revenue result government purchases cdcs strategic national stockpile mercks sales mmr ii vaccine help protect measles mumps rubella million million million sales varivax mmr ii affected unavailability proquad noted sales zostavax vaccine help prevent shingles herpes zoster recorded merck million million million sales years affected supply issues customers experienced backorders zostavax merck began filling backorders december company expects continue release doses product backorders expected continue least first quarter company anticipates sales future quarters affected availability supply due supply constraints new international launches immunization programs currently planned merck filed supplemental biologics license application fda use zostavax prevent shingles people years age sales pneumovax vaccine help prevent pneumococcal disease million million million increase compared due favorable pricing united states higher demand associated flu pandemic old merck entered exclusive agreement csl biotherapies csl subsidiary csl limited market distribute afluria csls seasonal influenza flu vaccine united states flu seasons terms agreement company assume responsibility aspects commercialization afluria united states csl supply afluria merck retain responsibility marketing vaccine outside united states afluria indicated active immunization persons age months older influenza disease caused influenza virus subtypes type b present vaccine sales afluria million january pedvaxhib became fully available united states routine vaccination well booster dose catchup vaccination timing availability outside united states dependent upon local regulatory requirements comvax became available third quarter pediatricadolescent formulation vaqta vaccine hepatitis available mercks adult formulation available united states outside united states supply vaqta limited availability vary region pediatricadolescent formulation recombivax hb vaccine hepatitis b available dialysis formulation became available third quarter company currently anticipates availability adult formulation recombivax hb first half april merck massbiologics mbl university massachusetts medical school entered agreement provides merck exclusive rights market distribute mbls tetanus diphtheria toxoids adsorbed td vaccine united states exception massachusetts mbl continue distributing vaccine merck began distributing td vaccine june womens health endocrine worldwide sales nuvaring contraceptive product million million postmerger period global sales follistim aq marketed countries outside united states puregon fertility treatment million million postmerger period puregon lost market exclusivity eu august products contained womens health endocrine franchise include among others implanon singlerod subdermal contraceptive implant cerazette progestin oral contraceptive elonva fertility treatment company currently experiencing difficulty manufacturing certain womens health products company working resolve issues january company azlp teva acquired ivax pharmaceuticals inc ivax entered settlement agreement resolve patent litigation respect esomeprazole nexium provides tevaivax bring generic esomeprazole product market united states may old merck azlp entered similar agreement ranbaxy laboratories ltd ranbaxy provides ranbaxy bring generic esomeprazole product market united states may company faces challenges respect outstanding patent infringement matters esomeprazole see note consolidated financial statements astrazeneca option buy old mercks interest nexium prilosec exercisable company believes likely astrazeneca exercise option see selected joint venture affiliate information animal health animal health includes pharmaceutical vaccine products prevention treatment control disease major farm companion animal species animal health sales affected intense competition frequent introduction generic products global sales animal health products totaled billion reflecting continued strong performance among cattle poultry companion animal swine products global sales animal health products totaled million postmerger period first quarter sanofi aventis exercised option require company seek combine animal health business merial limited form animal health joint venture formation animal health joint venture expected dilutive companys earnings first months transaction closes see selected joint venture affiliate information consumer care consumer care products include overthecounter foot care sun care products dr scholls foot care products claritin nondrowsy antihistamines miralax treatment occasional constipation coppertone sun care products global sales consumer care products billion reflecting strong performance number key brands including dr scholls coppertone consumer care product sales million postmerger period consumer care product sales affected competition frequent competitive product introductions consumer spending patterns april zegerid otc overthecounter option treating frequent heartburn without prescription became available drug stores grocery stores mass merchandisers club stores nationwide fda approved zegerid december overthecounter use costs expenses millions change c hange materials production marketing administrative research development restructuring costs equity income affiliates income expense net greater includes billion iprd impairment charges restructuring costs years materials production materials production costs billion billion billion materials production costs postmerger period include expenses related sale legacy scheringplough msp partnership products additionally costs unfavorably affected billion billion respectively expense amortization intangible assets billion billion respectively amortization purchase accounting adjustments scheringploughs inventories recognized merger also included materials production costs million million million respectively costs associated restructuring activities including accelerated depreciation asset writeoffs related planned sale closure manufacturing facilities separation costs associated manufacturingrelated headcount reductions incurred reflected restructuring costs discussed see note consolidated financial statements gross margin compared amortization intangible assets purchase accounting adjustments inventories recorded result merger restructuring charges reflected periods noted unfavorable impact percentage points percentage points percentage points marketing administrative marketing administrative expenses billion billion billion increases driven largely inclusion expenses related scheringplough activities postmerger period additionally million mergerrelated costs recognized consisting largely integration costs well costs incurred conjunction potential formation animal health joint venture sanofiaventis compared million mergerrelated costs recognized consisting largely transaction costs directly related merger including advisory legal fees integration costs addition expenses included million restructuring costs primarily related accelerated depreciation facilities closed divested increases partially offset initiatives reduce cost base separation costs associated sales force reductions incurred reflected restructuring costs discussed addition marketing administrative expenses benefited foreign exchange marketing administrative expenses included million million million respectively additional reserves solely future vioxx legal defense costs see note consolidated financial statements information vioxx litigation related matters research development research development expenses billion billion billion increases due part incremental expenditures associated inclusion scheringploughs operations postmerger period addition company recorded billion iprd impairment charges amount billion related writedown intangible asset vorapaxar resulting developments clinical program compound see research development remaining million iprd impairment charges attributable compounds abandoned determined either alternative use returned respective licensor well expected delays launch timing changes cash flow assumptions certain compounds company may recognize additional noncash impairment charges future cancellation delay legacy scheringplough pipeline programs measured fair value capitalized connection merger charges could material additionally research development expenses reflect million million million respectively costs associated restructuring activities including accelerated depreciation asset abandonment costs see note consolidated financial statements also research development expenses include million payment related restructuring mercks agreement ariad pharmaceuticals inc ariad see research development expenses reflect upfront payments associated external licensing activity research development expenses compared also reflect increase development spending support continued advancement research pipeline including investments latestage clinical trials segment reporting research development costs unallocated sharebased compensation total pretax sharebased compensation expense million million million december million total pretax unrecognized compensation expense related nonvested stock option restricted stock unit performance share unit awards recognized weighted average period years segment reporting sharebased compensation costs unallocated expenses restructuring costs restructuring costs million billion billion respectively restructuring costs recorded million related merger restructuring program million related restructuring program remaining difference related legacy scheringplough productivity transformation program included gain sale manufacturing facility restructuring costs recorded billion related merger restructuring program million related restructuring program million related legacy scheringplough productivity transformation program restructuring costs recorded million related restructuring program remainder associated restructuring program separation costs million billion million respectively incurred associated actual headcount reductions well estimated expenses existing severance programs headcount reductions probable could reasonably estimated merck eliminated positions related merger restructuring program related restructuring program remainder legacy scheringplough productivity transformation program positions related restructuring program positions approximately related restructuring program related restructuring program position eliminations comprised actual headcount reductions elimination contractors vacant positions also included restructuring costs curtailment settlement termination charges pension postretirement benefit plans well contract termination shutdown costs segment reporting restructuring costs unallocated expenses additional costs associated companys restructuring activities included materials production marketing administrative research development equity income affiliates equity income affiliates reflects performance companys joint ventures equity method affiliates declined million equity income affiliates longer includes equity income msp partnership became whollyowned company result merger therefore results included consolidated results company beginning date merger merial limited merial due sale old mercks interest september addition lower partnership returns azlp well lower equity income spmsd result restructuring charges recorded joint venture also contributed decline equity income affiliates declined billion primarily driven lower equity income msp partnership merial resulting mergerrelated events discussed partially offset higher partnership returns azlp see selected joint venture affiliate information income expense net change income expense net compared primarily reflects billion gain resulting recognizing mercks previously held equity interest msp partnership fair value result obtaining control msp partnership merger see note consolidated financial statements billion gain sale old mercks interest merial see note consolidated financial statements million charge vioxx liability reserve recorded see note consolidated financial statements lower recognized net gains companys investment portfolio charges recorded related settlement certain pending average wholesale prices litigation see note consolidated financial statements lower interest income higher interest expense result merger also contributed yearoveryear change addition discussed company recognized exchange losses million due two venezuelan currency devaluations year items partially offset million income recognized upon astrazenecas asset option exercise see note consolidated financial statements million income recognized settlement certain disputed royalties effective january company required remeasure local currency operations venezuela us dollars venezuelan economy determined hyperinflationary effective january venezuelan government devalued currency bsf per us dollar twotiered official exchange rate essentials rate bsf per us dollar nonessentials rate bsf per us dollar throughout company settled transactions essentials rate therefore remeasured monetary assets liabilities utilizing essentials rate december venezuelan government announced would eliminate essentials rate effective january transactions would settled official rate bsf per us dollar result announcement company remeasured december monetary assets liabilities new official rate included income expense net billion gain related mercks previously held interest msp partnership billion gain recognized sale old mercks interest merial also included income expense net million investment portfolio recognized net gains million charge related settlement vioxx thirdparty payor litigation united states included income expense net aggregate gain distribution azlp billion gain million related sale remaining worldwide rights aggrastat million expense contribution merck company foundation million investment portfolio recognized net losses million charge related resolution investigation whether old merck violated state consumer protection laws respect sales marketing vioxx merck experienced decline interest income compared primarily result lower interest rates change investment portfolio mix toward cash shorter dated securities anticipation merger merck recognized higher interest expense largely due million commitment fees incremental interest expense related financing merger segment profits millions pharmaceutical segment profits nonreportable segment profits income income taxes segment profits comprised segment revenues less certain elements materials production costs operating expenses including components equity income loss affiliates depreciation amortization expenses internal management reporting presented chief operating decision maker merck allocate production costs standard costs research development expenses general administrative expenses cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed assets utilized divisions therefore included segment profits also excluded determination segment profits vioxx liability reserve gain astrazenecas asset option exercise recognized gains related msp partnership disposition merial gain distribution azlp well amortization purchase accounting adjustments iprd impairment charges restructuring costs taxes paid joint venture level portion equity income additionally segment profits reflect expenses corporate manufacturing cost centers miscellaneous income expense unallocated items reflected table also included miscellaneous corporate profits operating profits related thirdparty manufacturing sales divested products businesses well supply sales adjustments eliminate effect double counting certain items income expense pharmaceutical segment profits rose increased increases largely driven inclusion legacy scheringplough results taxes income effective income tax rate effective tax rate reflects unfavorable impacts purchase accounting charges iprd impairment charges restructuring charges vioxx liability reserve tax impact recorded million charge associated change tax law requires taxation prescription drug subsidy companys retiree health benefit plans enacted first quarter part us health care reform legislation impact astrazenecas asset option exercise unfavorable impacts partially offset million tax benefit changes foreign entitys tax rate resulted reduction deferred tax liabilities product intangibles recorded conjunction merger favorable impact enactment tax extenders legislation including rd tax credit favorable impact foreign earnings dividends companys foreign subsidiaries effective tax rate reflects favorable impacts increased income lower tax jurisdictions includes favorable impact msp partnership gain higher expenses certain jurisdictions including amortization purchase accounting adjustments restructuring costs effective income tax rate also benefited tax settlements including previously announced settlement canada revenue agency cra favorable impacts partially offset unfavorable effect gain sale old mercks interest merial taxable united states combined federal state tax rate approximately effective tax rate reflects favorable impacts relating tax settlements resulted reduction liability unrecognized tax benefits approximately million realization foreign tax credits favorable tax impact foreign exchange rate changes fourth quarter particularly strengthening japanese yen us dollar partially offset unfavorable impact resulting azlp gain fully taxable united states combined federal state tax rate approximately first quarter old merck decided distribute certain prior years foreign earnings united states resulted utilization foreign tax credits foreign tax credits arose result tax payments made outside united states prior years became realizable first quarter based change old mercks decision distribute foreign earnings net income earnings per common share net income attributable merck co inc million billion billion earnings per common share assuming dilution available common shareholders eps declines net income eps compared primarily due gains recognized associated msp partnership result merger disposition merial well incremental costs result merger including recognition full year amortization intangible assets inventory stepup addition iprd impairment charges vioxx liability reserve lower equity income affiliates impact us health care reform legislation also contributed declines net income eps increases net income earnings per share compared largely driven msp partnership merial gains partially offset incremental charges associated merger including amortization intangible assets inventory stepup recognition mergerrelated costs eps also affected dilutive impact shares issued merger nongaap income nongaap eps nongaap income nongaap eps alternative views companys performance used management merck providing management believes information enhances investors understanding companys results nongaap income nongaap eps exclude certain items nature items impact analysis underlying business performance trends excluded items consist certain purchase accounting items related merger restructuring activities mergerrelated costs certain items excluded items significant components understanding assessing financial performance therefore information non gaap income non gaap eps considered addition lieu net income eps prepared accordance generally accepted accounting principles united states gaap additionally since nongaap income nongaap eps measures determined accordance gaap standardized meaning prescribed gaap therefore may comparable calculation similar measures companies nongaap income nongaap eps important internal measures company senior management receives monthly analysis operating results includes nongaap income nongaap eps performance company measured basis along performance metrics senior managements annual compensation derived part using nongaap income nongaap eps reconciliation gaap financial measures nongaap financial measures follows millions pretax income reported gaap increase decrease excluded items purchase accounting adjustments restructuring costs mergerrelated costs items vioxx liability reserve gain astrazeneca asset option exercise gain related msp partnership gain merial divestiture gain distribution azlp taxes income reported gaap estimated tax benefit expense excluded items tax benefit foreign entity tax rate changes tax charge related us health care reform legislation nongaap taxes income nongaap net income eps assuming dilution reported gaap eps difference nongaap eps assuming dilution represents difference calculated gaap eps calculated nongaap eps may different amount calculated dividing impact excluded items weighted average shares purchase accounting adjustments nongaap income nongaap eps exclude ongoing impact certain amounts recorded connection merger amounts include amortization intangible assets inventory stepup well iprd impairment charges see research development restructuring costs nongaap income nongaap eps exclude costs related restructuring actions including restructuring activities related merger see note consolidated financial statements amounts include employee separation costs accelerated depreciation associated facilities closed divested accelerated depreciation costs represent difference depreciation expense recognized revised useful life site based upon anticipated date site closed divested depreciation expense determined utilizing useful life prior restructuring actions company undertaken restructurings different types covered periods therefore charges considered nonrecurring however management excludes amounts nongaap income nongaap eps believes helpful understanding performance continuing business mergerrelated costs nongaap income nongaap eps exclude transaction costs associated directly merger well integration costs costs excluded management believes costs unique merger transaction representative ongoing normal business activities integration costs associated merger occur several years however impacts within year vary integration progresses costs include costs associated potential formation animal health joint venture sanofiaventis certain items nongaap income nongaap eps exclude certain items items represent substantive unusual items evaluated individual basis evaluation considers quantitative qualitative aspect unusual nature generally represent items either result nature magnitude management would anticipate would occur part companys normal business regular basis certain items include vioxx liability reserve gain recognized upon astrazenecas asset option exercise gain recognizing mercks previously held equity interest msp partnership fair value result obtaining controlling interest merger gain divestiture old mercks interest merial gain distribution azlp research development chart reflecting companys current research pipeline february set forth item business research development research development update connection merger company began assessing pipeline identify promising highpotential compounds development full prioritization process completed company currently number candidates regulatory review united states internationally boceprevir investigational oral hepatitis c virus protease inhibitor currently development full data results two pivotal latestage studies boceprevir presented november annual meeting american association study liver disease showed boceprevir demonstrated significantly higher sustained virologic response rates adult patients previously failed treatment adult patients new treatment chronic hepatitis c virus genotype compared control primary objective studies based data regulatory applications boceprevir submitted accepted expedited review united states eu mka xr companys investigational extendedrelease formulation janumet accepted standard review fda company also moving forward planned regulatory filings countries outside united states extendedrelease formulation janumet investigational treatment type diabetes combines sitagliptin active component januvia metformin extended release commonlyprescribed medication type diabetes single tablet formulation designed provide new treatment option health care providers patients need two oral agents help control blood sugar convenience daily dosing sch nomace oral contraceptive combines selective progestin beta estradiol estrogen identical one naturally present womens body drug currently review eu also phase iii development us market mk cubicin daptomycin injection currently review japan previously disclosed cubist pharmaceuticals inc cubist entered license agreement old merck development commercialization cubicin treatment staph infection japan company commercial rights drug candidate merck develop commercialize cubicin whollyowned subsidiary japan cubist commercializes cubicin united states mkd combination januvia zocor treatment diabetes dyslipidemia accepted standard review fda addition candidates regulatory review company drug candidates phase iii development vorapaxar thrombin receptor antagonist antiplatelet protease activated receptor inhibitor studied prevention treatment thrombosis merck studying vorapaxar two major clinical endpoint trials evaluate investigational medicine prevention cardiac events tracer study patients acute coronary syndrome ended trap also known timi study patients prior heart attack stroke peripheral artery disease continuing large part studies designed eventdriven trials patients planned followed minimum one year completed enrollment january merck announced combined dsmb two studies reviewed available safety efficacy data made recommendations study changes chairpersons steering committees two studies study chairpersons agreed implement changes result tracer study patients discontinue study drug investigators begin close study timely orderly fashion trap study study drug continued patients experienced previous heart attack peripheral arterial disease approximately patients enrolled study immediately discontinued patients experienced stroke prior entry study course study merck subsequently announced chairman trap study reported investigators dsmb communicated based data safety efficacy available trials recommended subjects history stroke receive vorapaxar dsmb observed increase intracranial hemorrhage patients history stroke outweighed considerations potential benefit merck plans update projections regulatory filings vorapaxar company received efficacy safety data tracer determine updated completion date trap tracer accumulated predefined number primary major secondary endpoints although patients continue receive study drug pre specified oneyear follow merck continues expect efficacy safety data tracer become available later submitted presentation appropriate medical meetings result developments company concluded impairment triggering event related vorapaxar intangible asset although great deal information related developments remains unknown company utilizing market participant assumptions considering several different scenarios company concluded best estimate current fair value intangible asset related vorapaxar million resulted recognition impairment charge billion company continue monitor remaining asset value impairment mk ridaforolimus novel mtor mammalian target rapamycin inhibitor evaluated treatment cancer merck currently developing ridaforolimus multiple cancer indications exclusive license collaboration agreement ariad january ariad announced topline data showing ridaforolimus met primary endpoint improved progressionfree survival compared placebo phase iii succeed trial conducted patients metastatic soft tissue bone sarcomas previously favorable response chemotherapy complete findings succeed trial submitted presentation upcoming medical meeting trial remains active study participants continue followed gather additional data secondary endpoints including overall survival safety profile ridaforolimus merck currently plans file nda fda oral ridaforolimus subject final collection analysis available data trial mk saflutan tafluprost preservative free synthetic analogue prostaglandin f reduction elevated intraocular pressure appropriate patients primary openangle glaucoma ocular hypertension april old merck santen pharmaceutical co ltd announced worldwide licensing agreement tafluprost company continues anticipate filing nda fda saflutan previously disclosed old merck submitted filing nda fda mkc ezetimibe combined atorvastatin investigational medication treatment dyslipidemia fda refused file application fda identified additional manufacturing stability data needed company anticipates filing nda previously disclosed old merck announced delaying filing us application mk telcagepant companys investigational calcitonin generelated peptide cgrpreceptor antagonist acute treatment migraine decision based findings phase iia exploratory study small number patients taking telcagepant twice daily three months prevention migraine found marked elevations liver transaminases daily dosing regimen prevention study different dosing regimen used phase iii studies telcagepant intermittently administered one two doses treat individual migraine attacks occurred following meetings regulatory agencies end merck conducting additional safety study part overall phase iii program telcagepant company continues anticipate filing nda fda sch bridion sugammadex medication designed rapidly reverse effects certain muscle relaxants used part general anesthesia ensure patients remain immobile surgical procedures bridion received regulatory approval eu australia new zealand japan number markets prior merger scheringplough received complete response letter fda bridion following communication fda company assessing agencys feedback order determine new timetable response sch investigational allergy immunotherapy sublingual tablet ait grass pollen allergy company north american rights march data phase iii study children adolescents ages years grass pollen allergic rhinoconjunctivitis presented american academy allergy asthma immunology annual meeting allergic rhinoconjunctivitis runny nose itchy watery eyes due allergies common condition children adolescents ait dissolvable oral tablet designed prevent allergy symptoms inducing protective immune response allergies thereby treating underlying cause disease merck investigating ait treatment grass pollen allergic rhinoconjunctivitis children adults anticipated us filing date sch assessment sch ait ragweed allergy also phase iii development north american market anticipated filing date sch assessment sch zenhale fixed dose combination two previously approved drugs treatment asthma mometasone furoate formoterol fumarate dehydrate november company advised european medicines agency ema withdrawing application marketing authorization zenhale approved use asthma patients years age older united states dulera inhalation aerosol company decided withdraw application zenhale address questions outstanding company committee medicinal products human use ema company expects resubmit application future mkc candidate currently phase iii clinical development combines januvia pioglitazone another type diabetes therapy company expects file nda mkc fda mk odanacatib oral onceweekly investigational treatment osteoporosis postmenopausal women osteoporosis disease reduces bone density strength results increased risk bone fractures odanacatib cathepsin k inhibitor selectively inhibits cathepsin k enzyme cathepsin k known play central role function osteoclasts cells break existing bone tissue particularly protein components bone inhibition cathepsin k novel approach treatment osteoporosis fouryear data odanacatib presented october american society bone mineral research annual meeting clinical preclinical studies continue provide data potential odanacatib increase bone density cortical thickness bone strength treating osteoporosis company continues anticipate filing nda fda v ninevalent hpv vaccine development expand protection cancercausing hpv types phase iii clinical program underway merck anticipates filing biologics license application bla fda mka drug candidate combines extendedrelease niacin novel flushing inhibitor laropiprant mka demonstrated ability lower ldlcholesterol ldlc bad cholesterol raise hdlcholesterol hdlc good cholesterol lower triglycerides significantly less flushing traditional extended release niacin alone high ldlc low hdlc elevated triglycerides risk factors associated heart attacks strokes april old merck received nonapprovable action letter fda response nda mka meeting discuss letter fda stated additional efficacy safety data required suggested old merck wait results treatment hdl reduce incidence vascular events hpsthrive cardiovascular outcomes study expected completed company anticipates filing nda fda mka mka approved countries outside united states treatment dyslipidemia particularly patients combined mixed dyslipidemia characterized elevated levels ldlc triglycerides low hdlc patients primary hypercholesterolemia heterozygous familial nonfamilial marketed tredaptive cordaptive certain countries tredaptive used patients combination statins cholesterol lowering effects statin monotherapy inadequate tredaptive used monotherapy patients statins considered inappropriate tolerated mkb drug candidate combines novel approach raising hdlc lowering triglycerides extendedrelease niacin combined laropiprant proven benefits simvastatin one combination product merck seek approval mkb united states files complete response relating mka mk investigational dual orexin receptor antagonist potential new approach treatment chronic insomnia currently phase iii development june clinical results phase iib study presented annual meeting associated professional sleep societies showed mk significantly effective placebo improving overall sleep efficiency night one end week four patients primary insomnia mk generally welltolerated study orexins neuropeptides chemical messengers released specialized neurons hypothalamus region brain believed important regulator brains sleepwake process phase iii trials studying efficacy safety mk elderly nonelderly insomnia patients ongoing merck anticipates filing regulatory applications mk sch elonva corifollitropin alpha injection approved eu controlled ovarian stimulation combination gnrh antagonist development multiple follicles women participating assisted reproductive technology program currently phase iii development united states company continues anticipate filing nda fda sch preladenant selective adenosine receptor antagonist phase iii development treatment parkinsons disease company continues anticipate filing nda fda beyond v inactivated varicellazoster virus vaccine phase iii development prevention herpes zoster company anticipates filing nda fda beyond mk anacetrapib investigational inhibitor cholesteryl ester transfer protein cetp investigated lipid management raise hdlc reduce ldlc november researchers presented results phase iii define determining efficacy tolerability cetp inhibition anacetrapib study anacetrapib american heart association scientific sessions trial patients coronary heart disease chd chd risk equivalents anacetrapib showed significant differences placebo primary safety measures studied significant differences mean changes blood pressure anacetrapib placebo treatment groups significant differences serum electrolytes aldosterone levels week treatment phase prespecified adjudicated cardiovascular endpoint defined cardiovascular death myocardial infarction unstable angina stroke occurred anacetrapibtreated patients compared placebotreated patients weeks anacetrapib decreased ldlc increased hdlc patients already treated statin guidelinerecommended ldlc goal based results company intends move forward study anacetrapib large cardiovascular clinical outcomes trial company anticipates filing nda fda beyond company maintains number longterm exploratory fundamental research programs biology chemistry well research programs directed toward product development companys research development model designed increase productivity improve probability success prioritizing companys research development resources disease areas unmet medical needs scientific opportunity commercial opportunity merck managing research development portfolio across diverse approaches discovery development balancing investments appropriately novel innovative targets potential major impact human health developing bestinclass approaches delivering maximum value new medicines vaccines new indications new formulations another important component companys sciencebased diversification based expanding companys portfolio modalities include small molecules vaccines also biologics peptides small proteins antibodies rnai merck moved diversify portfolio merck bioventures division potential harness market opportunity presented biological medicine patent expiries delivering high quality followon biologic products enhance access patients worldwide company continue pursue appropriate external licensing opportunities integration efforts research development continue focus integrating research operations legacy companies including providing effective transition employees realizing projected merger synergies form cost savings revenue growth opportunities maintaining momentum companys latestage pipeline overall companys global operating model align franchise function well align resources disease area priorities balance capacity across discovery phases allow company act upon programs highest probability success additionally across disease area priorities companys strategy designed expand access worldwide external science incorporate external research key component companys early discovery pipeline order translate basic research productivity latestage clinical success companys clinical pipeline includes candidates multiple disease areas including atherosclerosis cancer cardiovascular diseases diabetes infectious diseases inflammatoryautoimmune diseases insomnia migraine neurodegenerative diseases ophthalmics osteoporosis psychiatric diseases respiratory diseases womens health company supplements internal research aggressive licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well new technologies inprocess research development connection merger company recorded fair value human animal health research projects underway scheringplough msp partnership fair value projects allocated pharmaceutical animal health operating segments billion billion respectively fair values identifiable intangible assets related iprd determined using income approach fair value estimated based assets probability adjusted future net cash flows reflect different stages development product associated probability successful completion net cash flows discounted present value using discount rates ranged actual cash flows likely different assumed significant projects include boceprevir bridion vorapaxar well ezetimibeatorvastatin combination product projects discussed detail noted company filed nda fda boceprevir anticipates filing nda ezetimibeatorvastatin combination product fda company determined developments clinical research program vorapaxar discussed constituted triggering event required company evaluate vorapaxar intangible asset impairment although great deal information related developments remains unknown company utilizing market participant assumptions considering several different scenarios company concluded best estimate current fair value intangible asset related vorapaxar million resulted recognition impairment charge billion company continue monitor remaining asset value impairment company anticipates results tracer clinical trial available later also company recorded additional million iprd impairment charges attributable compounds abandoned determined either alternative use returned respective licensor well expected delays launch timing changes cash flow assumptions certain compounds company also recognized intangible assets fair value research projects underway connection smartcells inc smartcells acquisition insmed inc acquisition see note consolidated financial statements iprd projects remain development subject inherent risks uncertainties drug development possible company able successfully develop complete iprd programs profitably commercialize underlying product candidates time periods receive approvals fda regulatory agencies subject uncertainty significant delays approval process companys failure obtain approval would delay prevent company realizing revenues products additionally certain iprd programs fail abandoned development company realize future cash flows estimated recorded iprd merger acquisition date company may also recover research development expenditures made since merger develop program circumstances occur companys future operating results could adversely affected company may recognize impairment charges charges could material additional research development required programs reach technological feasibility costs complete research projects depend whether projects brought final stages development ultimately submitted fda regulatory agencies approval december estimated costs complete projects acquired connection merger phase iii development human health analogous stage development animal health approximately billion acquisitions research collaborations license agreements merck continues remain focused augmenting internal efforts capitalizing growth opportunities drive near longterm growth company completed transactions across broad range therapeutic categories including earlystage technology transactions merck actively monitoring landscape growth opportunities meet companys strategic criteria highlights activities include december company acquired outstanding stock smartcells private company developing glucose responsive insulin formulation treatment diabetes mellitus total purchase consideration company determined fair value acquisition date million included upfront cash payment contingent consideration consisting future clinical development regulatory milestones well contingent consideration future sales products resulting acquisition transaction accounted acquisition method accounting accordingly assets liabilities recorded respective fair values acquisition date determination fair value requires management make significant estimates assumptions connection acquisition substantially preliminary purchase price allocated iprd remaining net assets acquired significant fair value contingent consideration determined utilizing probability weighted estimated cash flow stream adjusted expected timing payment subsequent acquisition date quarterly basis contingent consideration liability remeasured current fair value changes recorded earnings results operations smartcells included companys results operations date acquisition significant certain estimated values yet finalized may subject change company expects finalize amounts soon possible later one year acquisition date february company completed acquisition avecia biologics limited avecia total purchase price approximately million avecia contract manufacturing organization specific expertise microbialderived biologics terms agreement company acquired avecia assets including avecias process development scaleup manufacturing quality business support operations located billingham united kingdom transaction accounted business combination accordingly assets acquired liabilities assumed recorded respective fair values acquisition date determination fair value requires management make significant estimates assumptions connection acquisition substantially purchase price allocated avecias property plant equipment goodwill remaining net assets acquired material transaction closed february accordingly results operations acquired business included companys results operations beginning acquisition date pro forma financial information included avecias historical financial results significant compared companys financial results may merck announced restructured codevelopment cocommercialization agreement ariad ridaforolimus mk investigational orally available mtor inhibitor currently evaluated treatment multiple cancer types exclusive license agreement restructured agreement merck acquired full control development worldwide commercialization ridaforolimus ariad received million upfront fee company recorded research development expense eligible receive milestone payments associated regulatory filings approvals ridaforolimus multiple cancer indications achievement significant sales thresholds lieu profit split us sales provided previous agreement ariad receive royalties global net sales ridaforolimus sales recorded merck merck assumed responsibility activities acquired decision rights matters relating development manufacturing commercialization ridaforolimus investigational new drug application transferred merck merck file marketing application worldwide oncology indications lead interactions regulatory agencies agreement terminable merck upon nine months notice immediately upon good faith determination serious safety issue agreement terminable either party result insolvency party uncured material breach party ariad failure merck perform certain product development responsibilities selected joint venture affiliate information expand research base realize synergies combining capabilities opportunities assets previous years old merck formed number joint ventures astrazeneca lp old merck entered agreement astra ab astra develop market astras products royaltybearing license old mercks total sales astra products reached level triggered first step establishment joint venture business carried astra merck inc ami old merck astra owned share joint venture formed developed marketed astras new prescription medicines united states including prilosec first class medications known proton pump inhibitors slows production acid cells stomach lining old merck astra completed restructuring ownership operations joint venture whereby old merck acquired astras interest ami renamed kbi inc kbi contributed kbis operating assets new us limited partnership astra pharmaceuticals lp partnership exchange limited partner interest astra contributed net assets wholly owned subsidiary astra usa inc partnership exchange general partner interest partnership renamed astrazeneca lp azlp upon astras merger zeneca group plc astrazeneca merger became exclusive distributor products kbi retained rights maintaining limited partner interest azlp merck consent protective rights intended preserve business economic interests including restrictions power general partner make certain distributions dispositions furthermore limited events default additional rights granted company including powers direct actions remove replace partnerships chief executive officer chief financial officer merck earns ongoing revenue based sales kbi products revenue billion billion billion respectively primarily relating sales nexium well prilosec addition merck earns certain partnership returns recorded equity income affiliates returns include priority return provided partnership agreement variable returns based part upon sales certain former astra usa inc products preferential return representing mercks share undistributed azlp gaap earnings returns aggregated million million million respectively astrazeneca merger constituted trigger event kbi restructuring agreements resulted partial redemption old mercks interest certain azlp product rights upon redemption old merck received billion azlp amount based primarily multiple old mercks average annual variable returns derived sales former astra usa inc products three years prior redemption limited partner share agreed value old merck recorded billion pretax gain partial redemption partial redemption old mercks interest product rights result change old mercks limited partnership interest result astrazeneca merger exchange old mercks relinquishment rights future astra products existing pending us patents time merger astra paid million advance payment advance payment deferred remained subject trueup calculation trueup amount directly dependent fair market value march astra product rights retained old merck calculated trueup amount million returned azlp old merck recognized pretax gain million related residual advance payment balance provisions kbi restructuring agreements trigger event occurred sum limited partner share agreed value appraised value discussed trueup amount guaranteed minimum billion distribution limited partner share agreed value less payment trueup amount resulted cash receipts old merck billion aggregate pretax gain billion included income expense net also march billion outstanding loan astra plus interest redemption date settled result transactions old merck received net proceeds azlp billion conjunction restructuring discussed astra purchased option asset option payment million recorded deferred income buy old mercks interest kbi products excluding gastrointestinal medicines nexium prilosec nonppi products april astrazeneca exercised asset option merck received million astrazeneca representing net present value march projected future pretax revenue received old merck nonppi products appraised value recorded reduction companys investment azlp company recognized million deferred income component income expense net addition old merck granted astra option shares option buy old mercks common stock interest kbi therefore old mercks interest nexium prilosec exercisable exercise price shares option based net present value estimated future net sales nexium prilosec determined time exercise subject certain trueup mechanisms company believes likely astrazeneca exercise shares option merckscheringplough partnership old merck scheringplough collectively partners entered agreement create equallyowned partnership develop market united states new prescription medicines cholesterol management ezetimibe first new class cholesterollowering agents launched united states zetia marketed ezetrol outside united states combination product containing active ingredients zetia zocor approved united states vytorin marketed inegy outside united states cholesterol agreements provided sharing operating income generated msp partnership based upon percentages varied product sales level country operating income included expenses partners contractually agreed share expenses incurred support msp partnership shared partners included equity income affiliates however costs reflected overall results partners sales joint venture products follows millions premerger postmerger total vytorin zetia amounts exclude sales products partners outside msp partnership results old mercks interest msp partnership prior merger reflected equity income affiliates billion billion result merger msp partnership whollyowned company activity resulting sale msp partnership products merger consolidated mercks results discussion performance products see sales merial limited old merck rhnepoulenc sa sanofiaventis combined animal health businesses form merial limited merial fully integrated animal health company standalone joint venture owned party merial provides comprehensive range pharmaceuticals vaccines enhance health wellbeing performance wide range animal species september old merck sold interest merial sanofiaventis billion cash sale resulted recognition billion pretax gain reflected income expense net connection sale merial old merck sanofiaventis scheringplough signed call option agreement provided sanofiaventis option require company combine intervetscheringplough animal health business merial form animal health joint venture would owned equally company sanofiaventis march sanofiaventis exercised option part call option agreement value merial fixed billion minimum total value received company contributing intervetscheringplough combined entity would billion subject customary transaction adjustments consisting floor valuation intervetscheringplough fixed minimum billion subject potential upward revision based valuation exercise two parties additional payment sanofiaventis million upon completion valuation exercise parties agreed future payment million would made sanofiaventis company addition million payment referred payments including adjustments debt certain liabilities made upon closing transaction formation new animal health joint venture sanofiaventis subject execution final agreements regulatory review united states europe countries customary closing conditions march parties signed contribution agreement obligates subject regulatory approval form joint venture company expects transaction close third quarter companys agreement sanofiaventis provides transaction consummated march either party may terminate proposed joint venture without paying breakup fee penalty sales joint venture products follows millions fipronil products biological products avermectin products products amounts include sales september divestiture date sanofi pasteur msd old merck pasteur mrieux connaught sanofi pasteur sa established equallyowned joint venture market vaccines europe collaborate development combination vaccines distribution europe sales joint venture products follows millions gardasil influenza vaccines viral vaccines rotateq hepatitis vaccines vaccines johnson johnsonmerck consumer pharmaceuticals company old merck formed joint venture johnson johnson develop market broad range nonprescription medicines us consumers owned venture subsequently expanded canada significant joint venture products pepcid ac overthecounter form companys ulcer medication pepcid well pepcid complete overthecounter product combines companys ulcer medication antacids sales joint venture products follows millions gastrointestinal products products capital expenditures capital expenditures billion billion billion expenditures united states million million million capital expenditures estimated billion depreciation expense billion billion billion billion billion billion respectively applied locations united states total depreciation expense included accelerated depreciation million million million respectively associated restructuring activities see note consolidated financial statements analysis liquidity capital resources mercks strong financial profile enables fully fund research development focus external alliances support inline products maximize upcoming launches providing significant cash returns shareholders selected data millions working capital total debt total liabilities equity cash provided operations total debt cash provided operating activities billion billion billion increase cash provided operating activities compared primarily reflects inclusion full year legacy scheringplough operations well billion payments vioxx settlement funds million payment made connection previously disclosed settlement canada revenue agency cra cash provided operating activities reflects billion received connection partial redemption old mercks partnership interest azlp representing distribution old mercks accumulated earnings investment azlp since inception cash provided operating activities also affected million payment made connection previously disclosed resolution investigations civil claims federal state authorities relating certain past marketing selling activities million payments vioxx settlement funds cash provided operating activities continues companys primary source funds finance operating needs capital expenditures treasury stock purchases dividends paid shareholders global economic downturn sovereign debt issues among factors caused foreign receivables deteriorate certain european countries company continues receive payment receivables conditions may continue result increase average length time takes collect accounts receivable outstanding impact cash provided operating activities cash used investing activities billion compared cash provided investing activities billion change reflects lower proceeds sales securities investments higher purchases securities investments well decrease restricted assets proceeds disposition old mercks interest merial partially offset use cash fund merger proceeds received related astrazenecas asset option exercise cash provided investing activities billion compared cash used investing activities billion change primarily driven release restricted cash primarily due release pledged collateral certain vioxxrelated matters lower purchases securities investments proceeds disposition old mercks interest merial increases cash used investing activities partially offset use cash fund merger well distribution azlp representing return old mercks investment azlp cash used financing activities billion compared billion reflecting lower proceeds issuance debt purchases treasury stock increased dividends paid stockholders higher payments debt partially offset increase shortterm borrowings cash used financing activities billion compared billion reflecting higher proceeds issuance debt purchases treasury stock lower payments debt partially offset net decrease shortterm borrowings dividends paid stockholders billion billion billion december total worldwide cash investments billion including billion cash cash equivalents shortterm investments billion longterm investments large portion cash investments held foreign jurisdictions working capital levels adequate meet operating requirements company previously disclosed october cra issued old merck notice reassessment containing adjustments related certain intercompany pricing matters february old merck cra negotiated settlement agreement regard matters accordance settlement old merck paid additional tax approximately million us dollars interest approximately million us dollars additional amounts penalties due assessment settlement accounted first quarter old merck previously established reserves matters significant portion taxes paid expected creditable us tax purposes resolution matters material effect old mercks financial position liquidity respect associated collateral discussed addition previously disclosed cra proposed additional adjustments relating intercompany pricing matters adjustments would increase canadian tax due approximately million us dollars plus approximately million us dollars interest december company disagrees positions taken cra believes without merit company continues contest assessments cra appeals process cra expected prepare similar adjustments later years management believes resolution matters material effect companys financial position liquidity connection appeals process discussed related old merck pledged cash investments collateral two financial institutions one provided guarantee cra quebec ministry revenue representing portion tax interest assessed guarantee quebec ministry revenue expired first quarter collateral associated guarantee cra totaled approximately million december included deferred income taxes current assets assets consolidated balance sheet guarantee replaced guarantee collateralized accordingly collateral associated original guarantee released reclassified cash investments irs finalized examination scheringploughs tax years audit cycle company reached agreement irs adjustment income related intercompany pricing matters income adjustment mostly reduced nols tax credit carryforwards additionally company seeking resolution one issue raised examination irs administrative appeals process companys reserves uncertain tax positions adequate cover adjustments related examination period irs began examination tax years company irss examination old mercks federal income tax returns ongoing expected conclude within next months companys contractual obligations december follows payments due period millions total thereafter purchase obligations loans payable current portion longterm debt longterm debt interest related debt obligations unrecognized tax benefits operating leases december companys consolidated balance sheet reflects liabilities unrecognized tax benefits interest penalties billion including million reflected current liability due high degree uncertainty regarding timing future cash outflows liabilities unrecognized tax benefits beyond one year reasonable estimate period cash settlement years beyond made purchase obligations consist primarily goods services enforceable legally binding include obligations minimum inventory contracts research development advertising amounts reflected research development obligations include contingent milestone payments loans payable current portion longterm debt also reflects million longdated notes subject repayment option holders annual basis required funding obligations relating companys pension postretirement benefit plans expected material however company currently anticipates contributing approximately million million respectively pension plans postretirement benefit plans table reflect million vioxx liability reserve recorded connection anticipated resolution dojs investigation related vioxx companys discussions government ongoing concluded certainty definitive resolution timing potential payment december merck closed underwritten public offering billion senior unsecured notes consisting million aggregate principal amount notes due billion aggregate principal amount notes due interest notes payable semiannually notes series redeemable whole part time companys option varying redemption prices proceeds notes used general corporate purposes including reduction shortterm debt december company filed securities registration statement securities exchange commission sec automatic shelf registration process available wellknown seasoned issuers effective three years company executed new billion day credit facility terminated old mercks billion incremental facility due expire november billion revolving credit facility scheduled mature april companys billion credit facility maturing august remains outstanding outstanding facilities provide backup liquidity companys commercial paper borrowing facility used general corporate purposes company drawn funding either facility connection merger effective november new merck executed full unconditional guarantee existing debt old merck old merck executed full unconditional guarantee existing debt new merck excluding commercial paper including payments principal interest guarantees extend debt issued subsequent merger companys longterm credit ratings assigned moodys investors service standard poors aa stable outlook aa stable outlook respectively ratings continue allow access capital markets flexibility obtaining funds competitive terms company continues maintain conservative financial profile company places cash investments instruments meet high credit quality standards specified investment policy guidelines guidelines also limit amount credit exposure one issuer despite strong financial profile certain contingent events realized discussed note consolidated financial statements could material adverse impact companys liquidity capital resources company participate offbalance sheet arrangements involving unconsolidated subsidiaries provide financing potentially expose company unrecorded financial obligations november february board directors declared quarterly dividend per share companys common stock first second quarters respectively november board directors approved purchases time billion mercks common stock treasury company purchased billion common stock program purchases treasury stock made old merck purchased billion treasury stock previous program approved old mercks board directors july financial instruments market risk disclosures company manages impact foreign exchange rate movements interest rate movements earnings cash flows fair values assets liabilities operational means use various financial instruments including derivative instruments significant portion companys revenues earnings foreign affiliates exposed changes foreign exchange rates objectives accounting related companys foreign currency risk management program well interest rate risk management activities discussed foreign currency risk management significant portion companys revenues denominated foreign currencies company established revenue hedging balance sheet risk management programs protect volatility future foreign currency cash flows changes fair value caused volatility foreign exchange rates objective revenue hedging program reduce potential longerterm unfavorable changes foreign exchange decrease us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen achieve objective company partially hedge forecasted foreign currency denominated thirdparty intercompany distributor entity sales expected occur planning cycle typically three years future company layer hedges time increasing portion thirdparty intercompany distributor entity sales hedged gets closer expected date forecasted foreign currency denominated sales probable hedged transaction occur portion sales hedged based assessments costbenefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments hedged anticipated sales specified component portfolio similarly denominated foreign currencybased sales transactions responds hedged risk manner company manages anticipated transaction exposure principally purchased local currency put options provide company right obligation sell foreign currencies future predetermined price us dollar strengthens relative currency hedged anticipated sales total changes options cash flows offset decline expected future us dollar cash flows hedged foreign currency sales conversely us dollar weakens options value reduces zero company benefits increase value anticipated foreign currency cash flows company also utilizes forward contracts revenue hedging program us dollar strengthens relative currency hedged anticipated sales increase fair value forward contracts offsets decrease expected future us dollar cash flows hedged foreign currency sales conversely us dollar weakens decrease fair value forward contracts offsets increase value anticipated foreign currency cash flows weaker us dollar would result net benefit market value mercks hedges would declined estimated million million respectively uniform weakening us dollar december market value determined using foreign exchange option pricing model holding factors except exchange rates constant merck principally uses purchased local currency put options uniform weakening us dollar would yield largest overall potential loss market value options sensitivity measurement assumes change one foreign currency relative us dollar would affect foreign currencies relative us dollar although predictive nature company believes threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar cash flows contracts reported operating activities consolidated statement cash flows primary objective balance sheet risk management program mitigate exposure foreign currency denominated net monetary assets foreign subsidiaries us dollar functional currency effects volatility foreign exchange might occur prior conversion us dollars instances merck principally utilizes forward exchange contracts enable company buy sell foreign currencies future fixed exchange rates economically offset consequences changes foreign exchange monetary assets merck routinely enters contracts offset effects exchange exposures denominated developed country currencies primarily euro japanese yen exposures developing country currencies company enter forward contracts partially offset effects exchange exposures deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate cost hedging instrument company also minimize effect exchange monetary assets liabilities managing operating activities net asset positions local level applicable company uses forward contracts hedge changes fair value certain foreign currency denominated availableforsale securities attributable fluctuations foreign currency exchange rates derivative contracts designated fair value hedges sensitivity analysis changes value us dollar foreign currency denominated derivatives investments monetary assets liabilities indicated us dollar uniformly weakened currency exposures company december income taxes would declined approximately million company net short position relative major foreign currencies consideration forward contracts uniform weakening us dollar yield largest overall potential net loss earnings due exchange december company net long position relative major foreign currencies consideration forward contracts therefore uniform strengthening us dollar would reduced income taxes million measurement assumes change one foreign currency relative us dollar would affect foreign currencies relative us dollar although predictive nature company believes threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar cash flows contracts reported operating activities consolidated statement cash flows effective january company required remeasure local currency operations venezuela us dollars venezuelan economy determined hyperinflationary effective january venezuelan government devalued currency bsf per us dollar twotiered official exchange rate essentials rate bsf per us dollar nonessentials rate bsf per us dollar throughout company settled transactions essentials rate therefore remeasured monetary assets liabilities utilizing essentials rate december venezuelan government announced would eliminate essentials rate effective january transactions would settled official rate bsf per us dollar result announcement company remeasured december monetary assets liabilities new official rate foreign exchange risk also managed use foreign currency debt companys senior unsecured eurodenominated notes designated effective economic hedges net investment foreign operation accordingly foreign currency transaction gains losses eurodenominated debt instruments included foreign currency translation adjustment within comprehensive income oci company began using forward exchange contracts hedge net investment foreign operations adverse movements exchange rates forward contracts designated hedges net investment foreign operation company hedges portion net investments certain foreign operations measures ineffectiveness based upon changes spot foreign exchange rates effective portion unrealized gains losses contracts recorded foreign currency translation adjustment within oci remains oci either sale complete substantially complete liquidation subsidiary cash flows contracts reported investing activities consolidated statement cash flows interest rate risk management addition revenue hedging balance sheet risk management programs company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal capital risk december company party payfloating receivefixed interest rate swap contracts designated fair value hedges fixedrate notes notional amounts match amount hedged fixedrate notes two swaps maturing notional amounts million effectively convert companys million fixedrate notes due floating rate instruments five swaps maturing notional amounts million effectively convert million companys billion fixedrate notes due floating rate instruments addition six swaps maturing two notional amounts million four notional amounts million effectively convert companys million fixedrate notes due floating rate instruments february company entered nine additional payfloating receivefixed interest rate swap contracts designated fair value hedges fixedrate notes notional amounts match amount hedged fixedrate notes four swaps maturing two notional amounts million one notional amount million effectively convert companys billion fixedrate notes due floating rate instruments one swap notional amount million effectively converts remainder companys billion fixedrate notes due floating rate instruments two swaps maturing notional amounts million million effectively convert billion fixedrate notes due floating rate instruments three swaps maturing two notional amounts million one notional amount million effectively convert companys billion fixedrate notes due floating rate instruments interest rate swap contracts designated hedges fair value changes notes attributable changes benchmark london interbank offered rate libor swap rate fair value changes notes attributable changes benchmark interest rate recorded interest expense offset fair value changes swap contracts cash flows contracts reported operating activities consolidated statement cash flows companys investment portfolio includes cash equivalents shortterm investments market values significantly affected changes interest rates market value companys medium longterm fixedrate investments modestly affected changes us interest rates changes medium longterm us interest rates significant impact market value companys fixedrate borrowings generally longer maturities sensitivity analysis measure potential changes market value mercks investments debt related swap contracts change interest rates indicated one percentage point increase interest rates december would positively affected net aggregate market value instruments billion million respectively one percentage point decrease december would negatively affected net aggregate market value billion year fair value mercks debt determined using pricing models reflecting one percentage point shifts appropriate yield curves fair values mercks investments determined using combination pricing duration models critical accounting policies matters companys consolidated financial statements include certain amounts based managements best estimates judgments estimates used accounting amounts recorded connection mergers acquisitions including fair value determinations assets liabilities primarily iprd intangible assets additionally estimates used determining items current fair values goodwill inprocess research development intangibles well provisions sales discounts returns depreciable amortizable lives recoverability inventories including produced preparation product launches amounts recorded contingencies environmental liabilities reserves pension postretirement benefit plan assumptions sharebased compensation assumptions restructuring costs impairments longlived assets including intangible assets goodwill investments taxes income uncertainty inherent estimates actual results may differ estimates application following accounting policies result accounting estimates potential significant impact financial statements mergers acquisitions business combination acquisition method accounting requires assets acquired liabilities assumed recorded date merger acquisition respective fair values limited exceptions assets acquired liabilities assumed business combination arise contingencies recognized fair value fair value reasonably estimated acquisition date fair value asset acquired liability assumed arises contingency determined asset liability recognized probable reasonably estimable criteria met asset liability recognized fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date accordingly company may required value assets fair value measures reflect companys intended use assets excess purchase price consideration transferred estimated fair values net assets acquired recorded goodwill transaction costs costs restructure acquired company expensed incurred operating results acquired business reflected companys consolidated financial statements date merger acquisition company determines assets acquired meet definition business acquisition method accounting transaction accounted acquisition assets rather business combination therefore goodwill recorded fair value intangible assets including acquired iprd based significant judgments made management accordingly significant items company typically obtains assistance third party valuation specialists amounts allocated acquired iprd capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project merck make separate determination useful life asset begin amortization valuations useful life assumptions based information available near merger acquisition date based expectations assumptions deemed reasonable management judgments made determining estimated fair values assigned assets acquired liabilities assumed well asset lives materially affect companys results operations fair values identifiable intangible assets related currently marketed products product rights primarily determined using income approach fair value estimated based assets discounted projected net cash flows companys estimates market participant net cash flows consider historical projected pricing margins expense levels performance competing products applicable relevant industry therapeutic area growth drivers factors current expected trends technology product life cycles time investment required develop products technologies ability obtain marketing regulatory approvals ability manufacture commercialize products extent timing potential new product introductions companys competitors life assets underlying patent net cash flows probability adjusted appropriate consider uncertainties associated underlying assumptions well risk profile net cash flows utilized valuation probabilityadjusted future net cash flows product discounted present value utilizing appropriate discount rate fair values identifiable intangible assets related iprd determined using income approach fair value estimated based assets probability adjusted future net cash flows reflect different stages development product associated probability successful completion net cash flows discounted present value using appropriate discount rate revenue recognition revenues sales products recognized time delivery title risk loss passes customer recognition revenue also requires reasonable assurance collection sales proceeds completion performance obligations domestically sales discounts issued customers direct discounts pointofsale indirectly intermediary wholesaler known chargebacks indirectly form rebates additionally sales generally made limited right return certain conditions revenues recorded net provisions sales discounts returns established time sale provision aggregate indirect customer discounts covers chargebacks rebates chargebacks discounts occur contracted customer purchases directly intermediary wholesaler contracted customer generally purchases product contracted price plus markup wholesaler wholesaler turn charges company back difference price initially paid wholesaler contract price paid wholesaler customer provision chargebacks based expected sellthrough levels companys wholesale customers contracted customers well estimated wholesaler inventory levels rebates amounts owed based upon definitive contractual agreements legal requirements private sector public sector medicaid medicare part benefit providers final dispensing product pharmacy benefit plan participant provision based expected payments driven patient usage contract performance benefit provider customers company uses historical customer segment mix adjusted known events order estimate expected provision amounts accrued aggregate indirect customer discounts evaluated quarterly basis comparison information provided wholesalers health maintenance organizations pharmacy benefit managers customers amounts accrued adjustments recorded trends significant events indicate change estimated provision appropriate company continually monitors provision aggregate indirect customer discounts material adjustments estimates associated aggregate indirect customer discount provision summarized information changes aggregate indirect customer discount accrual follows millions balance january current provision scheringplough accrual assumed merger adjustments prior years payments balance december accruals chargebacks reflected direct reduction accounts receivable accruals rebates current liabilities accrued balances relative provisions included accounts receivable accrued current liabilities million billion respectively december million billion respectively december company maintains returns policy allows us pharmaceutical customers return product within specified period prior subsequent expiration date generally three six months twelve months product expiration estimate provision returns based upon historical experience actual returns additionally company considers factors levels inventory distribution channel product dating expiration period whether products discontinued entrance market additional generic competition changes formularies launch overthecounter products among others product returns provision us pharmaceutical sales approximately net sales significant distribution programs us wholesalers company encourages wholesalers align purchases underlying demand maintain inventories specified levels terms programs allow wholesalers earn fees upon providing visibility inventory levels well achieving certain performance parameters inventory management customer service levels reducing shortage claims reducing product returns information provided wholesaler distribution programs includes items sales trends inventory onhand onorder quantity product returns wholesalers generally provide mentioned data company regulatory requirement report lot level information manufacturers level information needed determine remaining shelf life original sale date inventory given current wholesaler inventory levels generally less month company believes collection order lot information across wholesale customers would limited use estimating sales discounts returns inventories produced preparation product launches company capitalizes inventories produced preparation product launches sufficient support estimated initial market demand typically capitalization inventory begin related product candidates phase iii clinical trials considered high probability regulatory approval company monitors status respective product within regulatory approval process however company generally disclose specific timing regulatory approval company aware specific risks contingencies normal regulatory approval process specific issues identified research process relating safety efficacy manufacturing marketing labeling related inventory would generally capitalized expiry dates inventory affected stage completion company manages levels inventory stage optimize shelf life inventory relation anticipated market demand order avoid product expiry issues inventories capitalized anticipated future sales shelf lives support realization inventory value inventory shelf life sufficient meet initial product launch requirements inventories produced preparation product launches capitalized december million december million contingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well additional matters antitrust actions see note consolidated financial statements company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable december company aggregate reserve approximately million vioxx legal defense costs reserve solely future legal defense costs related vioxx product liability lawsuits ii vioxx shareholder lawsuits iii vioxx foreign lawsuits iv vioxx investigations collectively vioxx litigation see note consolidated financial statements merck spent approximately million aggregate legal defense costs worldwide including approximately million fourth quarter related vioxx litigation addition merck recorded charges million charges including million fourth quarter solely future legal defense costs vioxx litigation consequently december aggregate amount vioxx legal defense costs reserve approximately million solely future legal defense costs vioxx litigation significant factors considered review vioxx legal defense costs reserve follows actual costs incurred company development companys legal defense strategy structure light scope vioxx litigation including settlement agreement expectation certain lawsuits continue pending number cases brought company costs outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials vioxx litigation amount vioxx legal defense costs reserve december represents companys best estimate minimum amount defense costs incurred connection remaining aspects vioxx litigation however events additional trials vioxx litigation events could arise course vioxx litigation could affect ultimate amount defense costs incurred company company continue monitor legal defense costs review adequacy associated reserves may determine increase vioxx legal defense costs reserve time future based upon factors set forth believes would appropriate three us vioxx product liability lawsuits currently scheduled trial company predict timing trials related vioxx litigation company believes meritorious defenses vioxx lawsuits vigorously defend view inherent difficulty predicting outcome litigation particularly many claimants claimants seek indeterminate damages company unable predict outcome matters time reasonably estimate possible loss range loss respect vioxx lawsuits included settlement program vioxx liability reserve established respect department justice doj investigation noted company established reserves potential liability relating vioxx lawsuits vioxx investigations unfavorable outcomes vioxx litigation could material adverse effect companys financial position liquidity results operations addition vioxx legal defense costs reserve company established million vioxx liability reserve connection anticipated resolution dojs investigation related vioxx companys discussions government ongoing concluded certainty definitive resolution company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents legitimate claim contribution asserted liability initially accrued based upon estimated transaction costs manage site accruals adjusted site investigations feasibility studies related cost assessments remedial techniques completed extent potentially responsible parties may jointly severally liable expected contribute determined company also remediating environmental contamination resulting past industrial activity certain sites takes active role identifying providing costs past old merck performed worldwide survey assess sites potential contamination resulting past industrial activities assessment indicated physical investigation warranted investigation performed providing better evaluation need remedial action need identified remedial action initiated definitive information became available course investigations andor remedial efforts site estimates refined accruals established adjusted accordingly estimates related accruals continue refined annually similar process followed legacy scheringplough sites company believes compliance issues associated applicable environmental laws regulations would material adverse effect company expenditures remediation environmental liabilities million estimated million years managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively liabilities undiscounted consider potential recoveries parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures result material adverse effect companys financial position results operations liquidity capital resources year sharebased compensation company expenses sharebased payment awards employees including grants stock options requisite service period based grant date fair value awards company determines fair value certain sharebased awards using blackscholes optionpricing model uses historical current market data estimate fair value method incorporates various assumptions riskfree interest rate expected volatility expected dividend yield expected life options pensions postretirement benefit plans net pension postretirement benefit cost totaled million million million higher costs compared primarily due incremental costs associated merger pension postretirement benefit plan information financial reporting purposes calculated using actuarial assumptions including discount rate plan benefit obligations expected rate return plan assets company reassesses benefit plan assumptions regular basis pension postretirement benefit plans discount rate evaluated measurement dates modified reflect prevailing market rate portfolio highquality fixedincome debt instruments would provide future cash flows needed pay benefits included benefit obligation come due december discount rates companys us pension postretirement benefit plans ranged compared range december expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid developing expected rate return company considers longterm compound annualized returns historical market data well actual returns companys plan assets using reference information company develops forwardlooking return expectations asset category weighted average expected longterm rate return target portfolio allocated across investment categories expected portfolio performance reflects contribution active management appropriate result analysis companys expected rate return range compared range us pension postretirement benefit plans company established investment guidelines us pension postretirement plans create asset allocation expected deliver rate return sufficient meet longterm obligation plan given acceptable level risk target investment portfolio companys us pension postretirement benefit plans allocated us equities international equities fixedincome investments cash investments portfolios equity weighting consistent longterm nature plans benefit obligations expected annual standard deviation returns target portfolio approximates reflects equity allocation diversification benefits among asset classes portfolio invests nonus pension plans targeted investment portfolio varies based duration pension liabilities local government rules regulations although significant percentage plan assets invested us equities concentration risk mitigated use strategies diversified within management guidelines actuarial assumptions based upon managements best estimates judgment reasonably possible change plus minus basis points discount rate assumption assumptions held constant would estimated million favorable unfavorable impact net pension postretirement benefit cost reasonably possible change plus minus basis points expected rate return assumption assumptions held constant would estimated million favorable unfavorable impact net pension postretirement benefit cost required funding obligations relating companys pension postretirement benefit plans expected material preceding hypothetical changes discount rate expected rate return assumptions would impact companys funding requirements net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions recorded component accumulated comprehensive income expected returns pension plans based calculated marketrelated value assets methodology asset gainslosses resulting actual returns differ companys expected returns recognized marketrelated value assets ratably fiveyear period also net loss amounts accumulated comprehensive income excess certain thresholds amortized net pension postretirement benefit cost average remaining service life employees amortization net losses companys us plans december expected increase net pension postretirement benefit cost approximately million annually restructuring costs restructuring costs recorded connection restructuring programs designed reduce cost structure increase efficiency enhance competitiveness result company made estimates judgments regarding future plans including future termination benefits exit costs incurred restructuring actions take place accruing costs company recognize amount within range costs best estimate within range amount within range better estimate amount company recognizes minimum amount within range connection actions management also assesses recoverability longlived assets employed business certain instances asset lives shortened based changes expected useful lives affected assets severance related costs reflected within restructuring costs assetrelated charges reflected within materials production costs marketing administrative expenses research development expenses depending upon nature asset impairments longlived assets company assesses changes economic regulatory legal conditions makes assumptions regarding estimated future cash flows evaluating value companys property plant equipment goodwill intangible assets company periodically evaluates whether current facts circumstances indicate carrying values longlived assets held used may recoverable circumstances determined exist estimate undiscounted future cash flows assets appropriate asset groupings compared carrying value determine whether impairment exists asset determined impaired loss measured based difference assets fair value carrying value quoted market prices available company estimate fair value using discounted value estimated future cash flows approach company tests goodwill impairment least annually frequently impairment indicators exist using fair value based test goodwill represents excess consideration transferred fair value net assets businesses purchased assigned reporting units acquired intangibles excluding iprd recorded fair value amortized straightline basis estimated useful lives events circumstances warrant review company assess recoverability future operations using pretax undiscounted cash flows derived lowest appropriate asset groupings impairments recognized operating results extent carrying value intangible asset exceeds fair value determined based net present value estimated cash flows company tests indefinitelived intangibles including iprd impairment least annually frequently impairment indicators exist onestep test compares fair value indefinite lived intangible asset assets carrying value impairment testing purposes company may combine separately recorded indefinitelived intangible assets one unit account based relevant facts circumstances generally company combine indefinitelived intangible assets testing purposes operate single asset essentially inseparable fair value less carrying amount impairment loss recognized within companys operating results impairments investments company reviews investments impairments based determination whether decline market value investment carrying value otherthantemporary company considers available evidence evaluating potential impairments investments including duration extent fair value less cost equity securities companys ability intent hold investments debt security otherthantemporary impairment occurred company expect recover entire amortized cost basis debt security company intend sell impaired debt security likely required sell debt security recovery amortized cost basis amount otherthantemporary impairment recognized earnings limited portion attributed credit loss remaining portion otherthantemporary impairment related factors recognized oci taxes income companys effective tax rate based pretax income statutory tax rates tax planning opportunities available various jurisdictions company operates estimated effective tax rate year applied companys quarterly operating results event significant unusual onetime item recognized expected recognized companys quarterly operating results tax attributable item would separately calculated recorded time unusual onetime item company considers resolution prior year tax matters items significant judgment required determining companys tax provision evaluating tax positions recognition measurement tax position based managements best judgment given facts circumstances information available reporting date company evaluates tax positions determine whether benefits tax positions likely sustained upon audit based technical merits tax position tax positions likely sustained upon audit company recognizes largest amount benefit greater likely realized upon ultimate settlement financial statements tax positions likely sustained upon audit company recognize portion benefit financial statements likely threshold met period tax position taken company may subsequently recognize benefit tax position tax matter effectively settled statute limitations expires likely threshold met subsequent period see note consolidated financial statements tax regulations require items included tax return different times items reflected financial statements timing differences create deferred tax assets liabilities deferred tax assets generally represent items used tax deduction credit tax return future years company already recorded tax benefit financial statements company establishes valuation allowances deferred tax assets amount expected future taxable income likely support use deduction credit deferred tax liabilities generally represent tax expense recognized financial statements payment deferred expense company already taken deduction tax return yet recognized expense financial statements december foreign earnings billion retained indefinitely subsidiary companies reinvestment therefore provision made income taxes would payable upon distribution earnings recently issued accounting standards october fasb issued new guidance revenue recognition multiple deliverables effective revenue arrangements entered materially modified fiscal years beginning june although early adoption permitted guidance eliminates residual method current guidance replaces relative selling price method allocating revenue multiple deliverable arrangement selling price deliverable shall determined using vendor specific objective evidence selling price exists otherwise thirdparty evidence selling price shall used neither exists deliverable vendor shall use best estimate selling price deliverable adoption guidance also require expanded qualitative quantitative disclosures company currently assessing impact adoption financial position results operations january fasb amended existing disclosure guidance fair value measurements effective january except disclosures purchases sales issuances settlements roll forward activity level fair value measurements effective january among things updated guidance requires additional disclosure significant transfers level level measurements requires certain level disclosures gross basis additionally updates amend existing guidance require greater level disaggregated information robust disclosures valuation techniques inputs fair value measurements since amended guidance requires additional disclosures adoption provisions effective january affect companys financial position results operations cautionary factors may affect future results report written reports oral statements made time time company may contain socalled forwardlooking statements based managements current expectations subject risks uncertainties may cause results differ materially set forth statements one identify forwardlooking statements use words anticipates expects plans estimates forecasts projects words similar meaning one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product development product approvals product potential development programs one must carefully consider statement understand many factors could cause actual results differ materially companys forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially company assume obligation update forwardlooking statement one carefully evaluate statements light factors including risk factors described companys filings securities exchange commission especially forms k q k item risk factors annual report company discusses detail various important risk factors could cause actual results differ expected historic results company notes factors investors permitted private securities litigation reform act one understand possible predict identify factors consequently reader consider list complete statement potential risks uncertainties item quantitative qualitative disclosures market risk information required item incorporated reference discussion financial instruments market risk disclosures item managements discussion analysis financial condition results operations item financial statements supplementary data financial statements consolidated balance sheet merck co inc subsidiaries december related consolidated statements income equity cash flows three years period ended december notes consolidated financial statements report dated february pricewaterhousecoopers llp independent registered public accounting firm follows consolidated statement income merck co inc subsidiaries years ended december millions except per share amounts sales costs expenses materials production marketing administrative research development restructuring costs equity income affiliates income expense net income taxes taxes income net income less net income attributable noncontrolling interests net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders accompanying notes integral part consolidated financial statement consolidated balance sheet merck co inc subsidiaries december millions except per share amounts assets current assets cash cash equivalents shortterm investments accounts receivable net allowance doubtful accounts inventories excludes inventories classified assets see note deferred income taxes current assets total current assets investments property plant equipment cost land buildings machinery equipment office furnishings construction progress less allowance depreciation goodwill intangibles net assets liabilities equity current liabilities loans payable current portion longterm debt trade accounts payable accrued current liabilities income taxes payable dividends payable mandatory convertible preferred stock par value authorized shares issued outstanding shares total current liabilities longterm debt deferred income taxes noncurrent liabilities merck co inc stockholders equity common stock par value authorized shares issued shares paidin capital retained earnings accumulated comprehensive loss less treasury stock cost shares shares total merck co inc stockholders equity noncontrolling interests total equity accompanying notes integral part consolidated financial statement consolidated statement equity merck co inc subsidiaries years ended december millions except per share amounts accumulated non common paidin retained comprehensive treasury controlling stock capital earnings loss stock interests total balance january net income attributable merck co inc total comprehensive loss net tax comprehensive income net tax cash dividends declared common stock per share treasury stock shares purchased net income attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december net income attributable merck co inc total comprehensive loss net tax comprehensive income net tax scheringplough merger cancellations treasury stock preferred stock conversions cash dividends declared common stock per share net income attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december net income attributable merck co inc total comprehensive loss net tax comprehensive income net tax cash dividends declared common stock per share mandatory conversion convertible preferred stock treasury stock shares purchased net income attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december accompanying notes integral part consolidated financial statement consolidated statement cash flows merck co inc subsidiaries years ended december millions cash flows operating activities net income adjustments reconcile net income net cash provided operating activities depreciation amortization inprocess research development impairment charges gains distributions astrazeneca lp gain related merckscheringplough partnership gain disposition interest merial limited equity income affiliates dividends distributions equity affiliates deferred income taxes sharebased compensation net changes assets liabilities accounts receivable inventories trade accounts payable accrued current liabilities income taxes payable noncurrent liabilities net cash provided operating activities cash flows investing activities capital expenditures purchases securities investments proceeds sales securities investments proceeds sale interest merial limited scheringplough merger net cash acquired acquisitions businesses net cash acquired distributions astrazeneca lp decrease increase restricted assets net cash used provided investing activities cash flows financing activities net change shortterm borrowings proceeds issuance debt payments debt purchases treasury stock dividends paid stockholders dividends paid proceeds exercise stock options net cash used financing activities effect exchange rate changes cash cash equivalents net increase decrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year supplemental cash flow information see note accompanying notes integral part consolidated financial statement notes consolidated financial statements merck co inc subsidiaries millions except per share amounts nature operations company global health care company delivers innovative health solutions prescription medicines vaccines biologic therapies animal health consumer care products markets directly joint ventures companys operations principally managed products basis comprised four operating segments pharmaceutical animal health consumer care alliances segments one reportable segment pharmaceutical segment pharmaceutical segment includes human health pharmaceutical vaccine products marketed either directly company joint ventures human health pharmaceutical products consist therapeutic preventive agents sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities company also animal health operations discover develop manufacture market animal health products including vaccines company sells veterinarians distributors animal producers additionally company consumer care operations develop manufacture market overthecounter foot care sun care products sold wholesale retail drug food chain mass merchandiser outlets united states canada november merck co inc old merck scheringplough corporation scheringplough merged merger merger scheringplough acquired shares old merck became whollyowned subsidiary scheringplough renamed merck sharp dohme corp scheringplough continued surviving public company renamed merck co inc new merck company however accounting purposes merger treated acquisition old merck considered accounting acquirer accordingly accompanying financial statements reflect old mercks standalone operations existed prior completion merger results scheringploughs business included new mercks financial statements periods subsequent completion merger therefore new mercks financial results reflect full year legacy scheringplough operations references financial statements merck periods prior merger refer old merck periods completion merger new merck summary accounting policies principles consolidation consolidated financial statements include accounts company subsidiaries controlling interest maintained intercompany balances transactions eliminated controlling interest determined majority ownership interest absence substantive thirdparty participating rights case variable interest entities majority exposure expected losses residual returns consolidated subsidiaries merck ownership less outside shareholders interests shown noncontrolling interests equity investments affiliates company significant influence controlling interest interests entities owned equally company third party shared control carried equity basis mergers acquisitions business combination acquisition method accounting requires assets acquired liabilities assumed recorded date merger acquisition respective fair values limited exceptions assets acquired liabilities assumed business combination arise contingencies recognized fair value fair value reasonably estimated acquisition date fair value asset acquired liability assumed arises contingency determined asset liability recognized probable reasonably estimable criteria met asset liability recognized fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date accordingly company may required value assets fair value measures reflect companys intended use assets excess purchase price consideration transferred estimated fair values net assets acquired recorded goodwill transaction costs costs restructure acquired company expensed incurred operating results acquired business reflected companys consolidated financial statements date merger acquisition company determines assets acquired meet definition business acquisition method accounting transaction accounted acquisition assets rather business combination therefore goodwill recorded foreign currency translation net assets international subsidiaries local currencies determined functional currencies translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recorded foreign currency translation account included accumulated comprehensive income loss aoci reflected separate component equity subsidiaries operate highly inflationary economies subsidiaries us dollar determined functional currency nonmonetary foreign currency assets liabilities translated using historical rates monetary assets liabilities translated current rates us dollar effects rate changes included income expense net result merger functional currency operations companys international subsidiaries reevaluated resulted may result change functional currency cash equivalents cash equivalents comprised certain highly liquid investments original maturities less three months inventories inventories valued lower cost market cost substantial majority domestic pharmaceutical vaccine inventories determined using lastin firstout lifo method financial reporting tax purposes cost inventories determined using firstin firstout fifo method inventories consist currently marketed products certain products awaiting regulatory approval evaluating recoverability inventories produced preparation product launches company considers probability revenue obtained future sale related inventory together status product within regulatory approval process investments investments marketable debt equity securities classified availableforsale reported fair value fair value companys investments determined using quoted market prices active markets identical assets liabilities quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities changes fair value considered temporary reported net tax aoci declines fair value equity securities considered otherthantemporary impairment losses charged income expense net company considers available evidence evaluating potential impairments investments including duration extent fair value less cost equity securities companys ability intent hold investment debt securities otherthantemporary impairment occurred company expect recover entire amortized cost basis debt security company intend sell impaired debt security likely required sell debt security recovery amortized cost basis amount otherthantemporary impairment recognized earnings recorded income expense net limited portion attributed credit loss remaining portion otherthantemporary impairment related factors recognized aoci realized gains losses debt equity securities included income expense net revenue recognition revenues sales products recognized time delivery title risk loss passes customer recognition revenue also requires reasonable assurance collection sales proceeds completion performance obligations domestically sales discounts issued customers direct discounts pointofsale indirectly intermediary wholesaler known chargebacks indirectly form rebates additionally sales generally made limited right return certain conditions revenues recorded net provisions sales discounts returns established time sale accruals chargebacks reflected direct reduction accounts receivable accruals rebates recorded current liabilities accrued balances relative provisions included accounts receivable accrued current liabilities million billion respectively december million billion respectively december company recognizes revenue sales vaccines federal government placement vaccine stockpiles accordance securities exchange commission sec interpretation commission guidance regarding accounting sales vaccines bioterror countermeasures federal government placement pediatric vaccine stockpile strategic national stockpile depreciation depreciation provided estimated useful lives assets principally using straightline method tax purposes accelerated tax methods used estimated useful lives primarily range years buildings years machinery equipment office furnishings software capitalization company capitalizes certain costs incurred connection obtaining developing internaluse software including external direct costs material services payroll costs employees directly involved software development capitalized software costs included property plant equipment amortized beginning software project substantially complete asset ready intended use capitalized software costs associated companys multiyear implementation enterprisewide resource planning system amortized years december approximately million million respectively remaining unamortized capitalized software costs associated initiative capitalized software costs amortized periods ranging years costs incurred preliminary project stage postimplementation stage well maintenance training costs expensed incurred goodwill goodwill represents excess consideration transferred fair value net assets businesses purchased goodwill assigned reporting units evaluated impairment least annual basis frequently impairment indicators present using fair value based test based upon companys recent annual impairment test completed october fair value reporting unit excess carrying value acquired intangibles acquired intangibles include products product rights tradenames patents recorded fair value assigned estimated useful life amortized primarily straightline basis estimated useful lives ranging years see note events circumstances warrant review company assess recoverability future operations acquired intangibles using pretax undiscounted cash flows derived lowest appropriate asset groupings impairments recognized operating results extent carrying value intangible asset exceeds fair value determined based net present value estimated future cash flows inprocess research development inprocess research development iprd represents fair value assigned incomplete research projects company acquires business combinations time acquisition reached technological feasibility transactions closed prior fair value projects expensed upon acquisition transactions closed thereafter fair value research projects recorded intangible assets consolidated balance sheet rather expensed amounts capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project merck make determination useful life intangible asset generally determined period substantially cash flows expected generated begin amortization company tests indefinitelived intangibles including iprd impairment least annually frequently impairment indicators exist onestep test compares fair value indefinitelived intangible asset assets carrying value research development research development expensed incurred upfront milestone payments due third parties connection research development collaborations prior regulatory approval expensed incurred payments due third parties upon subsequent regulatory approval capitalized amortized shorter remaining license product patent life nonrefundable advance payments goods services used future research development activities expensed activity performed goods received rather payment made research development expenses include billion iprd impairment charges restructuring costs periods sharebased compensation company expenses sharebased payments employees requisite service period based grantdate fair value awards restructuring costs company records liabilities costs associated exit disposal activities period liability incurred accordance existing benefit arrangements employee termination costs accrued restructuring actions probable estimable accruing costs company recognize amount within range costs best estimate within range amount within range better estimate amount company recognizes minimum amount within range costs onetime termination benefits employee required render service termination order receive benefits recognized ratably future service period contingencies legal defense costs company records accruals contingencies legal defense costs expected incurred connection loss contingency probable liability incurred amount reasonably estimated taxes income deferred taxes recognized future tax effects temporary differences financial income tax reporting based enacted tax laws rates company evaluates tax positions determine whether benefits tax positions likely sustained upon audit based technical merits tax position tax positions likely sustained upon audit company recognizes largest amount benefit greater likely realized upon ultimate settlement financial statements tax positions likely sustained upon audit company recognize portion benefit financial statements company recognizes interest penalties associated uncertain tax positions component taxes income consolidated statement income use estimates consolidated financial statements prepared conformity accounting principles generally accepted united states gaap accordingly include certain amounts based managements best estimates judgments estimates used accounting amounts recorded connection mergers acquisitions including fair value determinations assets liabilities primarily iprd intangible assets additionally estimates used determining items current fair values goodwill iprd intangibles well provisions sales discounts returns depreciable amortizable lives recoverability inventories including produced preparation product launches amounts recorded contingencies environmental liabilities reserves pension postretirement benefit plan assumptions sharebased compensation assumptions restructuring costs impairments longlived assets including intangible assets goodwill investments taxes income uncertainty inherent estimates actual results may differ estimates reclassifications certain reclassifications made prior year amounts conform current year presentation recently adopted accounting standards several new accounting standards issued fasb adopted january company adopted new guidance accounting disclosure requirements transfers financial assets eliminated concept qualifying specialpurpose entity changed requirements derecognizing financial assets required enhanced disclosures provide financial statement users greater transparency transfers financial assets including securitization transactions entitys continuing involvement exposure risks related transferred financial assets effect adoption companys financial position results operations material january company adopted new accounting disclosure guidance consolidation variable interest entities required enhanced disclosures intended provide users financial statements transparent information enterprises involvement variable interest entity effect adoption companys financial position results operations material recently issued accounting standards fasb issued several new accounting pronouncements yet effective company october fasb issued new guidance revenue recognition multiple deliverables effective revenue arrangements entered materially modified fiscal years beginning june although early adoption permitted guidance eliminates residual method current guidance replaces relative selling price method allocating revenue multiple deliverable arrangement selling price deliverable shall determined using vendor specific objective evidence selling price exists otherwise thirdparty evidence selling price shall used neither exists deliverable vendor shall use best estimate selling price deliverable adoption guidance also require expanded qualitative quantitative disclosures company currently assessing impact adoption financial position results operations january fasb amended existing disclosure guidance fair value measurements effective january except disclosures purchases sales issuances settlements roll forward activity level fair value measurements effective january among things updated guidance requires additional disclosure amounts significant transfers level level measurements requires certain level disclosures gross basis additionally updates amend existing guidance require greater level disaggregated information robust disclosures valuation techniques inputs fair value measurements since amended guidance requires additional disclosures adoption provisions effective january provisions effective impact companys financial position results operations merger november old merck scheringplough completed merger merger scheringplough acquired shares old merck became whollyowned subsidiary scheringplough renamed merck sharp dohme corp scheringplough continued surviving public company renamed merck co inc however accounting purposes merger treated acquisition old merck considered accounting acquirer terms merger agreement issued outstanding share schering plough common stock converted right receive combination cash share common stock new merck issued outstanding share old merck common stock automatically converted share common stock new merck based closing price old merck stock november consideration received scheringplough shareholders valued per share billion aggregate cash portion consideration funded combination existing cash including sale old mercks interest merial limited sale redemption investments issuance debt upon completion merger issued outstanding share scheringplough mandatory convertible preferred stock scheringplough preferred stock converted accordance terms preferred stock remained outstanding one share merck mandatory convertible preferred stock preferred stock rights set forth new merck certificate incorporation rights substantially similar rights scheringplough preferred stock august outstanding preferred stock automatically converted terms right receive cash shares merck common stock see note merger expanded companys pipeline product candidates broadened companys commercial portfolio expanded global presence increased manufacturing capabilities additionally company expects realize substantial cost savings synergies including opportunities consolidation sales marketing research development calculation consideration transferred millions except per shareunit amounts scheringplough common stock shares outstanding november net treasury shares units merger consideration arising conversion preferred stock shares units eligible cash per shareunit cash consideration outstanding sharesunits preferred stock makewhole dividend payments value scheringplough deferred stock units settled cash total cash consideration shares units eligible common stock exchange ratio per shareunit equivalent new merck shares shares issued settle certain performancebased awards new merck shares issued old merck common stock share price november common stock equity consideration fair value preferred stock converted fair value sharebased compensation awards employee benefit related amounts payable result merger total consideration transferred upon completion merger period days thereafter holders preferred stock entitled convert share preferred stock number units merger consideration equal make whole conversion rate determined accordance terms preferred stock amount represents units merger consideration relating preferred stock converted holders day period following merger represents present value remaining dividend payments conversion date mandatory conversion date august paid holders preferred stock elected convert connection merger using discount rate stipulated terms preferred stock represents cash consideration paid holders scheringplough deferred stock units issued prior converted right receive cash specified merger agreement attributable precombination service represents fair value scheringplough stock option performance share unit deferred stock unit replacement awards attributable precombination service issued holders awards merger fair value outstanding scheringplough stock option performance share unit awards issued prior immediately vested effective time merger attributed precombination service included consideration transferred stock option performance share unit deferred stock unit awards immediately vest upon completion merger awards fair value awards attributed precombination service included part consideration transferred fair value attributed postcombination service recognized compensation cost requisite service period postcombination financial statements new merck allocation consideration transferred net assets acquired preliminary allocation consideration transferred net assets scheringplough made date merger merger date company adjusted preliminary values assigned certain assets liabilities order reflect additional information obtained since preliminary allocation made pertained facts circumstances existed merger date measurement period adjustments reflected opening balance sheet however since adjustments significant impact consolidated statements income cash flows period statements retrospectively adjusted following table summarizes determination fair value identifiable assets acquired liabilities assumed merger preliminary final allocation measurement allocation consideration period consideration transferred adjustments transferred cash cash equivalents inventories current assets property plant equipment identifiable intangible assets products product rights year weighted average useful life inprocess research development iprd tradenames year weighted average useful life noncurrent assets current liabilities deferred income tax liabilities longterm debt noncurrent liabilities total identifiable net assets goodwill consideration transferred connection merger company obtained controlling interest merckscheringplough partnership table reflects scheringploughs share fair value merckscheringplough partnerships net assets including intangibles inventories reflected table mercks share fair value merckscheringplough partnerships net assets recorded connection fair value adjustment mercks previously held equity interest partnership see merckscheringplough partnership iprd represents fair value assigned incomplete research projects time merger reached technological feasibility amounts capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project merck make determination useful life asset begin amortization see inprocess research development goodwill recognized largely attributable anticipated synergies expected arise merger approximately billion goodwill allocated pharmaceutical segment remainder goodwill allocated nonreportable segments goodwill deductible tax purposes measurement period adjustments primarily reflect adjustments income tax liabilities changes estimated fair value certain intangible assets corresponding impacts goodwill order allocate merger consideration company estimated fair value assets liabilities scheringplough contingent assets liabilities recognized fair value merger date fair value contingencies could determined contingent liabilities recorded extent amounts probable reasonably estimable see note accounting financial reporting purposes fair value defined price would received upon sale asset amount paid transfer liability orderly transaction market participants measurement date market participants assumed buyers sellers principal advantageous market asset liability additionally fair value measurements asset assume highest best use asset market participants use different estimates judgments could yield different results fair values identifiable intangible assets related currently marketed products product rights primarily determined using income approach fair value estimated based assets discounted projected net cash flows companys estimates market participant net cash flows considered historical projected pricing margins expense levels performance competing products applicable relevant industry therapeutic area growth drivers factors current expected trends technology product life cycles time investment required develop products technologies ability obtain marketing regulatory approvals ability manufacture commercialize products extent timing potential new product introductions companys competitors life assets underlying patent net cash flows probability adjusted appropriate consider uncertainties associated underlying assumptions well risk profile net cash flows utilized valuation probabilityadjusted future net cash flows product discounted present value utilizing appropriate discount rate inprocess research development connection merger company recorded fair value human animal health research projects underway scheringplough msp partnership fair value projects allocated pharmaceutical animal health operating segments billion billion respectively amounts capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project merck make determination useful life asset begin amortization fair values identifiable intangible assets related iprd determined using income approach fair value estimated based assets probability adjusted future net cash flows reflect different stages development product associated probability successful completion net cash flows discounted present value using discount rates ranged actual cash flows likely different assumed significant projects include boceprevir bridion vorapaxar well ezetimibeatorvastatin combination product boceprevir investigational hepatitis c protease inhibitor accepted expedited review united states european union eu bridion sugammadex medication designed rapidly reverse effects certain muscle relaxants used part general anesthesia bridion received regulatory approval eu several countries around world regulatory review markets ezetimibe combined atorvastatin investigational medication treatment dyslipidemia company recorded billion iprd impairment charges recorded research development expense amount billion related writedown vorapaxar intangible asset company determined developments clinical research program vorapaxar including termination clinical trial constituted triggering event required company evaluate vorapaxar intangible asset impairment although great deal information related developments remains unknown company utilizing market participant assumptions considering several different scenarios company concluded best estimate current fair value intangible asset related vorapaxar million resulted recognition impairment charge billion company continue monitor remaining asset value impairment company anticipates results tracer clinical trial available later also company recorded additional million iprd impairment charges attributable compounds abandoned determined either alternative use returned respective licensor well expected delays launch timing changes cash flow assumptions certain compounds iprd projects remain development subject inherent risks uncertainties drug development possible company able successfully develop complete iprd programs profitably commercialize underlying product candidates merckscheringplough partnership upon consummation merger company obtained controlling interest merckscheringplough partnership msp partnership whollyowned company previously company noncontrolling interest result obtaining controlling interest company required remeasure mercks previously held equity interest msp partnership merger date fair value recognize resulting gain billion earnings income expense net conjunction remeasurement company recorded intangible assets approximately billion included iprd approximately billion stepup inventories mergerrelated costs mergerrelated costs expensed incurred year ended december company incurred million integration costs billion restructuring costs including exit costs connection merger see note year ended december merck incurred million transaction costs directly related merger including advisory legal fees million integration costs billion restructuring costs costs recognized within marketing administrative expenses restructuring costs additionally million interest costs recognized connection debt issued partially fund merger supplemental pro forma data scheringploughs results operations included new mercks financial statements periods subsequent completion merger scheringplough contributed revenues billion estimated losses billion new merck period consummation merger december following unaudited supplemental pro forma data presents consolidated information merger completed january year ended december unaudited sales net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders unaudited supplemental pro forma data reflect application following adjustments consolidation msp partnership whollyowned company corresponding gain resulting companys remeasurement previously held equity interest msp partnership additional depreciation amortization expense would recognized assuming fair value adjustments inventory property plant equipment intangible assets additional interest expense financing costs would incurred borrowing arrangements loss interest income cash shortterm investments used fund merger transaction costs associated merger conversion portion outstanding preferred stock unaudited supplemental pro forma financial information reflect potential realization cost savings relating integration two companies pro forma data considered indicative results would occurred merger related borrowings consummated january indicative future results restructuring merger restructuring program february company commenced actions global restructuring program merger restructuring program conjunction integration legacy merck legacy scheringplough businesses merger restructuring program intended optimize cost structure combined company additional actions program continued part restructuring actions taken thus far merger restructuring program company expects reduce total workforce measured time merger approximately across company worldwide addition company eliminated positions vacant time merger workforce reductions primarily come elimination duplicative positions sales administrative headquarters organizations well sale closure certain manufacturing research development sites consolidation office facilities period company continue hire new employees strategic growth areas business necessary merck plans phase operations certain research manufacturing sites well continue consolidate office facilities worldwide eight research sites impacted include montreal canada boxmeer nobilon facility oss schaijk netherlands odense denmark waltrop germany newhouse scotland cambridge kendall square massachusetts second half company began phasing operations eight manufacturing facilities sites exit global network activities transferred locations specifically company intends cease manufacturing activities facilities comazzo italy cacem portugal azcapotzalco mexico coyoacan mexico santo amaro brazil intends sell mirador argentina miami lakes florida facilities singapore chemical manufacturing phased legacy merck site continue legacy scheringplough site companys extensive pharmaceutical manufacturing operations continue singapore facilities addition manufacturing operations kenilworth new jersey site discontinued activities consolidated existing operations merck facilities company continue pursue productivity efficiencies evaluate manufacturing supply chain capabilities ongoing basis may result future restructuring actions connection merger restructuring program separation costs companys existing severance programs worldwide recorded fourth quarter extent costs probable reasonably estimable company commenced accruing costs related enhanced termination benefits offered employees merger restructuring program first quarter necessary criteria met company recorded total pretax restructuring costs billion billion related program since inception merger restructuring program december merck recorded total pretax accumulated costs approximately billion eliminated approximately positions comprised employee separations elimination contractors vacant positions restructuring actions taken thus far merger restructuring program expected substantially completed end exception certain manufacturing facilities actions total cumulative pretax costs estimated approximately billion billion company estimates approximately twothirds cumulative pretax costs relate cash outlays primarily related employee separation expense approximately onethird cumulative pretax costs noncash relating primarily accelerated depreciation facilities closed divested global restructuring program october old merck announced global restructuring program restructuring program reduce cost structure increase efficiency enhance competitiveness part restructuring program company expects eliminate approximately positions active employees vacancies across company worldwide end reductions occur united states program includes roll new customercentric selling model company also making greater use outside technology resources centralizing common sales marketing activities consolidating streamlining operations mercks manufacturing division focusing capabilities core products outsourcing noncore manufacturing program also included implementation new model basic research global operating strategy legacy merck research laboratories sites pretax restructuring costs million million million recorded respectively related restructuring program since inception restructuring program december merck recorded total pretax accumulated costs billion eliminated approximately positions comprised employee separations elimination contractors vacant positions restructuring program expected completed end total cumulative pretax costs estimated billion billion company estimates twothirds cumulative pretax costs relate cash outlays primarily employee separation expense approximately onethird cumulative pretax costs noncash relating primarily accelerated depreciation facilities closed divested global restructuring program november old merck announced global restructuring program restructuring program designed reduce cost structure increase efficiency enhance competitiveness substantially complete end segment reporting restructuring charges unallocated expenses following table summarizes charges related merger restructuring program restructuring program activities type cost separation accelerated year ended december costs depreciation total merger restructuring program materials production marketing administrative research development restructuring costs restructuring program materials production marketing administrative research development restructuring costs year ended december merger restructuring program materials production research development restructuring costs restructuring program materials production research development restructuring costs year ended december restructuring program materials production research development restructuring costs restructuring program materials production research development restructuring costs separation costs associated actual headcount reductions well headcount reductions probable could reasonably estimated approximately positions eliminated related merger restructuring program approximately positions eliminated related restructuring program approximately positions eliminated related restructuring program approximately positions eliminated related merger restructuring program certain employees anticipated separated part planned restructuring actions restructuring program instead transferred buyer conjunction sale facility accordingly accrual separation costs associated employees reversed resulting reduction expenses approximately positions eliminated related restructuring program approximately positions eliminated related restructuring program position eliminations comprised actual headcount reductions elimination contractors vacant positions accelerated depreciation costs primarily relate manufacturing research administrative facilities sold closed part programs accelerated depreciation costs represent difference depreciation expense recognized revised useful life site based upon anticipated date site closed divested depreciation expense determined utilizing useful life prior restructuring actions sites continue operate respective closure dates since future cash flows sufficient recover respective book values merck required accelerate depreciation site assets rather write immediately site assets include manufacturing research administrative facilities equipment activity includes million million million respectively asset abandonment shutdown related costs approximately million contract termination costs additionally activity includes million million million respectively employeerelated costs curtailment settlement termination charges pension postretirement benefit plans see note sharebased compensation costs activity also reflects net pretax gains losses resulting sales facilities related assets million million million respectively adjustments recorded amounts material period following table summarizes charges spending relating merger restructuring program restructuring program activities separation accelerated costs depreciation total merger restructuring program restructuring reserves january expense payments receipts net noncash activity restructuring reserves december expense payments receipts net noncash activity restructuring reserves december restructuring program restructuring reserves january expense payments receipts net noncash activity restructuring reserves december expense payments receipts net noncash activity restructuring reserves december restructuring program restructuring reserves january payments receipts net restructuring reserves december payments receipts net restructuring reserves december cash outlays associated merger restructuring program expected substantially completed end cash outlays associated remaining restructuring reserve restructuring program expected completed end includes proceeds sales facilities connection restructuring actions legacy scheringplough program prior merger scheringplough commenced productivity transformation program designed reduce avoid costs increase productivity postmerger period december company recorded million costs related program including million employee separation costs included restructuring costs million accelerated depreciation costs included materials production costs remaining reserve associated program million december company recorded million accelerated depreciation costs included materials production costs million net gain restructuring costs primarily related sale manufacturing facility made payments million plan resulting remaining reserve million december connection program approximately positions eliminated positions eliminated postmerger period acquisitions research collaborations license agreements december company acquired outstanding stock smartcells private company developing glucose responsive insulin formulation treatment diabetes mellitus total purchase consideration company determined fair value acquisition date million included upfront cash payment contingent consideration consisting future clinical development regulatory milestones well contingent consideration future sales products resulting acquisition transaction accounted acquisition method accounting accordingly assets liabilities recorded respective fair values acquisition date determination fair value requires management make significant estimates assumptions connection acquisition substantially preliminary purchase price allocated iprd remaining net assets acquired significant fair value contingent consideration determined utilizing probability weighted estimated cash flow stream adjusted expected timing payment subsequent acquisition date quarterly basis contingent consideration liability remeasured current fair value changes recorded earnings results operations smartcells included companys results operations date acquisition significant certain estimated values yet finalized may subject change company expects finalize amounts soon possible later one year acquisition date february company completed acquisition avecia biologics limited avecia total purchase price approximately million avecia contract manufacturing organization specific expertise microbialderived biologics terms agreement company acquired avecia assets including avecias process development scaleup manufacturing quality business support operations located billingham united kingdom transaction accounted business combination accordingly assets acquired liabilities assumed recorded respective fair values acquisition date determination fair value requires management make significant estimates assumptions connection acquisition substantially purchase price allocated avecias property plant equipment goodwill remaining net assets acquired material transaction closed february accordingly results operations acquired business included companys results operations beginning acquisition date pro forma financial information included avecias historical financial results significant compared companys financial results may merck announced restructured codevelopment cocommercialization agreement ariad pharmaceuticals inc ariad ridaforolimus mk investigational orally available mtor inhibitor currently evaluated treatment multiple cancer types exclusive license agreement restructured agreement merck acquired full control development worldwide commercialization ridaforolimus ariad received million upfront fee company recorded research development expense eligible receive milestone payments associated regulatory filings approvals ridaforolimus multiple cancer indications achievement significant sales thresholds lieu profit split us sales provided previous agreement ariad receive royalties global net sales ridaforolimus sales recorded merck merck assumed responsibility activities acquired decision rights matters relating development manufacturing commercialization ridaforolimus investigational new drug application transferred merck merck file marketing application worldwide oncology indications lead interactions regulatory agencies agreement terminable merck upon nine months notice immediately upon good faith determination serious safety issue agreement terminable either party result insolvency party uncured material breach party ariad failure merck perform certain product development responsibilities july old merck portola pharmaceuticals inc portola signed exclusive global collaboration license agreement development commercialization betrixaban mk investigational oral factor xa inhibitor anticoagulant currently clinical development prevention stroke patients atrial fibrillation return exclusive worldwide license betrixaban old merck paid portola initial fee million closing recorded research development expense portola eligible receive additional cash payments totaling million upon achievement certain development regulatory commercialization milestones well doubledigit royalties worldwide sales betrixaban approved merck assumed development commercialization costs including costs phase iii clinical trials portola retains option cofund phase iii clinical trials return additional royalties b copromote betrixaban merck united states term agreement commenced august unless terminated earlier continue remaining royalty payment obligations country time agreement expire entirety country agreement may terminated either party event material uncured breach bankruptcy party agreement may terminated merck event parties merck decide cease development betrixaban safety efficacy addition merck may terminate agreement time upon days prior written notice portola may terminate agreement event merck challenges portola patent covering betrixaban upon termination agreement depending upon circumstances parties varying rights obligations respect continued development commercialization betrixaban case termination cause merck certain royalty obligations april old merck medarex inc medarex whollyowned subsidiary bristolmyers squibb massachusetts biologic laboratories mbl university massachusetts medical school announced exclusive worldwide license agreement cda cdb mka investigational fully human monoclonal antibody combination developed target neutralize clostridium difficile toxins b treatment c difficile infection cda cdb codeveloped medarex mbl terms agreement merck gained worldwide rights develop commercialize cda cdb medarex mbl received aggregate upfront payment million upon closing recorded research development expense potentially eligible receive additional cash payments million aggregate upon achievement certain milestones associated development approval drug candidate covered agreement upon commercialization medarex mbl also eligible receive doubledigit royalties product sales milestones certain sales targets met term agreement commenced closing date unless terminated earlier continue remaining royalty payment obligations country time agreement expire entirety country either party may terminate agreement uncured material breach party bankruptcy insolvency party merck may terminate agreement time upon providing days prior written notice medarex mbl also april old merck santen pharmaceutical co ltd santen announced worldwide licensing agreement tafluprost mk prostaglandin analogue investigation united states tafluprost preserved andor preservativefree formulations received marketing approval reduction elevated intraocular pressure openangle glaucoma ocular hypertension several european nordic countries well japan filed approval international markets terms agreement merck paid fee capitalized amortized materials production costs life underlying patent pay milestones royalty payments based future sales tafluprost preserved preservativefree formulations exchange exclusive commercial rights tafluprost western europe excluding germany north america south america africa middle east india australia santen retain commercial rights tafluprost countries eastern europe northern europe asia pacific including japan merck provide promotion support santen germany poland tafluprost approved united states santen option copromote agreement merck santen expires countrybycountry basis last occur expiry last expire valid patent claim b expiration last expire royalty merck may terminate agreement time upon days prior written notice also time upon days prior written notice merck determines product presents issues safety tolerability addition merck may terminate agreement event enumerated agreements santen coownerlicensor certain intellectual property terminate expire materially adversely affects merck either merck santen materially breaches agreement fails cure receiving notice nonbreaching party may terminate agreement agreement provides termination noninsolvent party due bankruptcy party finally agreement terminate term merck develops commercializes competitive product term defined agreement addition april old merck cardiome pharma corp cardiome announced collaboration license agreement development commercialization vernakalant mk investigational candidate treatment atrial fibrillation agreement provides merck exclusive global rights oral formulation vernakalant vernakalant oral maintenance normal heart rhythm patients atrial fibrillation provides merck affiliate merck sharp dohme switzerland gmbh exclusive rights outside united states canada mexico intravenous iv formulation vernakalant vernakalant iv rapid conversion acute atrial fibrillation normal heart rhythm terms agreement old merck paid cardiome initial fee million upon closing recorded research development expense addition cardiome eligible receive million payments based achievement certain milestones associated development approval vernakalant products including million paid submission regulatory approval europe vernakalant iv million paid upon receipt marketing approval vernakalant iv brinavess eu iceland norway potential future payments million initiation planned phase iii program vernakalant oral million milestones associated approvals subsequent indications intravenous oral formulations september merck announced vernakalant iv brinavess granted marketing approval eu iceland norway also cardiome receive tiered royalty payments sales approved products potential receive million milestone payments based achievement significant sales thresholds cardiome retained option copromote vernakalant oral merck hospitalbased sales force united states merck responsible future costs associated development manufacturing commercialization candidates agreement continues effect expiration cardiomes copromotion rights royalty milestone payment obligations agreement may terminated event insolvency material uncured breach either party additionally collaboration may terminated merck event merck determines good faith advisable continue development commercialization vernakalant product result serious safety issue addition merck may terminate agreement time upon months prior written notice cardiome may terminate agreement event merck challenges cardiome patent covering vernakalant upon termination agreement depending upon circumstances parties varying rights obligations respect continued development commercialization vernakalant cases continuing royalty obligations merck granted cardiome secured interestbearing credit facility million cardiome may access tranches several years commencing march old merck acquired insmed incs insmed portfolio followon biologic therapeutic candidates commercial manufacturing facilities located boulder colorado terms agreement old merck paid insmed aggregate million cash acquire rights boulder facilities insmeds pipeline followon biologic candidates insmeds followon biologics portfolio includes two clinical candidates mk investigational recombinant granulocytecolony stimulating factor gcsf evaluated ability prevent infections patients cancer receiving chemotherapy mk pegylated recombinant gcsf designed allow less frequent dosing transaction accounted business combination accordingly assets acquired liabilities assumed recorded respective fair values acquisition date determination fair value requires management make significant estimates assumptions connection acquisition substantially purchase price allocated insmeds followon biologics portfolio mk mk indefinitelived intangible asset recorded fair value determined based upon present value expected future cash flows new product candidates resulting insmeds followon biologics portfolio adjusted probability estimated technical marketing success utilizing income approach reflecting appropriate riskadjusted discount rates ongoing activity related mk mk expected material companys research development expense remaining net assets acquired material milestone royalty obligations associated acquisition transaction closed march accordingly results operations acquired business included mercks results operations beginning april collaborative arrangements company continues strategy establishing external alliances complement substantial internal research capabilities including research collaborations licensing preclinical clinical compounds technology platforms drive near longterm growth company supplements internal research aggressive licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well new technologies across broad range therapeutic areas arrangements often include upfront payments royalty profit share payments contingent upon occurrence certain future events linked success asset development well expense reimbursements payments third party cozaarhyzaar old merck ei dupont de nemours company dupont agreed form longterm research marketing collaboration develop class therapeutic agents high blood pressure heart disease discovered dupont called angiotensin ii receptor antagonists include cozaar hyzaar return old merck provided dupont marketing rights united states canada prescription medicines sinemet sinemet cr company recently regained global marketing rights sinemet sinemet cr pursuant agreement dupont company exclusive licensing agreement market cozaar hyzaar registered trademarks dupont return royalties profit share payments dupont patents provided market exclusivity united states cozaar hyzaar expired april addition cozaar hyzaar lost patent protection number major european markets march remicadesimponi subsidiary scheringplough entered licensing agreement centocor ortho biotech inc centocor johnson johnson company market remicade prescribed treatment inflammatory diseases scheringploughs subsidiary exercised option contract centocor license rights develop commercialize simponi golimumab fully human monoclonal antibody company exclusive marketing rights products outside united states japan certain asian markets december scheringplough centocor revised distribution agreement regarding development commercialization distribution remicade simponi extending companys rights exclusively market remicade match duration companys exclusive marketing rights simponi addition scheringplough centocor agreed share certain development costs relating simponis autoinjector delivery system october european commission approved simponi treatment rheumatoid arthritis immune system disorders two presentations novel autoinjector prefilled syringe result companys marketing rights products extend years first commercial sale simponi eu following receipt pricing reimbursement approval within eu operating expenses subject certain adjustments company entitled receive approximate share profits companys distribution companys marketing territory december beginning companys share profits change time share profits products share profits remain fixed thereafter remainder term company may independently develop market simponi crohns disease indication territories option centocor participate see note discussion arbitration involving companys rights market remicade simponi financial instruments derivative instruments hedging activities company manages impact foreign exchange rate movements interest rate movements earnings cash flows fair values assets liabilities operational means use various financial instruments including derivative instruments significant portion companys revenues earnings foreign affiliates exposed changes foreign exchange rates objectives accounting related companys foreign currency risk management program well interest rate risk management activities discussed foreign currency risk management significant portion companys revenues denominated foreign currencies company established revenue hedging balance sheet risk management programs protect volatility future foreign currency cash flows changes fair value caused volatility foreign exchange rates objective revenue hedging program reduce potential longerterm unfavorable changes foreign exchange decrease us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen achieve objective company partially hedge forecasted foreign currency denominated thirdparty intercompany distributor entity sales expected occur planning cycle typically three years future company layer hedges time increasing portion thirdparty intercompany distributor entity sales hedged gets closer expected date forecasted foreign currency denominated sales probable hedged transaction occur portion sales hedged based assessments costbenefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments hedged anticipated sales specified component portfolio similarly denominated foreign currencybased sales transactions responds hedged risk manner company manages anticipated transaction exposure principally purchased local currency put options provide company right obligation sell foreign currencies future predetermined price us dollar strengthens relative currency hedged anticipated sales total changes options cash flows offset decline expected future us dollar cash flows hedged foreign currency sales conversely us dollar weakens options value reduces zero company benefits increase value anticipated foreign currency cash flows company also utilizes forward contracts revenue hedging program us dollar strengthens relative currency hedged anticipated sales increase fair value forward contracts offsets decrease expected future us dollar cash flows hedged foreign currency sales conversely us dollar weakens decrease fair value forward contracts offsets increase value anticipated foreign currency cash flows fair value derivative contracts recorded either assets gain positions liabilities loss positions consolidated balance sheet changes fair value derivative contracts recorded period either current earnings comprehensive income oci depending whether derivative designated part hedge transaction type hedge transaction derivatives designated cash flow hedges effective portion unrealized gains losses contracts recorded aoci reclassified sales hedged anticipated revenue recognized hedge relationship highly effective hedge ineffectiveness de minimis derivatives designated cash flow hedges unrealized gains losses recorded sales period cash flows contracts reported operating activities consolidated statement cash flows company enter derivatives trading speculative purposes primary objective balance sheet risk management program mitigate exposure foreign currency denominated net monetary assets foreign subsidiaries us dollar functional currency effects volatility foreign exchange might occur prior conversion us dollars instances merck principally utilizes forward exchange contracts enable company buy sell foreign currencies future fixed exchange rates economically offset consequences changes foreign exchange monetary assets merck routinely enters contracts offset effects exchange exposures denominated developed country currencies primarily euro japanese yen exposures developing country currencies company enter forward contracts partially offset effects exchange exposures deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate cost hedging instrument company also minimize effect exchange monetary assets liabilities managing operating activities net asset positions local level foreign currency denominated monetary assets liabilities foreign subsidiaries us dollar functional currency remeasured spot rates effect balance sheet date effects changes spot rates reported income expense net forward contracts designated hedges marked market income expense net accordingly fair value changes forward contracts help mitigate changes value remeasured assets liabilities attributable changes foreign currency exchange rates except extent spotforward differences differences significant due shortterm nature contracts typically average maturities inception less one year applicable company uses forward contracts hedge changes fair value certain foreign currency denominated availableforsale securities attributable fluctuations foreign currency exchange rates derivative contracts designated fair value hedges accordingly changes fair value hedged securities due fluctuations spot rates recorded income expense net offset fair value changes forward contracts attributable spot rate fluctuations changes contracts fair value due spotforward differences excluded designated hedge relationship recognized income expense net amounts well hedge ineffectiveness significant years ended december cash flows contracts reported operating activities consolidated statement cash flows foreign exchange risk also managed use foreign currency debt companys senior unsecured eurodenominated notes designated effective economic hedges net investment foreign operation accordingly foreign currency transaction gains losses eurodenominated debt instruments included foreign currency translation adjustment within oci company began using forward exchange contracts hedge net investment foreign operations adverse movements exchange rates forward contracts designated hedges net investment foreign operation company hedges portion net investment certain foreign operations measures ineffectiveness based upon changes spot foreign exchange rates effective portion unrealized gains losses contracts recorded foreign currency translation adjustment within oci remains oci either sale complete substantially complete liquidation subsidiary cash flows contracts reported investing activities consolidated statement cash flows interest rate risk management december company party payfloating receivefixed interest rate swap contracts designated fair value hedges fixedrate notes notional amounts match amount hedged fixedrate notes two swaps maturing notional amounts million effectively convert companys million fixedrate notes due floating rate instruments five swaps maturing notional amounts million effectively convert million companys billion fixedrate notes due floating rate instruments addition six swaps maturing two notional amounts million four notional amounts million effectively convert companys million fixedrate notes due floating rate instruments interest rate swap contracts designated hedges fair value changes notes attributable changes benchmark london interbank offered rate libor swap rate fair value changes notes attributable changes benchmark interest rate recorded interest expense offset fair value changes swap contracts cash flows contracts reported operating activities consolidated statement cash flows presented table fair value derivatives segregated derivatives designated hedging instruments designated hedging instruments december fair value fair value derivative us dollar derivative us dollar millions balance sheet caption asset liability notional asset liability notional derivatives designated hedging instruments foreign exchange contracts current deferred income taxes current assets foreign exchange contracts noncurrent assets foreign exchange contracts current accrued current liabilities foreign exchange contracts noncurrent deferred income taxes noncurrent liabilities interest rate swaps noncurrent assets interest rate swaps noncurrent deferred income taxes noncurrent liabilities derivatives designated hedging instruments foreign exchange contracts current deferred income taxes current assets foreign exchange contracts current accrued current liabilities table provides information location pretax gain loss amounts derivatives designated fair value hedging relationship ii designated cash flow hedging relationship iii designated foreign currency hedging relationship net investment hedge iv designated hedging relationship years ended december derivatives designated fair value hedging relationships interest rate swap contracts amount gain recognized income expense net derivatives amount loss recognized income expense net hedged item foreign exchange contracts amount gain recognized income expense net derivatives amount loss recognized income expense net hedged item derivatives designated foreign currency cash flow hedging relationships foreign exchange contracts amount loss reclassified aoci sales amount gain loss recognized oci derivatives derivatives designated foreign currency net investment hedging relationships foreign exchange contracts amount gain recognized income expense net derivatives amount loss recognized oci derivatives derivatives designated hedging relationship foreign exchange contracts amount gain loss recognized income expense net derivatives amount gain recognized sales hedged item ineffectiveness hedge represents amount excluded hedge effectiveness testing derivative contracts mitigate changes value remeasured foreign currency denominated monetary assets liabilities attributable changes foreign currency exchange rates december company estimates million pretax net unrealized gain derivatives maturing within next months hedge foreign currency denominated sales period reclassified aoci sales amount ultimately reclassified sales may differ foreign exchange rates change realized gains losses ultimately determined actual exchange rates maturity fair value measurements fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date entities required use fair value hierarchy maximizes use observable inputs minimizes use unobservable inputs measuring fair value three levels inputs may used measure fair value level quoted prices active markets identical assets liabilities companys level assets include equity securities traded active exchange market level observable inputs level prices quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities companys level assets liabilities primarily include debt securities quoted prices traded less frequently exchangetraded instruments corporate notes bonds us foreign government agency securities certain mortgagebacked assetbacked securities municipal securities commercial paper derivative contracts whose values determined using pricing models inputs observable market derived principally corroborated observable market data level unobservable inputs supported little market activity financial instruments whose values determined using pricing models discounted cash flow methodologies similar techniques well instruments determination fair value requires significant judgment estimation companys level assets include certain mortgagebacked securities limited market activity december million approximately companys investment securities categorized level assets inputs used measure financial assets liabilities fall within one level described categorization based lowest level input significant fair value measurement instrument financial assets liabilities measured fair value recurring basis financial assets liabilities measured fair value recurring basis december summarized fair v alue measur em ents usin g fair value meas ur ements us ing quoted prices significant quoted prices significant active significant active significant markets observable unobservable markets observable unobservable identical assets inputs inputs identical assets inputs inputs level level level total level level level total assets investments corporate notes bonds commercial paper us government agency securities municipal securities assetbacked securities mortgagebacked securities foreign government bonds equity securities debt securities assets securities held employee compensation assets derivative assets purchased currency options forward exchange contracts interest rate swaps total assets liabilities derivative liabilities forward exchange contracts interest rate swaps total liabilities substantially assetbacked securities highlyrated standard poors rating aaa moodys investors service rating aaa secured primarily credit card auto loan home equity receivables weightedaverage lives primarily years less mortgagebacked securities represent aaarated securities issued unconditionally guaranteed payment principal interest us government agencies fair value determination derivatives includes assessment credit risk counterparties derivatives companys credit risk effects significant significant transfers level level december cash cash equivalents billion included billion cash equivalents level valuation techniques financial assets considered level fair values determined using pricing models discounted cash flow methodologies similar techniques least one significant model assumption input unobservable level financial assets also include certain investment securities limited market activity determination fair value requires significant judgment estimation companys level investment securities include certain mortgagebacked securities securities valued primarily using pricing models management understands methodologies models incorporate transaction details contractual terms maturity timing amount future cash inflows well assumptions liquidity credit valuation adjustments marketplace participants table provides summary changes fair value including net transfers andor financial assets measured fair value recurring basis using significant unobservable inputs level available available forsale forsale investments assets total investments assets total beginning balance january net transfers level purchases sales settlements net total realized unrealized gains losses included earnings comprehensive income ending balance december losses recorded earnings level assets still held december transfers level deemed occur beginning quarter transaction takes place investments aggregate amount million million respectively longer pledged collateral reclassified assets availableforsale investments amounts recorded income expense net financial instruments measured fair value companys financial instruments measured fair value recurring basis recorded amounts approximate fair value due liquid shortterm nature cash cash equivalents receivables payables estimated fair value loans payable longterm debt including current portion december billion compared carrying value billion december billion compared carrying value billion fair value estimated using quoted dealer prices summary gross unrealized gains losses availableforsale investments recorded aoci december follows fair amortized gross unrealized fair amortized gross unrealized value cost gains losses value cost gains losses corporate notes bonds commercial paper us government agency securities municipal securities assetbacked securities mortgagebacked securities foreign government bonds debt securities equity securities december amounts pledged collateral december gross unrealized gains losses related amounts pledged collateral see note million million december respectively availableforsale debt securities included shortterm investments totaled billion december remaining debt securities billion mature within five years december debt securities pledged collateral concentrations credit risk ongoing basis company monitors concentrations credit risk associated corporate issuers securities financial institutions conducts business credit exposure limits established limit concentration single issuer institution cash investments placed instruments meet high credit quality standards specified companys investment policy guidelines approximately half companys cash cash equivalents invested three highly rated money market funds majority companys accounts receivable arise product sales united states europe primarily due drug wholesalers retailers hospitals government agencies managed health care providers pharmacy benefit managers company monitors financial performance creditworthiness customers properly assess respond changes credit profile company also continues monitor economic conditions including volatility associated international sovereign economies associated impacts financial markets business taking consideration global economic downturn sovereign debt issues certain european countries company believes credit economic conditions within greece spain italy portugal among members eu deteriorated conditions well inherent variability timing cash receipts resulted may continue result increase average length time takes collect accounts receivable outstanding december companys accounts receivable greece italy spain portugal totaled approximately billion hospital public sector receivables greece approximately december companys total accounts receivable outstanding one year approximately million approximately million related accounts receivable greece italy spain portugal greek government announced would exchange zero coupon bonds outstanding accounts receivable related certain government sponsored institutions company received substantially bonds settlement million accounts receivable companys five largest us customers cardinal health inc amerisourcebergen corporation mckesson corporation walmart stores inc medco health solutions inc represented aggregate approximately onefifth accounts receivable december company monitors creditworthiness customers grants credit terms normal course business bad debts minimal company normally require collateral security support credit sales derivative financial instruments executed international swaps derivatives association master agreements master agreements several companys financial institution counterparties also include credit support annexes annexes contain provisions require collateral exchanged depending value derivative assets liabilities companys credit rating credit rating counterparty december company received cash collateral million million respectively various counterparties recorded accrued current liabilities company advanced cash collateral counterparties december inventories inventories december consisted finished goods raw materials work process supplies total approximates current cost reduction lifo costs recognized inventories assets december million billion respectively purchase accounting adjustments inventories remained recognized component materials production costs related inventories sold inventories valued lifo method comprised approximately inventories december respectively amounts recognized assets comprised almost entirely raw materials work process inventories december amounts included approximately billion inventories expected sold within one year million inventories produced preparation product launches goodwill intangibles result merger see note company recorded billion goodwill billion acquired identifiable intangible assets including acquired iprd company recorded additional billion intangible assets conjunction remeasurement mercks previously held equity interest msp partnership following table summarizes goodwill activity segment pharmaceutical total goodwill balance january additions goodwill balance december additions goodwill balance december includes cumulative translation adjustments goodwill balances intangibles december consisted gross gross carrying accumulated carrying accumulated amount amortization net amount amortization net products product rights inprocess research development tradenames total identifiable intangible assets amounts capitalized inprocess research development accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project company make separate determination useful life assets begin amortization company recorded billion inprocess research development iprd impairment charges see note also approximately million iprd reclassified products product rights upon receipt marketing approval major market aggregate amortization expense primarily recorded within materials production costs billion million million estimated aggregate amortization expense next five years follows billion billion billion billion billion joint ventures equity method affiliates equity income affiliates reflects performance companys joint ventures equity method affiliates comprised following years ended december astrazeneca lp merckscheringplough upon completion merger msp partnership became whollyowned company see primarily reflects results sanofi pasteur msd johnson johnsonmerck consumer pharmaceuticals company well merial limited disposed september astrazeneca lp old merck entered agreement astra ab astra develop market astras products royaltybearing license old mercks total sales astra products reached level triggered first step establishment joint venture business carried astra merck inc ami old merck astra owned share joint venture formed developed marketed astras new prescription medicines united states including prilosec first class medications known proton pump inhibitors slows production acid cells stomach lining old merck astra completed restructuring ownership operations joint venture whereby old merck acquired astras interest ami renamed kbi inc kbi contributed kbis operating assets new us limited partnership astra pharmaceuticals lp partnership exchange limited partner interest astra contributed net assets wholly owned subsidiary astra usa inc partnership exchange general partner interest partnership renamed astrazeneca lp azlp upon astras merger zeneca group plc astrazeneca merger became exclusive distributor products kbi retained rights maintaining limited partner interest azlp merck consent protective rights intended preserve business economic interests including restrictions power general partner make certain distributions dispositions furthermore limited events default additional rights granted company including powers direct actions remove replace partnerships chief executive officer chief financial officer merck earns ongoing revenue based sales kbi products revenue billion billion billion respectively primarily relating sales nexium well prilosec addition merck earns certain partnership returns recorded equity income affiliates reflected table returns include priority return provided partnership agreement variable returns based part upon sales certain former astra usa inc products preferential return representing mercks share undistributed azlp gaap earnings astrazeneca merger constituted trigger event kbi restructuring agreements resulted partial redemption old mercks interest certain azlp product rights upon redemption old merck received billion azlp amount based primarily multiple old mercks average annual variable returns derived sales former astra usa inc products three years prior redemption limited partner share agreed value old merck recorded billion pretax gain partial redemption partial redemption old mercks interest product rights result change old mercks limited partnership interest result astrazeneca merger exchange old mercks relinquishment rights future astra products existing pending us patents time merger astra paid million advance payment advance payment deferred remained subject trueup calculation trueup amount directly dependent fair market value march astra product rights retained old merck calculated trueup amount million returned azlp old merck recognized pretax gain million related residual advance payment balance provisions kbi restructuring agreements trigger event occurred sum limited partner share agreed value appraised value discussed trueup amount guaranteed minimum billion distribution limited partner share agreed value less payment trueup amount resulted cash receipts old merck billion aggregate pretax gain billion included income expense net also march billion outstanding loan astra plus interest redemption date settled result transactions old merck received net proceeds azlp billion conjunction restructuring discussed astra purchased option asset option payment million recorded deferred income buy old mercks interest kbi products excluding gastrointestinal medicines nexium prilosec nonppi products april astrazeneca exercised asset option merck received million astrazeneca representing net present value march projected future pretax revenue received old merck nonppi products appraised value recorded reduction companys investment azlp company recognized million deferred income component income expense net addition old merck granted astra option shares option buy old mercks common stock interest kbi therefore old mercks interest nexium prilosec exercisable exercise price shares option based net present value estimated future net sales nexium prilosec determined time exercise subject certain trueup mechanisms company believes likely astrazeneca exercise shares option summarized financial information azlp follows years ended december sales materials production costs expense net income taxes december current assets noncurrent assets total liabilities current merckscheringplough partnership old merck scheringplough collectively partners entered agreement create equallyowned partnership develop market united states new prescription medicines cholesterol management ezetimibe first new class cholesterollowering agents launched united states zetia marketed ezetrol outside united states combination product containing active ingredients zetia zocor approved united states vytorin marketed inegy outside united states cholesterol agreements provided sharing operating income generated msp partnership based upon percentages varied product sales level country operating income included expenses partners contractually agreed share expenses incurred support msp partnership shared partners included equity income affiliates however costs reflected overall results partners result merger msp partnership whollyowned company mercks share results msp partnership date merger reflected equity income affiliates activity resulting sale msp partnership products merger consolidated mercks results see note information respect litigation involving msp partnership partners related sale promotion zetia vytorin summarized financial information msp partnership follows period january year ended november december sales vytorin zetia materials production costs expense net income taxes mercks share income taxes old mercks share msp partnerships income taxes differs equity income recognized msp partnership primarily due timing recognition certain transactions old merck msp partnership periods presented including milestone payments merial limited old merck rhnepoulenc sa sanofiaventis combined animal health businesses form merial limited merial fully integrated animal health company standalone joint venture owned party merial provides comprehensive range pharmaceuticals vaccines enhance health wellbeing performance wide range animal species september old merck sold interest merial sanofiaventis billion cash sale resulted recognition billion pretax gain reflected income expense net connection sale merial old merck sanofiaventis scheringplough signed call option agreement provided sanofiaventis option require company combine intervetscheringplough animal health business merial form animal health joint venture would owned equally company sanofiaventis march sanofiaventis exercised option part call option agreement value merial fixed billion minimum total value received company contributing intervetscheringplough combined entity would billion subject customary transaction adjustments consisting floor valuation intervetscheringplough fixed minimum billion subject potential upward revision based valuation exercise two parties additional payment sanofiaventis million upon completion valuation exercise parties agreed future payment million would made sanofiaventis company addition million payment referred payments including adjustments debt certain liabilities made upon closing transaction formation new animal health joint venture sanofiaventis subject execution final agreements regulatory review united states europe countries customary closing conditions march parties signed contribution agreement obligates subject regulatory approval form joint venture company expects transaction close third quarter companys agreement sanofiaventis provides transaction consummated march either party may terminate proposed joint venture without paying breakup fee penalty merial sales billion period january september divestiture date billion sanofi pasteur msd old merck pasteur mrieux connaught sanofi pasteur sa established equallyowned joint venture market vaccines europe collaborate development combination vaccines distribution europe joint venture vaccine sales billion billion billion johnson johnsonmerck consumer pharmaceuticals company old merck formed joint venture johnson johnson develop market broad range nonprescription medicines us consumers owned venture subsequently expanded canada significant joint venture products pepcid ac overthecounter form companys ulcer medication pepcid well pepcid complete overthecounter product combines companys ulcer medication antacids sales products marketed joint venture million million million investments affiliates accounted using equity method including joint ventures totaled million december million december amounts reported assets amounts due joint ventures included deferred income taxes current assets million december million december summarized information affiliates excluding msp partnership azlp disclosed separately follows years ended december sales materials production costs expense net income taxes december current assets noncurrent assets current liabilities noncurrent liabilities includes information merial divestiture september loans payable longterm debt commitments loans payable december included billion notes due million commercial paper million shortterm foreign borrowings addition loans payable included million longdated notes subjected repayment option holders million subject repayment beginning reclassified longterm debt loans payable december included million eurodenominated notes due shortterm foreign borrowings million also included loans payable december million longdated notes subject repayment option holders longterm debt december consisted eurodenominated notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due floating rate eurodenominated term loan due notes due debentures due notes due debentures due notes due debentures due december company party interest rate swap contracts effectively convert fixedrate notes million fixedrate notes floatingrate instruments addition company party interest rate swap contracts effectively convert fixedrate notes due included loans payable current portion longterm debt floatingrate instruments see note presented table december consisted million million borrowings variable rates averaging respectively borrowings million subject repayment option holders beginning reclassified longterm debt also included foreign borrowings million million december respectively varying rates company repaid million eurodenominated notes due mature funding repay notes provided issuance commercial paper december merck closed underwritten public offering billion senior unsecured notes consisting million aggregate principal amount notes due billion aggregate principal amount notes due interest notes payable semiannually notes series redeemable whole part time companys option varying redemption prices proceeds notes used general corporate purposes including reduction shortterm debt eurodenominated notes due notes due notes due notes due notes due redeemable whole part mercks option time redemption prices specified notes associated prospectus respect eurodenominated notes notes notes change control triggering event defined therein occurs certain circumstances defined notes associated prospectus holders notes right require merck repurchase part notes cash payment equal aggregate principal amount notes repurchased plus accrued unpaid interest date purchase connection merger effective november new merck executed full unconditional guarantee existing debt old merck old merck executed full unconditional guarantee existing debt new merck excluding commercial paper including payments principal interest guarantees extend debt issued subsequent merger aggregate maturities longterm debt next five years follows billion million billion billion billion company executed new billion day credit facility terminated old mercks billion incremental facility due expire november billion revolving credit facility scheduled mature april companys billion credit facility maturing august remains outstanding outstanding facilities provide backup liquidity companys commercial paper borrowing facility used general corporate purposes company drawn funding either facility rental expense operating leases net sublease income million million million minimum aggregate rental commitments noncancellable leases follows million million million million million thereafter million company significant capital leases contingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well additional matters antitrust actions company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable companys decision obtain insurance coverage dependent market conditions including cost availability existing time decisions made result number factors product liability insurance become less available cost increased significantly company evaluated risks determined cost obtaining product liability insurance outweighs likely benefits coverage available insurance certain product liabilities effective august including liability old merck products first sold date company continue evaluate insurance needs costs availability benefits product liability insurance future vioxx litigation product liability lawsuits previously disclosed individual putative class actions filed old merck state federal courts alleging personal injury andor economic loss respect purchase use vioxx actions filed federal court coordinated multidistrict litigation us district court eastern district louisiana mdl district judge eldon e fallon number actions filed state court coordinated separate coordinated proceedings state courts california texas counties philadelphia pennsylvania washoe clark counties nevada october new jersey supreme court dissolved new jersey coordinated vioxx proceeding actions discussed paragraph lawsuits collectively referred vioxx product liability lawsuits plaintiff groups vioxx product liability lawsuits described vast majority enrolled vioxx settlement program described december approximately plaintiff groups otherwise eligible settlement program participate claims remain pending old merck addition claims approximately plaintiff groups eligible settlement program remain pending old merck number plaintiff groups subject various motions dismiss failure comply courtordered deadlines claims plaintiffs dismissed december vast majority dismissed result settlement process discussed november old merck announced entered agreement settlement agreement law firms comprise executive committee plaintiffs steering committee psc federal vioxx mdl well representatives plaintiffs counsel texas new jersey california state coordinated proceedings resolve state federal myocardial infarction mi ischemic stroke claims filed date united states settlement agreement applied us legal residents alleged mi occurred united states settlement agreement provided old merck pay fixed aggregate amount billion two funds billion mi claims million claims settlement program december processing mi claims settlement program completed final payments made claimants majority claimants yet paid finalizing documents one us vioxx product liability lawsuit trial held trial louisiana attorney general matter discussed three us vioxx product liability lawsuits currently scheduled trial old merck previously disclosed outcomes several vioxx product liability lawsuits tried prior cases went trial two unresolved posttrial appeals ernst v merck garza v merck merck previously disclosed details associated cases grounds mercks appeals lawsuits still pending various us courts putative class actions purportedly brought behalf individual purchasers users vioxx seeking reimbursement alleged economic loss mdl proceeding approximately class actions remain june old merck moved strike class claims judgment pleadings regarding master complaint includes abovereferenced cases briefing motion completed september mdl court heard oral argument old mercks motion october took advisement june missouri state court certified class missouri plaintiffs seeking reimbursement outofpocket costs relating vioxx trial scheduled begin october addition indiana plaintiffs filed motion certify class indiana vioxx purchasers case pending circuit court marion county indiana april kentucky state court denied old mercks motion summary judgment certified class kentucky plaintiffs seeking reimbursement outofpocket costs relating vioxx intermediate appellate court denied old mercks petition writ mandamus old merck appealed decision kentucky supreme court old merck also named defendant several lawsuits brought behalf government entities twelve suits brought state attorneys general one behalf county one brought private citizen qui tam suit actions except suit brought attorney general michigan mdl proceeding michigan attorney general case remanded state court actions allege old merck misrepresented safety vioxx one suits seeks recovery expenditures vioxx governmentfunded health care programs medicaid along relief penalties attorneys fees action brought attorney general kentucky seeks penalties alleged consumer fraud violations lawsuit brought county class action filed santa clara county california behalf similarly situated california counties old merck moved dismiss false claims act claims brought qui tam plaintiff behalf district columbia november court heard oral argument motion december took advisement old merck also moved dismiss case brought attorney general oklahoma december march judge fallon partially granted partially denied old mercks motion summary judgment louisiana attorney general case trial remaining claims judge fallon began april completed april judge fallon found favor old merck june dismissing attorney generals remaining claims prejudice louisiana attorney general appealing ruling shareholder lawsuits previously disclosed addition vioxx product liability lawsuits various putative class actions individual lawsuits federal state securities laws filed old merck various current former officers directors vioxx securities lawsuits previously disclosed vioxx securities lawsuits transferred judicial panel multidistrict litigation jpml us district court district new jersey district judge stanley r chesler inclusion nationwide mdl shareholder mdl consolidated purposes june old merck moved dismiss fifth amended class action complaint consolidated securities action plaintiffs filed opposition august old merck filed reply september motion currently pending district court previously disclosed several individual securities lawsuits filed foreign institutional investors also consolidated vioxx securities lawsuits stipulation defendants required respond complaints resolution motions dismiss consolidated securities class action addition previously disclosed various putative class actions filed federal court employee retirement income security act erisa old merck certain current former officers directors vioxx erisa lawsuits cases consolidated shareholder mdl judge chesler fact discovery vioxx erisa lawsuits closed september parties filed proposed schedule expert discovery dispositive motions trial international lawsuits previously disclosed addition lawsuits discussed old merck named defendant litigation relating vioxx australia brazil canada europe israel collectively vioxx foreign lawsuits following trial representative action federal court australia entered orders dismissed claims old merck regard old mercks australian subsidiary merck sharp dohme australia pty ltd court dismissed certain claims awarded named plaintiff court found suffered mi ingesting vioxx approximately months au based statutory claims vioxx fit purpose merchantable quality even though court rejected applicants claim old merck australian subsidiary knew ought known prior voluntary withdrawal vioxx september vioxx materially increased risk mi court also determined findings fact law common claims group members whose individual claims would proceed reference findings old mercks subsidiary appealed adverse findings full federal court scheduled hear appeal crossappeal august canada superior court quebec authorized class action behalf vioxx users quebec alleged negligence superior court ontario certified class vioxx users canada except quebec saskatchewan alleged negligence entitlement elect waive tort procedural decisions canadian litigation address merits plaintiffs claims litigation canada remains early stage insurance previously disclosed company directors officers insurance coverage applicable vioxx securities lawsuits remaining stated upper limits approximately million company fiduciary insurance vioxx erisa lawsuits stated upper limits approximately million result previously disclosed arbitration additional insurance coverage claims also available needed upperlevel excess policies provide coverage variety risks disputes insurers availability companys insurance coverage claims likely additional disputes amounts actually recovered policies discussed paragraph may less stated upper limits investigations previously disclosed old merck received subpoenas department justice doj requesting information related old mercks research marketing selling activities respect vioxx federal health care investigation criminal statutes investigation included subpoenas witnesses appear grand jury previously disclosed march old merck received letter us attorneys office district massachusetts identifying target grand jury investigation regarding vioxx october company announced established million reserve vioxx liability reserve connection anticipated resolution dojs investigation companys discussions government ongoing concluded certainty definitive resolution previously disclosed investigations conducted local authorities certain cities europe order determine whether criminal charges brought concerning vioxx company cooperating governmental entities including doj respective investigations vioxx investigations company predict outcome inquiries however could result potential civil andor criminal remedies reserves one us vioxx product liability lawsuit tried three us vioxx product liability lawsuits currently scheduled trial company predict timing trials related vioxx litigation defined company believes meritorious defenses vioxx product liability lawsuits vioxx shareholder lawsuits vioxx foreign lawsuits collectively vioxx lawsuits vigorously defend view inherent difficulty predicting outcome litigation particularly many claimants claimants seek indeterminate damages company unable predict outcome matters time reasonably estimate possible loss range loss respect vioxx lawsuits included settlement program vioxx liability reserve established respect doj investigation noted company established reserves potential liability relating vioxx lawsuits vioxx investigations unfavorable outcomes vioxx litigation could material adverse effect companys financial position liquidity results operations legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable december company aggregate reserve approximately million vioxx legal defense costs reserve solely future legal defense costs related vioxx litigation company spent approximately million aggregate legal defense costs worldwide including approximately million fourth quarter related vioxx product liability lawsuits ii vioxx shareholder lawsuits iii vioxx foreign lawsuits iv vioxx investigations collectively vioxx litigation also merck recorded million charges including million fourth quarter solely future legal defense costs vioxx litigation consequently december aggregate amount vioxx legal defense costs reserve approximately million solely future legal defense costs vioxx litigation significant factors considered review vioxx legal defense costs reserve follows actual costs incurred company development companys legal defense strategy structure light scope vioxx litigation including settlement agreement expectation certain lawsuits continue pending number cases brought company costs outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials vioxx litigation amount vioxx legal defense costs reserve december represents companys best estimate minimum amount defense costs incurred connection remaining aspects vioxx litigation however events additional trials vioxx litigation events could arise course vioxx litigation could affect ultimate amount defense costs incurred company company continue monitor legal defense costs review adequacy associated reserves may determine increase vioxx legal defense costs reserve time future based upon factors set forth believes would appropriate product liability litigation fosamax previously disclosed old merck defendant product liability lawsuits united states involving fosamax fosamax litigation december approximately cases include approximately plaintiff groups filed pending old merck either federal state court including one case seeks class action certification well damages andor medical monitoring actions plaintiffs allege among things suffered osteonecrosis jaw generally subsequent invasive dental procedures tooth extraction dental implants andor delayed healing association use fosamax addition plaintiffs approximately actions allege sustained stress andor low energy femoral fractures association use fosamax august jpml ordered certain fosamax product liability cases pending federal courts nationwide transferred consolidated one multidistrict litigation fosamax mdl coordinated pretrial proceedings fosamax mdl transferred judge john keenan us district court southern district new york result jpml order approximately cases judge keenan judge keenan issued case management order various amendments thereto set forth schedule governing proceedings focused primarily upon resolving class action certification motions completing fact discovery initial group cases october briefing argument plaintiffs motions certification medical monitoring classes completed judge keenan issued order denying motions january january judge keenan issued order dismissing prejudice class claims asserted first four class action lawsuits filed old merck sought personal injury damages andor medical monitoring relief class wide basis daubert motions filed may judge keenan conducted daubert hearing july july judge keenan issued ruling parties respective daubert motions ruling denied plaintiff steering committees motion granted part denied part old mercks motion first fosamax mdl trial boles v merck fosamax mdl court declared mistrial eight person jury could reach unanimous verdict boles case retried june resulted verdict favor plaintiff amount million merck filed posttrial motions seeking judgment matter law alternative new trial october court denied mercks posttrial motions sua sponte ordered remittitur reducing verdict million plaintiff rejected remittitur ordered court requested new trial damages company filed motion interlocutory appeal next fosamax mdl case set trial maley v merck jury may returned unanimous verdict mercks favor february judge keenan selected new bellwether case judith graves v merck replace flemings bellwether case fosamax mdl court dismissed granted summary judgment favor old merck november second circuit affirmed courts granting summary judgment favor old merck flemings case graves jury returned unanimous verdict favor old merck november next trials scheduled fosamax mdl secrest v merck scheduled begin march hester v merck scheduled begin may addition judge keenan ordered february two bellwether trials conducted fosamax mdl cases tried trial dates cases yet determined outside fosamax mdl trial florida scheduled begin june florida state court postponed trial date sometime january addition july application made atlantic county superior court new jersey requesting fosamax cases pending new jersey considered mass tort designation centralized management one judge new jersey october new jersey supreme court ordered pending future actions filed new jersey arising use fosamax seeking damages existing dental jawrelated injuries including osteonecrosis jaw solely seeking medical monitoring designated mass tort centralized management purposes judge higbee atlantic county superior court december approximately cases pending old merck atlantic county new jersey july judge higbee entered case management order various amendments thereto setting forth schedule contemplates completing fact expert discovery initial group cases worked trial february jury rosenberg v merck first trial new jersey coordinated proceeding returned verdict mercks favor discovery ongoing fosamax mdl litigation new jersey coordinated proceeding remaining jurisdictions fosamax cases pending company intends defend lawsuits nuvaring beginning may number complaints filed various jurisdictions asserting claims companys subsidiaries organon usa inc organon pharmaceuticals usa inc organon international collectively organon scheringplough arising organons marketing sale nuvaring combined hormonal contraceptive vaginal ring plaintiffs contend organon scheringplough failed adequately warn alleged increased risk venous thromboembolism vte posed nuvaring andor downplayed risk vte plaintiffs seek damages injuries allegedly sustained product use including alleged deaths heart attacks strokes majority cases currently pending federal multidistrict litigation nuvaring mdl venued missouri new jersey state court december approximately nuvaring cases cases pending nuvaring mdl us district court eastern district missouri judge rodney sippel approximately pending consolidated discovery proceedings bergen county superior court new jersey judge brian r martinotti four additional cases pending various state courts pursuant january february orders judge sippel nuvaring mdl parties selected trial pool cases subject fact discovery pursuant judge martinottis january case management order parties selected additional trial pool cases subject fact discovery new jersey consolidated proceedings based revised scheduling order entered jurisdictions september fact discovery trial pool cases end june expert discovery end february first trials scheduled jurisdiction company intends defend lawsuits commercial litigation awp litigation investigations previously disclosed company andor certain subsidiaries remain defendants cases brought various states certain new york counties alleging manipulation pharmaceutical manufacturers average wholesale prices awp sometimes used public private payors calculating provider reimbursement levels outcome litigations could include substantial damages imposition substantial fines penalties injunctive administrative remedies january us district court district massachusetts held unit company eight drug makers overcharged new york city new york counties certain generic drugs court reserved issue damages penalties future proceedings period september january company settled awp cases brought states hawaii arizona kansas utah south carolina period company several manufacturers named defendants awp cases brought states oklahoma louisiana result company andor certain subsidiaries continue defendants twelve cases brought states new york counties jury us district court district massachusetts found company liable approximately million compensatory damages september ground units scheringplough caused massachusetts overpay pharmacists prescriptions albuterol penalties case could substantial court deferred decision calculated massachusetts state law significant legal issues remain decided penalties could imposed amount company intends pursue reversal verdict trial court appeal necessary centocor distribution agreement may centocor wholly owned subsidiary johnson johnson delivered scheringplough notice initiating arbitration proceeding resolve whether result merger centocor permitted terminate companys rights distribute commercialize remicade simponi sales remicade simponi billion aggregate arbitration hearing concluded company awaiting arbitration panels decision unfavorable outcome arbitration would material adverse effect companys financial position liquidity results operations governmental proceedings effective august merck hhsoig executed unified corporate integrity agreement unified cia replaced individual cias signed old merck scheringplough prior merger unified cia incorporates certain requirements individual cias old merck scheringplough similar although identical legacy cias merck assumed compliance obligations unified cia february old merck cia company believes promotional practices medicaid price reports meet requirements unified cia previously disclosed company received letters doj sec seek information activities number countries reference foreign corrupt practices act company cooperating agencies requests believes inquiry part broader review pharmaceutical industry practices foreign countries regard company received may continue receive additional requests information either doj sec vytorinzetia litigation previously disclosed april old merck shareholder filed putative class action lawsuit federal court eastern district pennsylvania alleging old merck violated federal securities laws suit since withdrawn refiled district new jersey consolidated another federal securities lawsuit caption merck co inc vytorin securities litigation amended consolidated complaint filed october names defendants old merck merckscheringplough pharmaceuticals llc certain companys current former officers directors specifically complaint alleges old merck delayed releasing unfavorable results enhance clinical trial regarding efficacy vytorin old merck made false misleading statements expected earnings knowing results vytorin study released sales vytorin would decline old mercks earnings would suffer december old merck defendants moved dismiss lawsuit grounds plaintiffs failed state claim relief granted september court issued opinion order denying defendants motion dismiss lawsuit october old merck defendants filed answer amended consolidated complaint similar consolidated putative class action securities lawsuit pending district new jersey filed scheringplough shareholder scheringplough former chairman president chief executive officer fred hassan caption scheringplough corporationenhance securities litigation amended consolidated complaint filed september names defendants scheringplough merckscheringplough pharmaceuticals llc certain companys current former officers directors underwriters participated august public offering scheringploughs common preferred stock december scheringplough defendants filed motions dismiss lawsuit grounds plaintiffs failed state claim relief granted september court issued opinion order denying defendants motion dismiss lawsuit defendants filed answer consolidated amended complaint november previously disclosed april member old merck erisa plan filed putative class action lawsuit old merck certain companys current former officers directors alleging breached fiduciary duties erisa since time similar erisa lawsuits filed old merck district new jersey lawsuits consolidated caption merck co inc vytorin erisa litigation consolidated amended complaint filed february names defendants old merck various current former members companys board directors plaintiffs allege erisa plans investment old merck stock imprudent old mercks earnings dependent commercial success cholesterol drug vytorin defendants knew known results scientific study would cause medical community turn less expensive drugs cholesterol management april old merck defendants moved dismiss lawsuit grounds plaintiffs failed state claim relief granted september court issued opinion order denying defendants motion dismiss lawsuit november plaintiffs moved strike certain defendants affirmative defenses motion denied part granted part june amended answer filed july similar consolidated putative class action erisa lawsuit currently pending district new jersey filed member scheringplough erisa plan schering plough certain current former officers directors alleging breached fiduciary duties erisa caption scheringplough corp enhance erisa litigation consolidated amended complaint filed october names defendants scheringplough various current former members scheringploughs board directors current former members committees scheringploughs board directors november company defendants filed motion dismiss lawsuit grounds plaintiffs failed state claim relief granted plaintiffs opposition motion dismiss filed december motion fully briefed january motion denied june september defendants filed answer amended complaint matter november stockholder company filed shareholder derivative lawsuit local international brotherhood electrical workers pension fund v clark local district new jersey behalf nominal defendant company shareholders company company certain companys officers directors alleged insiders certain predecessor companies former officers directors alleged insiders alleged breaches fiduciary duties waste unjust enrichment gross mismanagement similar shareholder derivative lawsuit cain v hassan filed scheringplough stockholder currently pending district new jersey amended complaint filed may scheringplough stockholder behalf nominal defendant scheringplough scheringplough shareholders lawsuit company schering ploughs thencurrent board directors certain scheringploughs current former officers directors alleged insiders plaintiffs local cain v hassan allege defendants withheld enhance study results made false misleading statements thereby deceiving causing harm company scheringplough respectively investing public unjustly enriching insiders wasting corporate assets defendants local intend move dismiss plaintiffs complaint defendants cain v hassan moved dismiss amended complaint july motion fully briefed october decision remains pending november company shareholder filed derivative lawsuit state court new jersey case captioned rose v hassan asserts claims substantially identical claims alleged cain v hassan discovery cases referred section coordinated commenced company intends defend lawsuits referred section unfavorable outcomes resulting government investigations civil litigations could material adverse effect companys financial position liquidity results operations insurance company directors officers insurance coverage applicable vytorin shareholder lawsuits stated upper limits approximately million company fiduciary insurance vytorin erisa lawsuits approximately million disputes insurers availability companys insurance coverage claims likely additional disputes amounts actually recovered policies discussed paragraph may less stated limits securities class action litigation kdur antitrust litigation june january scheringplough settled patent litigation upshersmith inc upshersmith esi lederle inc lederle respectively relating generic versions kdur scheringploughs longacting potassium chloride product supplement used cardiac patients lederle upshersmith filed abbreviated new drug applications andas following commencement administrative proceeding united states federal trade commission ftc alleging anticompetitive effects settlements resolved scheringploughs favor alleged class action suits filed federal state courts behalf direct indirect purchasers kdur scheringplough upshersmith lederle suits claimed violations federal state antitrust laws well state statutory common law causes action suits sought unspecified damages april indirect purchasers voluntarily dismissed case february special master recommended us district court district new jersey dismiss class action lawsuits summary judgment march district court adopted recommendation granted summary judgment defendants dismissed matter entirety plaintiffs appealed decision third circuit court appeals defendants simultaneously appealing december decision district court certify certain direct purchaser plaintiffs claims class action may superior court alameda county california also granted summary judgment defendants favor dismissing related california state law case making similar allegations regarding scheringploughs settlements upshersmith lederle decision final vaccine litigation previously disclosed old merck party individual product liability lawsuits claims united states involving pediatric vaccines eg hepatitis b vaccine contained thimerosal preservative used vaccines december approximately thimerosal related lawsuits pending old merck defendant although vast majority lawsuits currently active defendants include vaccine manufacturers produced pediatric vaccines containing thimerosal well manufacturers thimerosal actions plaintiffs allege among things suffered neurological injuries result exposure thimerosal pediatric vaccines cases currently scheduled trial company defend lawsuits however possible unfavorable outcomes could material adverse effect companys financial position liquidity results operations old merck successful cases type either dismissed stayed ground action prohibited national childhood vaccine injury act vaccine act vaccine act prohibits person filing maintaining civil action state federal court seeking damages vaccine manufacturer vaccinerelated injuries unless petition first filed united states court federal claims hereinafter vaccine court vaccine act filing civil action vaccine manufacturer petitioner must either pursue petition conclusion vaccine court timely file election proceed civil action lieu accepting vaccine courts adjudication petition b timely exercise right withdraw petition prior vaccine court adjudication accordance certain statutorily prescribed time periods old merck party vaccine court proceedings petitions brought united states department health human services company aware approximately cases pending vaccine court involving allegations thimerosalcontaining vaccines andor mmr ii vaccine cause autism spectrum disorders thimerosalcontaining vaccines involved vaccine court proceeding company vaccines company sole source mmr ii vaccine domestically special masters presiding vaccine court proceedings held hearings three test cases involving theory combination mmr ii vaccine thimerosal vaccines causes autism spectrum disorders february special masters issued decisions cases finding theory unsupported valid scientific evidence petitioners three cases therefore entitled compensation two three cases appealed may united states court appeals federal circuit issued opinion affirming one appealed cases august court issued opinion affirming second case special masters also held similar hearings three different test cases involving theory thimerosal vaccines alone causes autism spectrum disorders march special masters issued decisions second set test cases finding theory also unsupported valid scientific evidence petitioners cases also entitled compensation petitioners second set test cases exercise options seek review decisions accordingly april final judgments entered second set test cases special masters previously indicated would hold similar hearings involving theory mmr ii alone causes autism spectrum disorders stated longer intend vaccine court indicated intends use evidence presented test case hearings guide adjudication remaining autism spectrum disorder cases patent litigation time time generic manufacturers pharmaceutical products file andas fda seeking market generic forms companys products prior expiration relevant patents owned company protect patent rights company may file patent infringement lawsuits generic companies certain products company marketed via agreements companies currently involved patent infringement litigation united states include cancidas integrilin nasonex nexium propecia temodar vytorin zetia similar lawsuits defending companys patent rights may exist countries company intends vigorously defend patents believes valid infringement generic companies attempting market products prior expiration patents litigation assurance outcomes adverse could result significantly shortened periods exclusivity products cancidas november patent infringement lawsuit filed united states teva parenteral medicines inc tpm respect tpms application fda seeking prepatent expiry approval sell generic version cancidas lawsuit automatically stays fda approval tpms application april adverse decision whichever may occur first also march patent infringement lawsuit filed united states sandoz inc sandoz respect sandozs application fda seeking pre patent expiry approval sell generic version cancidas lawsuit automatically stays fda approval sandozs application august adverse court decision whichever may occur earlier integrilin february patent infringement lawsuit filed jointly millennium pharmaceuticals inc millennium united states tpm respect tpms application fda seeking approval sell generic version integrilin prior expiry last expire listed patent tpm challenge certain patents expire november fda approval tpm application occur earlier november however could later event favorable decision lawsuit company millennium nasonex december patent infringement suit filed united states apotex respect apotexs application fda seeking prepatent expiry approval market generic version nasonex lawsuit automatically stays fda approval apotexs anda may adverse court decision whichever may occur earlier nexium november patent infringement lawsuit filed jointly astrazeneca united states ranbaxy respect ranbaxys application fda seeking prepatent expiry approval sell generic version nexium previously disclosed astrazeneca merck ranbaxy entered settlement agreement provided ranbaxy would entitled bring generic esomeprazole product market united states may company astrazeneca received cid ftc july regarding settlement agreement ranbaxy company cooperating ftc responding cid march patent infringement lawsuit filed jointly astrazeneca ivax later acquired teva pharmaceuticals inc teva respect ivaxs application fda seeking prepatent expiry approval sell generic version nexium january astrazeneca merck tevaivax entered settlement agreement provides tevaivax would entitled bring generic esomeprazole product market united states may patent infringement lawsuits also filed united states dr reddys laboratories dr reddys sandoz lupin ltd lupin respect eachs respective application fda seeking prepatent expiry approval sell generic versions nexium lawsuits ongoing trial dates presently scheduled february patent infringement lawsuit filed jointly astrazeneca united states hamni usa inc hamni respect hanmis application fda seeking prepatent expiry approval sell generic version nexium january astrazeneca merck dr reddys entered settlement agreement provides dr reddys would entitled bring generic esomeprazole product market united states may lawsuits sandoz lupin ongoing trial dates presently scheduled patent infringement lawsuit also filed jointly astrazeneca united states sun pharma global fze respect application fda seeking prepatent expiry approval sell generic version nexium iv propecia december patent infringement lawsuit filed united states hetero drugs limited hetero respect heteros application fda seeking prepatent expiry approval sell generic version propecia lawsuit automatically stays fda approval heteros anda april adverse court decision whichever may occur earlier temodar july patent infringement action filed jointly cancer research technologies limited crt united states barr later acquired teva respect barrs application fda seeking prepatent expiry approval sell generic version temodar january court issued decision finding crt patent unenforceable grounds prosecution laches inequitable conduct november appeals court issued decision reversing trial courts finding december barr filed petition seeking rehearing en banc appeal virtue agreement barr launch product appeal process company agreed barr launch product august september patent infringement lawsuit filed jointly crt united states sun pharmaceutical industries inc sun respect suns application fda seeking prepatent expiry approval sell generic version temodar lawsuit automatically stays fda approval suns anda february adverse court decision whichever may occur earlier november patent infringement lawsuit filed jointly crt accord healthcare inc accord respect application fda seeking prepatent expiry approval sell generic version temodar company crt accord entered agreement stay lawsuit pending outcome appeal en banc process barr lawsuit vytorin december patent infringement lawsuit filed united states mylan respect mylans application fda seeking prepatent expiry approval sell generic version vytorin lawsuit automatically stays fda approval mylans application may adverse court decision whichever may occur earlier february patent infringement lawsuit filed united states teva respect tevas application fda seeking prepatent expiry approval sell generic version vytorin lawsuit automatically stays fda approval tevas application august adverse court decision whichever may occur earlier august patent infringement lawsuit filed united states impax laboratories inc impax respect impaxs application fda seeking prepatent expiry approval sell generic version vytorin agreement reached impax stay lawsuit pending outcome lawsuit mylan zetia march patent infringement lawsuit filed united states glenmark pharmaceuticals inc usa parent corporation collectively glenmark respect glenmarks application fda seeking prepatent expiry approval sell generic version zetia may glenmark agreed settlement virtue glenmark permitted launch generic product united states december subject receiving final fda approval june patent infringement lawsuit filed united states mylan respect mylans application fda seeking prepatent expiry approval sell generic version zetia lawsuit automatically stays fda approval mylans application december adverse court decision whichever may occur earlier september patent infringement lawsuit filed united states teva respect tevas application fda seeking prepatent expiry approval sell generic version zetia lawsuit automatically stays fda approval tevas application january adverse court decision whichever may occur earlier september lawsuit filed federal court canada teva seeking order prohibition tevas application seeking prepatent expiry approval sell generic version ezetimibe canada teva responded asserting patent invalid september federal court canada issued decision upholding validity companys canadian ezetimibe patent decision appealed august lawsuit filed federal court canada mylan seeking order prohibition mylans application seeking prepatent expiry approval sell generic version ezetimibe canada december mylan withdrew application product approval prior patent expiration september subject lawsuit withdrawn litigation various legal proceedings principally product liability intellectual property suits involving company pending feasible predict outcome proceedings proceedings discussed note opinion company proceedings either adequately covered insurance covered ultimately result liability would material adverse effect financial position liquidity results operations company proceedings separate assessment provided note environmental matters company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents proceedings seek require operators hazardous waste disposal facilities transporters waste sites generators hazardous waste disposed sites clean sites reimburse government cleanup costs company made party proceedings alleged generator waste disposed sites case government alleges defendants jointly severally liable cleanup costs although joint several liability alleged proceedings frequently resolved allocation cleanup costs among parties nearly reflects relative contributions parties site situation companys potential liability varies greatly site site sites potential liability de minimis others final costs cleanup yet determined feasible predict outcome many proceedings brought federal state agencies private litigants opinion company proceedings ultimately result liability would material adverse effect financial position results operations liquidity capital resources company company taken active role identifying providing costs amounts include reduction anticipated recoveries cleanup costs former site owners operators recalcitrant potentially responsible parties previously disclosed approximately plaintiffs filed amended complaint old merck defendants us district court eastern district california asserting claims clean water act resource conservation recovery act well negligence nuisance suit seeks damages personal injury diminution property value medical monitoring alleged real personal property damage associated groundwater soil contamination found site former old merck subsidiary merced california certain defendants suit settled plaintiffs regarding aspects plaintiffs claims lawsuit proceeding phased manner jury trial commenced february jury asked make certain factual findings regarding whether contamination moved offsite areas plaintiffs could exposed contamination amounts defendants phase trial include old merck three original defendants depending results phase trial later phases litigation may required address issues related causation damages related specific plaintiffs previously disclosed environmental protection agency epa merck tentatively agreed fine resolve alleged environmental violations mercks las piedras puerto rico facility alleged violations arise epa air inspection conducted july primarily based sites leak detection repair program managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively liabilities undiscounted consider potential recoveries parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures result material adverse effect companys financial position results operations liquidity capital resources year equity accordance merck certificate incorporation shares common stock shares preferred stock authorized authorized shares preferred stock series shares designated mandatory convertible preferred stock mandatory convertible preferred stock connection merger holders scheringplough preferred stock received preferred stock rights substantially similar rights scheringplough preferred stock accordance new merck restated certificate incorporation result merger preferred stock became subject makewhole acquisition provisions preferred stock effective november makewhole acquisition conversion period ended november preferred stock convertible makewhole conversion rate share preferred stock converted period holder received cash new merck common shares holders also received dividend makewhole payment per share depending date conversion total shares preferred stock converted shares new merck common stock cash payments approximately million made holders converted addition makewhole dividend payments million made holders converted representing present value remaining future dividend payments conversion date mandatory conversion date august using discount rate stipulated terms preferred stock august outstanding mandatory convertible preferred stock automatically converted terms right receive cash shares merck common stock share mandatory convertible preferred stock holders received cash shares merck common stock result conversion approximately million paid holders approximately million merck common shares issued capital stock summary common stock treasury stock transactions shares millions follows common treasury common treasury common treasury stock stock stock stock stock stock balance january mandatory conversion convertible preferred stock issuances shares connection merger issuances purchases treasury stock cancellations treasury stock balance december issuances primarily reflect activity sharebased compensation plans pursuant merger agreement certain old mercks treasury shares cancelled noncontrolling interests connection restructuring ami old merck assumed billion par value preferred stock obligation dividend rate per annum carried kbi included noncontrolling interests astrazeneca exercises shares option see note preferred stock obligation settled sharebased compensation plans company sharebased compensation plans employees nonemployee directors employees certain companys equity method investees may granted options purchase shares company common stock fair market value time grant addition stock options company grants performance share units psus restricted stock units rsus certain management level employees plans approved companys shareholders result merger scheringplough stock incentive plan scheringplough sip amended restated sharebased compensation instruments remain available future grant scheringplough sip new merck employees employees scheringplough prior merger outstanding sharebased compensation instruments well sharebased compensation instruments available future grant old merck new merck incentive plans also result merger certain sharebased compensation instruments previously granted scheringplough sip legacy scheringplough incentive plans exchanged new merck replacement awards awards related precombination services became payable cash addition certain stock options scheringplough legacy incentive plans contained lockin feature whereby award holder could elected receive cash payment stock options fixed amount based price scheringploughs common stock days prior merger liability associated provision million december upon expiration exercise period associated lockin feature amount reclassified liabilities equity fair value replacement awards attributable precombination service million included calculation consideration transferred see note significant portion legacy scheringplough awards vested opening balance sheet time merger scheringplough sharebased compensation instruments immediately vest upon completion merger exchanged new merck replacement awards generally vest basis original grants made scheringplough legacy incentive plans immediately vest employee terminated company within two years merger certain circumstances fair value new merck replacement awards attributed postcombination services recognized compensation cost subsequent merger requisite service period awards december million shares collectively authorized future grants companys sharebased compensation plans prior merger employee sharebased compensation awards settled primarily treasury shares subsequent merger awards either settled newly issued shares treasury shares employee stock options granted purchase shares company stock fair market value time grant awards generally vest onethird year threeyear period contractual term years rsus stock awards granted employees entitle holder shares common stock awards vest fair value stock option rsu awards determined fixed grant date based companys stock price psus stock awards ultimate number shares issued contingent companys performance preset objective set objectives fair value psu determined date grant based companys stock price rsus certain psus granted december employees participate dividends basis common shares dividends nonforfeitable holder rsus psus issued january dividends declared vesting period payable employees upon vesting fair value stock option rsu psu replacement awards determined fixed time merger psu performance period number shares stock expected issued adjusted based probability achievement performance target final compensation expense recognized based ultimate number shares issued rsu psu distributions shares company stock end vesting performance period generally three years subject terms applicable awards total pretax sharebased compensation cost recorded million million million respectively related income tax benefits million million million respectively company uses blackscholes option pricing model determining fair value option grants applying model company uses historical data current market data estimate fair value options blackscholes model requires several assumptions including expected dividend yield riskfree interest rate volatility term options expected dividend yield based historical patterns dividend payments riskfree rate based rate grant date zerocoupon us treasury notes term equal expected term option expected volatility estimated using blend historical implied volatility historical component based historical monthly price changes implied volatility obtained market data companys traded options expected life represents amount time options granted expected outstanding based historical forecasted exercise behavior weighted average grant price options granted per option respectively weighted average fair value options granted per option respectively determined using following assumptions years ended december expected dividend yield riskfree interest rate expected volatility expected life years summarized information relative stock option plan activity options thousands follows weighted average average remaining aggregate number exercise contractual intrinsic options price term value balance january granted exercised forfeited outstanding december exercisable december additional information pertaining stock option plans provided table years ended december total intrinsic value stock options exercised fair value stock options vested cash received exercise stock options fair value stock options vested excludes fair value options vested result merger attributable precombination service summary nonvested rsu psu activity shares thousands follows rsus psus weighted weighted average average number grant date number grant date shares fair value shares fair value nonvested january granted vested forfeited nonvested december december million total pretax unrecognized compensation expense related nonvested stock options rsu psu awards recognized weighted average period years segment reporting sharebased compensation costs unallocated expenses pension postretirement benefit plans company defined benefit pension plans covering eligible employees united states certain international subsidiaries pension benefits united states based formula considers final average pay years credited service addition company provides medical dental life insurance benefits principally eligible us retirees similar benefits dependents postretirement benefit plans company uses december yearend measurement date pension plans postretirement benefit plans net periodic benefit cost net periodic benefit cost pension postretirement benefit plans consisted following components pens ion ne fits ot r postreti rem e n benefits years ended december service cost interest cost expected return plan assets net amortization termination benefits curtailments settlements net periodic benefit cost higher costs compared primarily due incremental costs associated legacy scheringplough benefit plans recognized subsequent merger net periodic benefit cost attributable us pension plans included table million million million connection restructuring actions see note termination charges recorded pension postretirement benefit plans related expanded eligibility certain employees exiting merck also connection restructuring activities curtailments recorded pension postretirement benefit plans addition settlements recorded certain domestic international pension plans employee benefit plans exception recognition fair value measurement principles business combinations employee benefit plan obligations recognized measured accordance existing authoritative literature accounting benefit plans rather fair value accordingly company remeasured benefit plans sponsored scheringplough recognized asset liability funded status plans merger date obligations funded status summarized information changes plan assets benefit obligation funded status amounts recorded december follows oth er postretiremen pension benefits benefits fair value plan assets january actual return plan assets company contributions mergers acquisitions effects exchange rate changes benefits paid settlements fair value plan assets december benefit obligation january service cost interest cost mergers acquisitions actuarial losses benefits paid effects exchange rate changes plan amendments curtailments termination benefits settlements benefit obligation december funded status december recognized assets accrued current liabilities deferred income taxes noncurrent liabilities fair value us pension plan assets included preceding table billion billion december respectively pension projected benefit obligation us plans billion billion respectively approximately companys pension projected benefit obligation december respectively relates international defined benefit plans individual plan significant relative total benefit obligation december accumulated benefit obligation billion billion respectively pension plans billion billion respectively related us pension plans pension plans benefit obligations excess plan assets december fair value plan assets billion billion respectively benefit obligations billion billion respectively plans accumulated benefit obligations excess plan assets december fair value plan assets billion billion respectively accumulated benefit obligations billion billion respectively plan assets entities required use fair value hierarchy maximizes use observable inputs minimizes use unobservable inputs measuring fair value three levels inputs may used measure fair value level quoted prices active markets identical assets liabilities plans level assets primarily include registered investment companies mutual funds equity securities level observable inputs level prices quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities plans level assets primarily include investments commoncollective trusts certain fixed income investments government agency securities corporate obligations level unobservable inputs supported little market activity financial instruments whose values determined using pricing models discounted cash flow methodologies similar techniques well instruments determination fair value requires significant judgment estimation plans level assets primarily include investments insurance contracts real estate funds valued using methodologies management understands plans level investments insurance contracts generally valued using crediting rate approximates market returns invest underlying securities whose market values unobservable determined using pricing models discounted cash flow methodologies similar techniques plans level investments real estate generally valued market appraisals may infrequent nature december million million respectively approximately companys pension investments year end categorized level assets inputs used measure financial assets fall within one level described categorization based lowest level input significant fair value measurement instrument fair values companys pension plan assets december asset category follows fair value measu rem ents using fair v alue measur em ents u sing quoted prices significant quoted prices significant active significant active significant markets observable unobservable markets observable unobservable identical assets inputs inputs identical assets inputs inputs level level level total level level level total assets cash cash equivalents securities lending collateral shortterm investments investment funds us large cap equities us smallmid cap equities nonus developed markets equities nonus emerging markets equities government agency obligations corporate obligations fixed income obligations real estate equity securities us large cap us smallmid cap nonus developed markets fixed income securities government agency obligations corporate obligations mortgage assetbacked securities investments insurance contracts derivatives liabilities liability return collateral securities loaned derivatives total liabilities table provides summary changes fair value including net transfers andor financial assets measured fair value using significant unobservable inputs level companys pension plan assets insurance real insurance real contracts estate total contracts estate total beginning balance january actual return plan assets relating assets still held december relating assets sold year purchases sales settlements net net transfers level scheringplough merger ending balance december fair values companys postretirement benefit plan assets december asset category follows f air v alue measure ents us ing f air va lue measu r em ents u sing quoted prices significant quoted prices significant active significant active significant markets observable unobservable markets observable unobservable identical assets inputs inputs identical assets inputs inputs level level level total level level level total assets cash cash equivalents securities lending collateral shortterm investments investment funds us large cap equities us smallmid cap equities nonus developed markets equities nonus emerging markets equities fixed income obligations equity securities us large cap us smallmid cap nonus developed markets fixed income securities government agency obligations corporate obligations mortgage asset backed securities fixed income obligations liabilities liability return collateral securities loaned total pension postretirement benefit plan assets excluded fair value hierarchy include interest receivable well payables receivables related purchases sales investments respectively company established investment guidelines us pension postretirement plans create asset allocation expected deliver rate return sufficient meet longterm obligation plan given acceptable level risk target investment portfolio companys us pension postretirement benefit plans allocated us equities international equities fixedincome investments cash investments portfolios equity weighting consistent longterm nature plans benefit obligations expected annual standard deviation returns target portfolio approximates reflects equity allocation diversification benefits among asset classes portfolio invests nonus pension plans targeted investment portfolio varies based duration pension liabilities local government rules regulations although significant percentage plan assets invested us equities concentration risk mitigated use strategies diversified within management guidelines expected contributions contributions pension plans postretirement benefit plans expected approximately million million respectively expected benefit payments expected benefit payments follows pension postretirement benefits benefits expected benefit payments based assumptions used measure benefit obligations include estimated future employee service amounts recognized comprehensive income net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions net loss amounts excess certain thresholds amortized net pension postretirement benefit cost average remaining service life employees following amounts reflected components oci po stre tir ement pension plans benefit plans years ended december net gain loss arising period prior service credit cost arising period net loss amortization included benefit cost prior service cost credit amortization included benefit cost estimated net loss prior service cost credit amounts amortized aoci net pension postretirement benefit cost million million respectively pension plans million million respectively postretirement benefit plans actuarial assumptions company reassesses benefit plan assumptions regular basis weighted average assumptions used determining pension plan us pension postretirement benefit plan information follows u pensi ther postretirement pension plans benefit plans december net cost discount rate expected rate return plan assets salary growth rate benefit obligation discount rate salary growth rate net cost rates preceding table include costs associated scheringplough benefit plans date merger december expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid determined country basis developing expected rate return within country longterm historical returns data considered well actual returns plan assets capital markets experience using reference information longterm return expectations asset category weighted average expected return countrys target portfolio developed according allocation among investment categories expected portfolio performance reflects contribution active management appropriate companys expected rate return range compared range us pension postretirement benefit plans health care cost trend rate assumptions postretirement benefit plans follows december health care cost trend rate assumed next year rate cost trend rate assumed decline year trend rate reaches ultimate trend rate one percentage point change health care cost trend rate would following effects e percentag e point increase decrease effect total service interest cost components effect benefit obligation savings plans company also maintains defined contribution savings plans united states including plans assumed connection merger company matches percentage employees contributions consistent provisions plan employee eligible total employer contributions plans million million million respectively income expense net years ended december interest income interest expense exchange losses gains net decline interest income increase interest expense compared largely attributable merger increase exchange losses primarily due recognition million exchange losses due two venezuelan currency devaluations discussed change net presented table compared primarily reflects billion gain resulting recognizing mercks previously held equity interest msp partnership fair value result obtaining control msp partnership merger see note billion gain sale old mercks interest merial see note million charge vioxx liability reserve recorded see note lower recognized net gains companys investment portfolio charges recognized related settlement certain pending awp litigation see note items partially offset million income recognized upon astrazenecas asset option exercise see note million income recognized settlement certain disputed royalties effective january company required remeasure local currency operations venezuela us dollars venezuelan economy determined hyperinflationary effective january venezuelan government devalued currency bsf per us dollar twotiered official exchange rate essentials rate bsf per us dollar nonessentials rate bsf per us dollar throughout company settled transactions essentials rate therefore remeasured monetary assets liabilities utilizing essentials rate december venezuelan government announced would eliminate essentials rate effective january transactions would settled official rate bsf per us dollar result announcement company remeasured december monetary assets liabilities new official rate decline interest income compared primarily result lower interest rates change investment portfolio mix toward cash shorterdated securities anticipation merger increase interest expense largely due million commitment fees incremental interest expense related financing merger included net billion gain result obtaining control msp partnership merger billion gain sale old mercks interest merial million investment portfolio recognized net gains million charge related settlement vioxx thirdparty payor litigation united states included net aggregate gain distribution azlp billion see note gain million related sale remaining worldwide rights aggrastat million expense contribution merck company foundation million investment portfolio recognized net losses interest paid million million million excludes commitment fees taxes income reconciliation effective tax rate us statutory rate follows amount tax rate amount tax rate amount tax rate us statutory rate applied income taxes differential arising foreign earnings foreign entity tax rate change unremitted foreign earnings state taxes state tax settlements amortization purchase accounting adjustments iprd impairment charges vioxx liability reserve us health care reform legislation restructuring gain equity investments foreign tax credit utilization includes tax effect contingency reserves research credits export incentives miscellaneous items tax rate reconciliation percentages reflect impact significant decline companys income taxes resulting primarily full year purchase accounting adjustments including iprd impairment charges restructuring charges vioxx liability reserve income taxes consisted years ended december domestic foreign taxes income consisted years ended december current provision federal foreign state deferred provision federal foreign state deferred income taxes december consisted assets liabilities assets liabilities intangibles inventory related accelerated depreciation unremitted foreign earnings equity investments pensions postretirement benefits compensation related unrecognized tax benefits net operating losses tax credit carryforwards subtotal valuation allowance total deferred taxes net deferred income taxes recognized deferred income taxes current assets assets income taxes payable deferred income taxes noncurrent liabilities company net operating loss nol carryforwards several jurisdictions december approximately million deferred taxes nol carryforwards relate foreign jurisdictions none individually significant approximately million valuation allowances established foreign nol carryforwards addition company approximately million deferred tax assets relating various us tax credit carryforwards state tax nol carryforwards amounts million expected fully utilized prior expiry income taxes paid billion million billion respectively stock option exercises significant impact taxes paid reconciliation beginning ending amount unrecognized tax benefits follows balance january additions related current year positions additions related prior year positions additons related merger reductions tax positions prior years settlements lapse statute limitations balance december company recognize unrecognized tax benefits billion december income tax provision would reflect favorable net impact billion company old merck examination numerous tax authorities various jurisdictions globally company believes reasonably possible total amount unrecognized tax benefits december could decrease billion next months company old merck result various audit closures settlements expiration statute limitations ultimate finalization companys examinations relevant taxing authorities include formal administrative legal proceedings could significant impact timing reversal unrecognized tax benefits company believes reserves uncertain tax positions adequate cover risks exposures interest penalties associated uncertain tax positions amounted expense benefit million million million liabilities accrued interest penalties billion billion december respectively previously disclosed october canada revenue agency cra issued old merck notice reassessment containing adjustments related certain intercompany pricing matters february old merck cra negotiated settlement agreement regard matters accordance settlement old merck paid additional tax approximately million us dollars interest approximately million us dollars additional amounts penalties due assessment settlement accounted first quarter old merck previously established reserves matters significant portion taxes paid expected creditable us tax purposes resolution matters material effect old mercks financial position liquidity respect associated collateral discussed addition previously disclosed cra proposed additional adjustments relating intercompany pricing matters adjustments would increase canadian tax due approximately million us dollars plus approximately million us dollars interest december company disagrees positions taken cra believes without merit company continues contest assessments cra appeals process cra expected prepare similar adjustments later years management believes resolution matters material effect companys financial position liquidity connection appeals process discussed related old merck pledged cash investments collateral two financial institutions one provided guarantee cra quebec ministry revenue representing portion tax interest assessed guarantee quebec ministry revenue expired first quarter collateral associated guarantee cra totaled approximately million december included deferred income taxes current assets assets consolidated balance sheet guarantee replaced guarantee collateralized accordingly collateral associated original guarantee released reclassified cash investments october internal revenue service irs auditors asserted two interest rate swaps scheringplough entered unrelated party recharacterized loans affiliated companies resulting additional tax liability tax years september scheringplough made payments irs amount million income taxes million interest companys tax reserves adequate cover payments scheringplough filed refund claims taxes interest irs december following irss denial scheringploughs claims refund scheringplough filed suit may us district court district new jersey refund full amount taxes interest decision favor government announced august company appealing decision district court us court appeals third circuit appeal scheduled heard march irs finalized examination scheringploughs tax years audit cycle company reached agreement irs adjustment income related intercompany pricing matters income adjustment mostly reduced nols tax credit carryforwards additionally company seeking resolution one issue raised examination irs administrative appeals process companys reserves uncertain tax positions adequate cover adjustments related examination period irs began examination tax years company irss examination old mercks federal income tax returns ongoing expected conclude within next months addition various state foreign tax examinations progress significant tax jurisdictions us state foreign companys income tax returns open examination period december foreign earnings billion retained indefinitely subsidiary companies reinvestment therefore provision made income taxes would payable upon distribution earnings addition company subsidiaries operating puerto rico singapore tax incentive grants begin expire earnings per share company calculates earnings per share pursuant twoclass method earnings allocation formula determines earnings per share common stock participating securities according dividends declared participation rights undistributed earnings method earnings distributed undistributed allocated common shares participating securities based respective rights receive dividends rsus certain psus granted december certain management level employees see note participate dividends basis common shares dividends nonforfeitable holder result rsus psus meet definition participating security rsus psus issued january dividends declared vesting period payable employees upon vesting therefore rsus psus meet definition participating security calculations earnings per share twoclass method follows years ended december basic earnings per common share net income attributable merck co inc common shareholders less income allocated participating securities net income allocated common shareholders average common shares outstanding earnings per common share assuming dilution net income attributable merck co inc common shareholders less income allocated participating securities net income allocated common shareholders average common shares outstanding common shares issuable average common shares outstanding assuming dilution issuable primarily sharebased compensation plans million million million respectively common shares issuable sharebased compensation plans excluded computation earnings per common share assuming dilution effect would antidilutive comprehensive income components comprehensive income loss follows pretax tax tax year ended december net unrealized gain derivatives net loss realization derivatives net unrealized gain investments net gain realization investments benefit plan net loss gain prior service cost credit net amortization cumulative translation adjustment year ended december net unrealized loss derivatives net loss realization derivatives net unrealized gain investments net gain realization investments benefit plan net loss gain prior service cost credit net amortization cumulative translation adjustment year ended december net unrealized gain derivatives net gain realization derivatives net unrealized loss investments net loss realization investments benefit plan net loss gain prior service cost credit net amortization cumulative translation adjustment components accumulated comprehensive loss follows december net unrealized gain loss derivatives net unrealized gain investments pension plan net loss postretirement benefit plan net loss pension plan prior service cost postretirement benefit plan prior service credit cumulative translation adjustment included cumulative translation adjustment pretax gains million million postmerger period eurodenominated notes designated effective economic hedges net investment foreign operation segment reporting companys operations principally managed products basis comprised four operating segments pharmaceutical animal health consumer care alliances includes revenue equity income companys relationship azlp animal health consumer care alliances segments material separate reporting included table pharmaceutical segment includes human health pharmaceutical vaccine products marketed either directly company joint ventures human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities large component pediatric adolescent vaccines sold us centers disease control prevention vaccines children program funded us government company also animal health operations discover develop manufacture market animal health products including vaccines company sells veterinarians distributors animal producers additionally company consumer care operations develop manufacture market overthecounter foot care sun care products sold wholesale retail drug food chain mass merchandiser outlets united states canada accounting policies segments described described note revenues profits segments follows pharmaceutical total year ended december segment revenues segment profits included segment profits equity income affiliates depreciation amortization year ended december segment revenues segment profits included segment profits equity income affiliates depreciation amortization year ended december segment revenues segment profits included segment profits equity income affiliates depreciation amortization segment profits comprised segment revenues less certain elements materials production costs operating expenses including components equity income loss affiliates depreciation amortization expenses internal management reporting presented chief operating decision maker merck allocate production costs standard costs research development expenses general administrative expenses cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed assets utilized divisions therefore included segment profits sales companys products follows years ended december pharmaceutical bone respiratory immunology dermatology singulair remicade nasonex fosamax clarinex arcoxia proventil asmanex cardiovascular zetia vytorin integrilin diabetes obesity januvia janumet diversified brands cozaarhyzaar zocor propecia claritin rx vasotecvaseretic remeron proscar infectious disease isentress pegintron cancidas primaxin invanz avelox rebetol crixivanstocrin neurosciences ophthalmology maxalt cosopttrusopt subutexsuboxone oncology temodar emend caelyx intron vaccines proquadmmr iivarivax gardasil rotateq pneumovax zostavax womens health endocrine nuvaring follistim aq implanon cerazette pharmaceutical total pharmaceutical segment sales segment sales total segment sales sales legacy scheringplough products reflect results postmerger period addition prior merger substantially sales zetia vytorin recognized msp partnership results old mercks interest msp partnership recorded equity income affiliates result merger msp partnership whollyowned company accordingly sales msp partnership products merger reflected table sales zetia vytorin reflect old mercks sales products latin america part msp partnership amounts reflect sales vaccines sold major european markets companys joint venture sanofi pasteur msd results reflected equity income affiliates amounts however reflect supply sales sanofi pasteur msd pharmaceutical primarily reflects sales human pharmaceutical products including products within franchises listed separately reflects nonreportable segments including animal health consumer care revenue companys relationship azlp primarily relating sales nexium well prilosec revenue azlp billion billion billion respectively revenues primarily comprised miscellaneous corporate revenues thirdparty manufacturing sales sales related divested products businesses supply sales included segment results consolidated revenues geographic area derived follows years ended december united states europe middle east africa japan reconciliation total segment profits consolidated income taxes follows years ended december segment profits profits losses adjustments unallocated interest income interest expense equity income affiliates depreciation amortization research development amortization purchase accounting adjustments restructuring costs gain astrazeneca asset option exercise gain related msp partnership gain merial divestiture gain distribution astrazeneca lp vioxx liability reserve expenses net profits losses primarily comprised miscellaneous corporate profits losses well operating profits losses related thirdparty manufacturing sales divested products businesses supply sales adjustments represent elimination effect double counting certain items income expense equity income affiliates includes taxes paid joint venture level portion equity income reported segment profits expenses net include expenses corporate manufacturing cost centers miscellaneous income expense net property plant equipment net geographic area located follows years ended december united states europe middle east africa japan company disaggregate assets products services basis internal management reporting therefore information presented report independent registered public accounting firm board directors shareholders merck co inc opinion accompanying consolidated balance sheets related consolidated statements income equity cash flows present fairly material respects financial position merck co inc subsidiaries december december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also opinion merck maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso mercks management responsible financial statements maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included managements report item responsibility express opinions financial statements mercks internal control financial reporting based integrated audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audits obtain reasonable assurance whether financial statements free material misstatement whether effective internal control financial reporting maintained material respects audits financial statements included examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation audit internal control financial reporting included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk audits also included performing procedures considered necessary circumstances believe audits provide reasonable basis opinions companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company ii provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company iii provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate pricewaterhousecoopers llp florham park new jersey february b supplementary data selected quarterly financial data contained condensed interim financial data table condensed interim financial data unaudited millions except per share amounts th q rd q nd q st q sales materials production costs marketing administrative expenses research development expenses restructuring costs equity income affiliates income expense net loss income taxes net loss income attributable merck co inc basic loss earnings per common share attributable merck co inc common shareholders loss earnings per common share assuming dilution attributable merck co inc common shareholders sales materials production costs marketing administrative expenses research development expenses restructuring costs equity income affiliates income expense net income taxes net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders amounts include inprocess research development impairment charges amounts include gain fair value adjustment mercks previously held interest msp partnership see note amounts include impact vioxx liability reserve see note amounts include gain sale old mercks interest merial limited see note amounts reflect impact gain astrazenecas exercise asset option see note amounts reflect impacts merger including amortization purchase accounting adjustments see note amounts also include impact restructuring actions see note item changes disagreements accountants accounting financial disclosure applicable item controls procedures management company participation chief executive officer chief financial officer evaluated effectiveness companys disclosure controls procedures based evaluation end period covered companys chief executive officer chief financial officer concluded companys disclosure controls procedures defined rules ae de securities exchange act amended act effective management responsible establishing maintaining adequate internal control financial reporting term defined rule af act management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated framework issued committee sponsoring organizations treadway commission coso based evaluation management concluded internal control financial reporting effective december pricewaterhousecoopers llp independent registered public accounting firm performed assessment effectiveness companys internal control financial reporting attestation report included filing company previously disclosed process multiyear implementation enterprisewide resource planning system successfully completed legacy merck us deployment second quarter response business integration activities company continue align streamline design operation financial control environment responsive changing business model needs actions include adoption revised implementation plan enterprisewide resource planning system includes expected deployment system canada several major european markets early managements report managements responsibility financial statements responsibility integrity objectivity companys financial statements rests management financial statements report managements stewardship company assets statements prepared conformity generally accepted accounting principles accordingly include amounts based managements best estimates judgments nonfinancial information included annual report also prepared management consistent financial statements assure financial information reliable assets safeguarded management maintains effective system internal controls procedures important elements include careful selection training development operating financial managers organization provides appropriate division responsibility communications aimed assuring company policies procedures understood throughout organization staff internal auditors regularly monitors adequacy application internal controls worldwide basis ensure personnel continue understand system internal controls procedures policies concerning good prudent business practices company periodically conducts managements stewardship program key management financial personnel program reinforces importance understanding internal controls reviewing key corporate policies procedures systems addition company compliance programs including ethical business practices program reinforce companys longstanding commitment high ethical standards conduct business financial statements financial information included annual report fairly present material respects companys financial condition results operations cash flows formal certification securities exchange commission included filing managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule af securities exchange act companys internal control financial reporting designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles united states america management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated framework issued committee sponsoring organizations treadway commission based evaluation management concluded internal control financial reporting effective december inherent limitations internal control financial reporting may prevent detect misstatements projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate effectiveness companys internal control financial reporting december audited pricewaterhousecoopers llp independent registered public accounting firm stated report appears herein kenneth c frazier peter n kellogg president executive vice president chief executive officer chief financial officer item b information none part iii item directors executive officers corporate governance required information directors nominees incorporated reference discussion item election directors companys proxy statement annual meeting shareholders held may information executive officers set forth part document pages required information compliance section securities exchange act incorporated reference discussion heading section beneficial ownership reporting compliance companys proxy statement annual meeting shareholders held may company adopted code conduct values standards applicable employees including principal executive officer principal financial officer principal accounting officer code conduct available companys website wwwmerckcomaboutcodeofconductpdf company intends post website amendments waivers code conduct printed copy sent without charge shareholder requests writing chief ethics officer merck co inc one merck drive whitehouse station nj required information identification audit committee audit committee financial expert incorporated reference discussion heading board committees companys proxy statement annual meeting shareholders held may item executive compensation information required executive compensation incorporated reference discussion headings compensation discussion analysis summary compensation table compensation table grants planbased awards table outstanding equity awards fiscal yearend table option exercises stock vested table retirement plan benefits related pension benefits table nonqualified deferred compensation related tables potential payments upon termination change control including discussion subheadings separation individual agreements change control separation plan payment change control payment benefit estimates table well footnote information various tables companys proxy statement annual meeting shareholders held may required information director compensation incorporated reference discussion heading director compensation related director compensation table schedule director fees table companys proxy statement annual meeting shareholders held may required information headings compensation committee interlocks insider participation compensation benefits committee report incorporated reference companys proxy statement annual meeting shareholders held may item security ownership certain beneficial owners management related stockholder matters information respect securities authorized issuance equity compensation plans set forth part ii document information respect security ownership certain beneficial owners management incorporated reference discussion heading security ownership certain beneficial owners management companys proxy statement annual meeting shareholders held may item certain relationships related transactions director independence required information transactions related persons incorporated reference discussion heading related person transactions companys proxy statement annual meeting shareholders held may required information director independence incorporated reference discussion heading independence directors companys proxy statement annual meeting shareholders held may item principal accountant fees services information required item incorporated reference discussion audit committee beginning caption preapproval policy services independent registered public accounting firm fees companys proxy statement annual meeting shareholders held may part iv item